,source,target,value,type,source layer,target layer,normalized value
0,KVD20,Initial triggering of complement,0.002230053689532033,0,0,1,0.0025317878198877763
1,KVD20,Initial triggering of complement,0.002603667685343283,1,0,1,0.00295595310719663
2,KVD20,Regulation of Complement cascade,0.002230053689532033,0,0,1,0.0025317878198877763
3,KVD20,Regulation of Complement cascade,0.002603667685343283,1,0,1,0.00295595310719663
4,KVD20,FCGR activation,0.002230053689532033,0,0,1,0.0025317878198877763
5,KVD20,FCGR activation,0.002603667685343283,1,0,1,0.00295595310719663
6,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.002230053689532033,0,0,1,0.0025317878198877763
7,KVD20,Regulation of actin dynamics for phagocytic cup formation,0.002603667685343283,1,0,1,0.00295595310719663
8,KVD20,Role of phospholipids in phagocytosis,0.002230053689532033,0,0,1,0.0025317878198877763
9,KVD20,Role of phospholipids in phagocytosis,0.002603667685343283,1,0,1,0.00295595310719663
10,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.002230053689532033,0,0,1,0.0025317878198877763
11,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,0.002603667685343283,1,0,1,0.00295595310719663
12,KVD20,FCERI mediated MAPK activation,0.002230053689532033,0,0,1,0.0025317878198877763
13,KVD20,FCERI mediated MAPK activation,0.002603667685343283,1,0,1,0.00295595310719663
14,KVD20,FCERI mediated Ca+2 mobilization,0.002230053689532033,0,0,1,0.0025317878198877763
15,KVD20,FCERI mediated Ca+2 mobilization,0.002603667685343283,1,0,1,0.00295595310719663
16,KVD20,FCERI mediated NF-kB activation,0.002230053689532033,0,0,1,0.0025317878198877763
17,KVD20,FCERI mediated NF-kB activation,0.002603667685343283,1,0,1,0.00295595310719663
18,KVD20,Parasite infection,0.002230053689532033,0,0,1,0.0025317878198877763
19,KVD20,Parasite infection,0.002603667685343283,1,0,1,0.00295595310719663
20,KVD20,Leishmania parasite growth and survival,0.002230053689532033,0,0,1,0.0025317878198877763
21,KVD20,Leishmania parasite growth and survival,0.002603667685343283,1,0,1,0.00295595310719663
22,KVD20,Potential therapeutics for SARS,0.002230053689532033,0,0,1,0.0025317878198877763
23,KVD20,Potential therapeutics for SARS,0.002603667685343283,1,0,1,0.00295595310719663
24,KVD20,CD22 mediated BCR regulation,0.002230053689532033,0,0,1,0.0025317878198877763
25,KVD20,CD22 mediated BCR regulation,0.002603667685343283,1,0,1,0.00295595310719663
26,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002230053689532033,0,0,1,0.0025317878198877763
27,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002603667685343283,1,0,1,0.00295595310719663
28,KVD20,Cell surface interactions at the vascular wall,0.002230053689532033,0,0,1,0.0025317878198877763
29,KVD20,Cell surface interactions at the vascular wall,0.002603667685343283,1,0,1,0.00295595310719663
30,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002230053689532033,0,0,1,0.0025317878198877763
31,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002603667685343283,1,0,1,0.00295595310719663
32,KVD20,Scavenging of heme from plasma,0.002230053689532033,0,0,1,0.0025317878198877763
33,KVD20,Scavenging of heme from plasma,0.002603667685343283,1,0,1,0.00295595310719663
34,IGLC7,Initial triggering of complement,0.002854448257870346,0,0,1,0.003240665175775453
35,IGLC7,Initial triggering of complement,0.001969415316924992,1,0,1,0.0022358841561063215
36,IGLC7,Regulation of Complement cascade,0.002854448257870346,0,0,1,0.003240665175775453
37,IGLC7,Regulation of Complement cascade,0.001969415316924992,1,0,1,0.0022358841561063215
38,IGLC7,FCGR activation,0.002854448257870346,0,0,1,0.003240665175775453
39,IGLC7,FCGR activation,0.001969415316924992,1,0,1,0.0022358841561063215
40,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.002854448257870346,0,0,1,0.003240665175775453
41,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.001969415316924992,1,0,1,0.0022358841561063215
42,IGLC7,Role of phospholipids in phagocytosis,0.002854448257870346,0,0,1,0.003240665175775453
43,IGLC7,Role of phospholipids in phagocytosis,0.001969415316924992,1,0,1,0.0022358841561063215
44,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.002854448257870346,0,0,1,0.003240665175775453
45,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.001969415316924992,1,0,1,0.0022358841561063215
46,IGLC7,FCERI mediated MAPK activation,0.002854448257870346,0,0,1,0.003240665175775453
47,IGLC7,FCERI mediated MAPK activation,0.001969415316924992,1,0,1,0.0022358841561063215
48,IGLC7,FCERI mediated Ca+2 mobilization,0.002854448257870346,0,0,1,0.003240665175775453
49,IGLC7,FCERI mediated Ca+2 mobilization,0.001969415316924992,1,0,1,0.0022358841561063215
50,IGLC7,FCERI mediated NF-kB activation,0.002854448257870346,0,0,1,0.003240665175775453
51,IGLC7,FCERI mediated NF-kB activation,0.001969415316924992,1,0,1,0.0022358841561063215
52,IGLC7,Parasite infection,0.002854448257870346,0,0,1,0.003240665175775453
53,IGLC7,Parasite infection,0.001969415316924992,1,0,1,0.0022358841561063215
54,IGLC7,Leishmania parasite growth and survival,0.002854448257870346,0,0,1,0.003240665175775453
55,IGLC7,Leishmania parasite growth and survival,0.001969415316924992,1,0,1,0.0022358841561063215
56,IGLC7,Potential therapeutics for SARS,0.002854448257870346,0,0,1,0.003240665175775453
57,IGLC7,Potential therapeutics for SARS,0.001969415316924992,1,0,1,0.0022358841561063215
58,IGLC7,CD22 mediated BCR regulation,0.002854448257870346,0,0,1,0.003240665175775453
59,IGLC7,CD22 mediated BCR regulation,0.001969415316924992,1,0,1,0.0022358841561063215
60,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002854448257870346,0,0,1,0.003240665175775453
61,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001969415316924992,1,0,1,0.0022358841561063215
62,IGLC7,Cell surface interactions at the vascular wall,0.002854448257870346,0,0,1,0.003240665175775453
63,IGLC7,Cell surface interactions at the vascular wall,0.001969415316924992,1,0,1,0.0022358841561063215
64,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002854448257870346,0,0,1,0.003240665175775453
65,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001969415316924992,1,0,1,0.0022358841561063215
66,IGLC7,Scavenging of heme from plasma,0.002854448257870346,0,0,1,0.003240665175775453
67,IGLC7,Scavenging of heme from plasma,0.001969415316924992,1,0,1,0.0022358841561063215
68,FCN3,Initial triggering of complement,0.0005266764158255769,0,0,1,0.0005979375926546236
69,FCN3,Initial triggering of complement,0.0005148619833085154,1,0,1,0.0005845246257444595
70,CERU,Metal ion SLC transporters,0.00870237866844616,0,0,1,0.009879841198552772
71,CERU,Metal ion SLC transporters,0.008723845529212777,1,0,1,0.009904212601302071
72,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.00870237866844616,0,0,1,0.009879841198552772
73,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.008723845529212777,1,0,1,0.009904212601302071
74,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.00870237866844616,0,0,1,0.009879841198552772
75,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.008723845529212777,1,0,1,0.009904212601302071
76,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00870237866844616,0,0,1,0.009879841198552772
77,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008723845529212777,1,0,1,0.009904212601302071
78,CERU,Post-translational protein phosphorylation,0.00870237866844616,0,0,1,0.009879841198552772
79,CERU,Post-translational protein phosphorylation,0.008723845529212777,1,0,1,0.009904212601302071
80,F13A,Interleukin-4 and Interleukin-13 signaling,0.0041350437407913394,0,0,1,0.004694529744633898
81,F13A,Interleukin-4 and Interleukin-13 signaling,0.004367662248056768,1,0,1,0.0049586223564573725
82,F13A,Platelet degranulation ,0.0041350437407913394,0,0,1,0.004694529744633898
83,F13A,Platelet degranulation ,0.004367662248056768,1,0,1,0.0049586223564573725
84,F13A,Common Pathway of Fibrin Clot Formation,0.0041350437407913394,0,0,1,0.004694529744633898
85,F13A,Common Pathway of Fibrin Clot Formation,0.004367662248056768,1,0,1,0.0049586223564573725
86,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.013053023598905552,0,0,1,0.014819143734315943
87,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.011754860194131621,1,0,1,0.013345334241809788
88,THRB,Regulation of Complement cascade,0.013053023598905552,0,0,1,0.014819143734315943
89,THRB,Regulation of Complement cascade,0.011754860194131621,1,0,1,0.013345334241809788
90,THRB,Class A/1 (Rhodopsin-like receptors),0.013053023598905552,0,0,1,0.014819143734315943
91,THRB,Class A/1 (Rhodopsin-like receptors),0.011754860194131621,1,0,1,0.013345334241809788
92,THRB,G alpha (q) signalling events,0.013053023598905552,0,0,1,0.014819143734315943
93,THRB,G alpha (q) signalling events,0.011754860194131621,1,0,1,0.013345334241809788
94,THRB,Defective factor XII causes hereditary angioedema,0.013053023598905552,0,0,1,0.014819143734315943
95,THRB,Defective factor XII causes hereditary angioedema,0.011754860194131621,1,0,1,0.013345334241809788
96,THRB,Defective factor VIII causes hemophilia A,0.013053023598905552,0,0,1,0.014819143734315943
97,THRB,Defective factor VIII causes hemophilia A,0.011754860194131621,1,0,1,0.013345334241809788
98,THRB,Cell surface interactions at the vascular wall,0.013053023598905552,0,0,1,0.014819143734315943
99,THRB,Cell surface interactions at the vascular wall,0.011754860194131621,1,0,1,0.013345334241809788
100,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.013053023598905552,0,0,1,0.014819143734315943
101,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.011754860194131621,1,0,1,0.013345334241809788
102,THRB,Common Pathway of Fibrin Clot Formation,0.013053023598905552,0,0,1,0.014819143734315943
103,THRB,Common Pathway of Fibrin Clot Formation,0.011754860194131621,1,0,1,0.013345334241809788
104,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.013053023598905552,0,0,1,0.014819143734315943
105,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011754860194131621,1,0,1,0.013345334241809788
106,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.013053023598905552,0,0,1,0.014819143734315943
107,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.011754860194131621,1,0,1,0.013345334241809788
108,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.016238273033268396,0,0,1,0.018435368652612215
109,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.01207875587351869,1,0,1,0.013713054149108762
110,FA9,Defective factor VIII causes hemophilia A,0.016238273033268396,0,0,1,0.018435368652612215
111,FA9,Defective factor VIII causes hemophilia A,0.01207875587351869,1,0,1,0.013713054149108762
112,FA9,Defective factor IX causes hemophilia B,0.016238273033268396,0,0,1,0.018435368652612215
113,FA9,Defective factor IX causes hemophilia B,0.01207875587351869,1,0,1,0.013713054149108762
114,FA9,Defective factor IX causes thrombophilia,0.016238273033268396,0,0,1,0.018435368652612215
115,FA9,Defective factor IX causes thrombophilia,0.01207875587351869,1,0,1,0.013713054149108762
116,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.016238273033268396,0,0,1,0.018435368652612215
117,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.01207875587351869,1,0,1,0.013713054149108762
118,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.016238273033268396,0,0,1,0.018435368652612215
119,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.01207875587351869,1,0,1,0.013713054149108762
120,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.005519667859945149,0,0,1,0.006266498391152039
121,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.004314680347824838,1,0,1,0.00489847181823878
122,FA10,Defective factor VIII causes hemophilia A,0.005519667859945149,0,0,1,0.006266498391152039
123,FA10,Defective factor VIII causes hemophilia A,0.004314680347824838,1,0,1,0.00489847181823878
124,FA10,Defective factor IX causes hemophilia B,0.005519667859945149,0,0,1,0.006266498391152039
125,FA10,Defective factor IX causes hemophilia B,0.004314680347824838,1,0,1,0.00489847181823878
126,FA10,Defective factor IX causes thrombophilia,0.005519667859945149,0,0,1,0.006266498391152039
127,FA10,Defective factor IX causes thrombophilia,0.004314680347824838,1,0,1,0.00489847181823878
128,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.005519667859945149,0,0,1,0.006266498391152039
129,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.004314680347824838,1,0,1,0.00489847181823878
130,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.005519667859945149,0,0,1,0.006266498391152039
131,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.004314680347824838,1,0,1,0.00489847181823878
132,FA10,Common Pathway of Fibrin Clot Formation,0.005519667859945149,0,0,1,0.006266498391152039
133,FA10,Common Pathway of Fibrin Clot Formation,0.004314680347824838,1,0,1,0.00489847181823878
134,PLMN,Platelet degranulation ,0.0038571277748059266,0,0,1,0.004379010768145998
135,PLMN,Platelet degranulation ,0.003485273364579674,1,0,1,0.003956843144558452
136,PLMN,Dissolution of Fibrin Clot,0.0038571277748059266,0,0,1,0.004379010768145998
137,PLMN,Dissolution of Fibrin Clot,0.003485273364579674,1,0,1,0.003956843144558452
138,PLMN,Activation of Matrix Metalloproteinases,0.0038571277748059266,0,0,1,0.004379010768145998
139,PLMN,Activation of Matrix Metalloproteinases,0.003485273364579674,1,0,1,0.003956843144558452
140,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0038571277748059266,0,0,1,0.004379010768145998
141,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003485273364579674,1,0,1,0.003956843144558452
142,PLMN,Signaling by PDGF,0.0038571277748059266,0,0,1,0.004379010768145998
143,PLMN,Signaling by PDGF,0.003485273364579674,1,0,1,0.003956843144558452
144,FA12,Defective factor XII causes hereditary angioedema,0.0005225003295307767,0,0,1,0.0005931964671536522
145,FA12,Defective factor XII causes hereditary angioedema,0.0003071514542902931,1,0,1,0.0003487101294839972
146,FA12,Defective SERPING1 causes hereditary angioedema,0.0005225003295307767,0,0,1,0.0005931964671536522
147,FA12,Defective SERPING1 causes hereditary angioedema,0.0003071514542902931,1,0,1,0.0003487101294839972
148,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0005225003295307767,0,0,1,0.0005931964671536522
149,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0003071514542902931,1,0,1,0.0003487101294839972
150,CAH2,Reversible hydration of carbon dioxide,0.013238199972283241,0,0,1,0.015029375124192034
151,CAH2,Reversible hydration of carbon dioxide,0.0028285305752870364,1,0,1,0.003211240739318091
152,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.013238199972283241,0,0,1,0.015029375124192034
153,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.0028285305752870364,1,0,1,0.003211240739318091
154,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.013238199972283241,0,0,1,0.015029375124192034
155,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.0028285305752870364,1,0,1,0.003211240739318091
156,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.0002618949555632531,0,0,1,0.0002973302668440396
157,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.00024699107529993963,1,0,1,0.0002804098390100169
158,ANT3,Common Pathway of Fibrin Clot Formation,0.0002618949555632531,0,0,1,0.0002973302668440396
159,ANT3,Common Pathway of Fibrin Clot Formation,0.00024699107529993963,1,0,1,0.0002804098390100169
160,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002618949555632531,0,0,1,0.0002973302668440396
161,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00024699107529993963,1,0,1,0.0002804098390100169
162,ANT3,Post-translational protein phosphorylation,0.0002618949555632531,0,0,1,0.0002973302668440396
163,ANT3,Post-translational protein phosphorylation,0.00024699107529993963,1,0,1,0.0002804098390100169
164,ANGT,Class A/1 (Rhodopsin-like receptors),0.016615220655568662,0,0,1,0.01886331861783289
165,ANGT,Class A/1 (Rhodopsin-like receptors),0.008088348429022493,1,0,1,0.009182730501840425
166,ANGT,G alpha (q) signalling events,0.016615220655568662,0,0,1,0.01886331861783289
167,ANGT,G alpha (q) signalling events,0.008088348429022493,1,0,1,0.009182730501840425
168,ANGT,G alpha (i) signalling events,0.016615220655568662,0,0,1,0.01886331861783289
169,ANGT,G alpha (i) signalling events,0.008088348429022493,1,0,1,0.009182730501840425
170,ANGT,PPARA activates gene expression,0.016615220655568662,0,0,1,0.01886331861783289
171,ANGT,PPARA activates gene expression,0.008088348429022493,1,0,1,0.009182730501840425
172,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.016615220655568662,0,0,1,0.01886331861783289
173,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.008088348429022493,1,0,1,0.009182730501840425
174,A2MG,Platelet degranulation ,0.00010372536522242639,0,0,1,0.0001177597730118587
175,A2MG,Platelet degranulation ,0.00011409420532935506,1,0,1,0.00012953155375970013
176,A2MG,HDL assembly,0.00010372536522242639,0,0,1,0.0001177597730118587
177,A2MG,HDL assembly,0.00011409420532935506,1,0,1,0.00012953155375970013
178,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.00010372536522242639,0,0,1,0.0001177597730118587
179,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.00011409420532935506,1,0,1,0.00012953155375970013
180,CO3,Initial triggering of complement,0.00795116219799425,0,0,1,0.009026982489851305
181,CO3,Initial triggering of complement,0.010207836406130131,1,0,1,0.011588992678409703
182,CO3,Activation of C3 and C5,0.00795116219799425,0,0,1,0.009026982489851305
183,CO3,Activation of C3 and C5,0.010207836406130131,1,0,1,0.011588992678409703
184,CO3,Regulation of Complement cascade,0.00795116219799425,0,0,1,0.009026982489851305
185,CO3,Regulation of Complement cascade,0.010207836406130131,1,0,1,0.011588992678409703
186,CO3,Class A/1 (Rhodopsin-like receptors),0.00795116219799425,0,0,1,0.009026982489851305
187,CO3,Class A/1 (Rhodopsin-like receptors),0.010207836406130131,1,0,1,0.011588992678409703
188,CO3,G alpha (i) signalling events,0.00795116219799425,0,0,1,0.009026982489851305
189,CO3,G alpha (i) signalling events,0.010207836406130131,1,0,1,0.011588992678409703
190,CO3,Cell recruitment (pro-inflammatory response),0.00795116219799425,0,0,1,0.009026982489851305
191,CO3,Cell recruitment (pro-inflammatory response),0.010207836406130131,1,0,1,0.011588992678409703
192,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00795116219799425,0,0,1,0.009026982489851305
193,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010207836406130131,1,0,1,0.011588992678409703
194,CO3,Neutrophil degranulation,0.00795116219799425,0,0,1,0.009026982489851305
195,CO3,Neutrophil degranulation,0.010207836406130131,1,0,1,0.011588992678409703
196,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00795116219799425,0,0,1,0.009026982489851305
197,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.010207836406130131,1,0,1,0.011588992678409703
198,CO3,Post-translational protein phosphorylation,0.00795116219799425,0,0,1,0.009026982489851305
199,CO3,Post-translational protein phosphorylation,0.010207836406130131,1,0,1,0.011588992678409703
200,CO5,Terminal pathway of complement,0.006328244355336607,0,0,1,0.0071844781384958
201,CO5,Terminal pathway of complement,0.009358261741926001,1,0,1,0.010624467565398352
202,CO5,Activation of C3 and C5,0.006328244355336607,0,0,1,0.0071844781384958
203,CO5,Activation of C3 and C5,0.009358261741926001,1,0,1,0.010624467565398352
204,CO5,Regulation of Complement cascade,0.006328244355336607,0,0,1,0.0071844781384958
205,CO5,Regulation of Complement cascade,0.009358261741926001,1,0,1,0.010624467565398352
206,CO5,Class A/1 (Rhodopsin-like receptors),0.006328244355336607,0,0,1,0.0071844781384958
207,CO5,Class A/1 (Rhodopsin-like receptors),0.009358261741926001,1,0,1,0.010624467565398352
208,CO5,G alpha (i) signalling events,0.006328244355336607,0,0,1,0.0071844781384958
209,CO5,G alpha (i) signalling events,0.009358261741926001,1,0,1,0.010624467565398352
210,CYTC,Neutrophil degranulation,0.004431647015443926,0,0,1,0.005031264488568171
211,CYTC,Neutrophil degranulation,0.004303627860675779,1,0,1,0.004885923890592551
212,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004431647015443926,0,0,1,0.005031264488568171
213,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004303627860675779,1,0,1,0.004885923890592551
214,CYTC,Amyloid fiber formation,0.004431647015443926,0,0,1,0.005031264488568171
215,CYTC,Amyloid fiber formation,0.004303627860675779,1,0,1,0.004885923890592551
216,CYTC,Post-translational protein phosphorylation,0.004431647015443926,0,0,1,0.005031264488568171
217,CYTC,Post-translational protein phosphorylation,0.004303627860675779,1,0,1,0.004885923890592551
218,KNG1,Class A/1 (Rhodopsin-like receptors),0.00368643337365896,0,0,1,0.004185220812426315
219,KNG1,Class A/1 (Rhodopsin-like receptors),0.004622405414060138,1,0,1,0.0052478331713872685
220,KNG1,G alpha (q) signalling events,0.00368643337365896,0,0,1,0.004185220812426315
221,KNG1,G alpha (q) signalling events,0.004622405414060138,1,0,1,0.0052478331713872685
222,KNG1,G alpha (i) signalling events,0.00368643337365896,0,0,1,0.004185220812426315
223,KNG1,G alpha (i) signalling events,0.004622405414060138,1,0,1,0.0052478331713872685
224,KNG1,Platelet degranulation ,0.00368643337365896,0,0,1,0.004185220812426315
225,KNG1,Platelet degranulation ,0.004622405414060138,1,0,1,0.0052478331713872685
226,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.00368643337365896,0,0,1,0.004185220812426315
227,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.004622405414060138,1,0,1,0.0052478331713872685
228,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00368643337365896,0,0,1,0.004185220812426315
229,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004622405414060138,1,0,1,0.0052478331713872685
230,KNG1,Post-translational protein phosphorylation,0.00368643337365896,0,0,1,0.004185220812426315
231,KNG1,Post-translational protein phosphorylation,0.004622405414060138,1,0,1,0.0052478331713872685
232,IGJ,Cell surface interactions at the vascular wall,0.00012377721736929416,0,0,1,0.0001405247114839381
233,IGJ,Cell surface interactions at the vascular wall,0.0005049692991765093,1,0,1,0.0005732934265545126
234,IGJ,Scavenging of heme from plasma,0.00012377721736929416,0,0,1,0.0001405247114839381
235,IGJ,Scavenging of heme from plasma,0.0005049692991765093,1,0,1,0.0005732934265545126
236,KV117,Initial triggering of complement,0.0023210105442213217,0,0,1,0.0026350514578524597
237,KV117,Initial triggering of complement,0.001753380646162274,1,0,1,0.0019906192323612387
238,KV117,Regulation of Complement cascade,0.0023210105442213217,0,0,1,0.0026350514578524597
239,KV117,Regulation of Complement cascade,0.001753380646162274,1,0,1,0.0019906192323612387
240,KV117,FCGR activation,0.0023210105442213217,0,0,1,0.0026350514578524597
241,KV117,FCGR activation,0.001753380646162274,1,0,1,0.0019906192323612387
242,KV117,Regulation of actin dynamics for phagocytic cup formation,0.0023210105442213217,0,0,1,0.0026350514578524597
243,KV117,Regulation of actin dynamics for phagocytic cup formation,0.001753380646162274,1,0,1,0.0019906192323612387
244,KV117,Role of phospholipids in phagocytosis,0.0023210105442213217,0,0,1,0.0026350514578524597
245,KV117,Role of phospholipids in phagocytosis,0.001753380646162274,1,0,1,0.0019906192323612387
246,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023210105442213217,0,0,1,0.0026350514578524597
247,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,0.001753380646162274,1,0,1,0.0019906192323612387
248,KV117,FCERI mediated MAPK activation,0.0023210105442213217,0,0,1,0.0026350514578524597
249,KV117,FCERI mediated MAPK activation,0.001753380646162274,1,0,1,0.0019906192323612387
250,KV117,FCERI mediated Ca+2 mobilization,0.0023210105442213217,0,0,1,0.0026350514578524597
251,KV117,FCERI mediated Ca+2 mobilization,0.001753380646162274,1,0,1,0.0019906192323612387
252,KV117,FCERI mediated NF-kB activation,0.0023210105442213217,0,0,1,0.0026350514578524597
253,KV117,FCERI mediated NF-kB activation,0.001753380646162274,1,0,1,0.0019906192323612387
254,KV117,Parasite infection,0.0023210105442213217,0,0,1,0.0026350514578524597
255,KV117,Parasite infection,0.001753380646162274,1,0,1,0.0019906192323612387
256,KV117,Leishmania parasite growth and survival,0.0023210105442213217,0,0,1,0.0026350514578524597
257,KV117,Leishmania parasite growth and survival,0.001753380646162274,1,0,1,0.0019906192323612387
258,KV117,Potential therapeutics for SARS,0.0023210105442213217,0,0,1,0.0026350514578524597
259,KV117,Potential therapeutics for SARS,0.001753380646162274,1,0,1,0.0019906192323612387
260,KV117,CD22 mediated BCR regulation,0.0023210105442213217,0,0,1,0.0026350514578524597
261,KV117,CD22 mediated BCR regulation,0.001753380646162274,1,0,1,0.0019906192323612387
262,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023210105442213217,0,0,1,0.0026350514578524597
263,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001753380646162274,1,0,1,0.0019906192323612387
264,KV117,Cell surface interactions at the vascular wall,0.0023210105442213217,0,0,1,0.0026350514578524597
265,KV117,Cell surface interactions at the vascular wall,0.001753380646162274,1,0,1,0.0019906192323612387
266,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023210105442213217,0,0,1,0.0026350514578524597
267,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001753380646162274,1,0,1,0.0019906192323612387
268,KV117,Scavenging of heme from plasma,0.0023210105442213217,0,0,1,0.0026350514578524597
269,KV117,Scavenging of heme from plasma,0.001753380646162274,1,0,1,0.0019906192323612387
270,KVD16,Initial triggering of complement,0.005128959510028037,0,0,1,0.005822925823329167
271,KVD16,Initial triggering of complement,0.006681398114764296,1,0,1,0.007585414847268146
272,KVD16,Regulation of Complement cascade,0.005128959510028037,0,0,1,0.005822925823329167
273,KVD16,Regulation of Complement cascade,0.006681398114764296,1,0,1,0.007585414847268146
274,KVD16,FCGR activation,0.005128959510028037,0,0,1,0.005822925823329167
275,KVD16,FCGR activation,0.006681398114764296,1,0,1,0.007585414847268146
276,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.005128959510028037,0,0,1,0.005822925823329167
277,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.006681398114764296,1,0,1,0.007585414847268146
278,KVD16,Role of phospholipids in phagocytosis,0.005128959510028037,0,0,1,0.005822925823329167
279,KVD16,Role of phospholipids in phagocytosis,0.006681398114764296,1,0,1,0.007585414847268146
280,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.005128959510028037,0,0,1,0.005822925823329167
281,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.006681398114764296,1,0,1,0.007585414847268146
282,KVD16,FCERI mediated MAPK activation,0.005128959510028037,0,0,1,0.005822925823329167
283,KVD16,FCERI mediated MAPK activation,0.006681398114764296,1,0,1,0.007585414847268146
284,KVD16,FCERI mediated Ca+2 mobilization,0.005128959510028037,0,0,1,0.005822925823329167
285,KVD16,FCERI mediated Ca+2 mobilization,0.006681398114764296,1,0,1,0.007585414847268146
286,KVD16,FCERI mediated NF-kB activation,0.005128959510028037,0,0,1,0.005822925823329167
287,KVD16,FCERI mediated NF-kB activation,0.006681398114764296,1,0,1,0.007585414847268146
288,KVD16,Parasite infection,0.005128959510028037,0,0,1,0.005822925823329167
289,KVD16,Parasite infection,0.006681398114764296,1,0,1,0.007585414847268146
290,KVD16,Leishmania parasite growth and survival,0.005128959510028037,0,0,1,0.005822925823329167
291,KVD16,Leishmania parasite growth and survival,0.006681398114764296,1,0,1,0.007585414847268146
292,KVD16,Potential therapeutics for SARS,0.005128959510028037,0,0,1,0.005822925823329167
293,KVD16,Potential therapeutics for SARS,0.006681398114764296,1,0,1,0.007585414847268146
294,KVD16,CD22 mediated BCR regulation,0.005128959510028037,0,0,1,0.005822925823329167
295,KVD16,CD22 mediated BCR regulation,0.006681398114764296,1,0,1,0.007585414847268146
296,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005128959510028037,0,0,1,0.005822925823329167
297,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006681398114764296,1,0,1,0.007585414847268146
298,KVD16,Cell surface interactions at the vascular wall,0.005128959510028037,0,0,1,0.005822925823329167
299,KVD16,Cell surface interactions at the vascular wall,0.006681398114764296,1,0,1,0.007585414847268146
300,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005128959510028037,0,0,1,0.005822925823329167
301,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006681398114764296,1,0,1,0.007585414847268146
302,KVD16,Scavenging of heme from plasma,0.005128959510028037,0,0,1,0.005822925823329167
303,KVD16,Scavenging of heme from plasma,0.006681398114764296,1,0,1,0.007585414847268146
304,KV105,Initial triggering of complement,0.0009296435123043524,0,0,1,0.0010554275586897445
305,KV105,Initial triggering of complement,0.00036913894073760156,1,0,1,0.00041908474149869146
306,KV105,Regulation of Complement cascade,0.0009296435123043524,0,0,1,0.0010554275586897445
307,KV105,Regulation of Complement cascade,0.00036913894073760156,1,0,1,0.00041908474149869146
308,KV105,FCGR activation,0.0009296435123043524,0,0,1,0.0010554275586897445
309,KV105,FCGR activation,0.00036913894073760156,1,0,1,0.00041908474149869146
310,KV105,Regulation of actin dynamics for phagocytic cup formation,0.0009296435123043524,0,0,1,0.0010554275586897445
311,KV105,Regulation of actin dynamics for phagocytic cup formation,0.00036913894073760156,1,0,1,0.00041908474149869146
312,KV105,Role of phospholipids in phagocytosis,0.0009296435123043524,0,0,1,0.0010554275586897445
313,KV105,Role of phospholipids in phagocytosis,0.00036913894073760156,1,0,1,0.00041908474149869146
314,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009296435123043524,0,0,1,0.0010554275586897445
315,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.00036913894073760156,1,0,1,0.00041908474149869146
316,KV105,FCERI mediated MAPK activation,0.0009296435123043524,0,0,1,0.0010554275586897445
317,KV105,FCERI mediated MAPK activation,0.00036913894073760156,1,0,1,0.00041908474149869146
318,KV105,FCERI mediated Ca+2 mobilization,0.0009296435123043524,0,0,1,0.0010554275586897445
319,KV105,FCERI mediated Ca+2 mobilization,0.00036913894073760156,1,0,1,0.00041908474149869146
320,KV105,FCERI mediated NF-kB activation,0.0009296435123043524,0,0,1,0.0010554275586897445
321,KV105,FCERI mediated NF-kB activation,0.00036913894073760156,1,0,1,0.00041908474149869146
322,KV105,Parasite infection,0.0009296435123043524,0,0,1,0.0010554275586897445
323,KV105,Parasite infection,0.00036913894073760156,1,0,1,0.00041908474149869146
324,KV105,Leishmania parasite growth and survival,0.0009296435123043524,0,0,1,0.0010554275586897445
325,KV105,Leishmania parasite growth and survival,0.00036913894073760156,1,0,1,0.00041908474149869146
326,KV105,Potential therapeutics for SARS,0.0009296435123043524,0,0,1,0.0010554275586897445
327,KV105,Potential therapeutics for SARS,0.00036913894073760156,1,0,1,0.00041908474149869146
328,KV105,CD22 mediated BCR regulation,0.0009296435123043524,0,0,1,0.0010554275586897445
329,KV105,CD22 mediated BCR regulation,0.00036913894073760156,1,0,1,0.00041908474149869146
330,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009296435123043524,0,0,1,0.0010554275586897445
331,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00036913894073760156,1,0,1,0.00041908474149869146
332,KV105,Cell surface interactions at the vascular wall,0.0009296435123043524,0,0,1,0.0010554275586897445
333,KV105,Cell surface interactions at the vascular wall,0.00036913894073760156,1,0,1,0.00041908474149869146
334,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009296435123043524,0,0,1,0.0010554275586897445
335,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00036913894073760156,1,0,1,0.00041908474149869146
336,KV105,Scavenging of heme from plasma,0.0009296435123043524,0,0,1,0.0010554275586897445
337,KV105,Scavenging of heme from plasma,0.00036913894073760156,1,0,1,0.00041908474149869146
338,KV320,Initial triggering of complement,0.004815093032043597,0,0,1,0.00546659210375902
339,KV320,Initial triggering of complement,0.004432027470412569,1,0,1,0.005031696420436066
340,KV320,Regulation of Complement cascade,0.004815093032043597,0,0,1,0.00546659210375902
341,KV320,Regulation of Complement cascade,0.004432027470412569,1,0,1,0.005031696420436066
342,KV320,FCGR activation,0.004815093032043597,0,0,1,0.00546659210375902
343,KV320,FCGR activation,0.004432027470412569,1,0,1,0.005031696420436066
344,KV320,Regulation of actin dynamics for phagocytic cup formation,0.004815093032043597,0,0,1,0.00546659210375902
345,KV320,Regulation of actin dynamics for phagocytic cup formation,0.004432027470412569,1,0,1,0.005031696420436066
346,KV320,Role of phospholipids in phagocytosis,0.004815093032043597,0,0,1,0.00546659210375902
347,KV320,Role of phospholipids in phagocytosis,0.004432027470412569,1,0,1,0.005031696420436066
348,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.004815093032043597,0,0,1,0.00546659210375902
349,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.004432027470412569,1,0,1,0.005031696420436066
350,KV320,FCERI mediated MAPK activation,0.004815093032043597,0,0,1,0.00546659210375902
351,KV320,FCERI mediated MAPK activation,0.004432027470412569,1,0,1,0.005031696420436066
352,KV320,FCERI mediated Ca+2 mobilization,0.004815093032043597,0,0,1,0.00546659210375902
353,KV320,FCERI mediated Ca+2 mobilization,0.004432027470412569,1,0,1,0.005031696420436066
354,KV320,FCERI mediated NF-kB activation,0.004815093032043597,0,0,1,0.00546659210375902
355,KV320,FCERI mediated NF-kB activation,0.004432027470412569,1,0,1,0.005031696420436066
356,KV320,Parasite infection,0.004815093032043597,0,0,1,0.00546659210375902
357,KV320,Parasite infection,0.004432027470412569,1,0,1,0.005031696420436066
358,KV320,Leishmania parasite growth and survival,0.004815093032043597,0,0,1,0.00546659210375902
359,KV320,Leishmania parasite growth and survival,0.004432027470412569,1,0,1,0.005031696420436066
360,KV320,Potential therapeutics for SARS,0.004815093032043597,0,0,1,0.00546659210375902
361,KV320,Potential therapeutics for SARS,0.004432027470412569,1,0,1,0.005031696420436066
362,KV320,CD22 mediated BCR regulation,0.004815093032043597,0,0,1,0.00546659210375902
363,KV320,CD22 mediated BCR regulation,0.004432027470412569,1,0,1,0.005031696420436066
364,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004815093032043597,0,0,1,0.00546659210375902
365,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004432027470412569,1,0,1,0.005031696420436066
366,KV320,Cell surface interactions at the vascular wall,0.004815093032043597,0,0,1,0.00546659210375902
367,KV320,Cell surface interactions at the vascular wall,0.004432027470412569,1,0,1,0.005031696420436066
368,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004815093032043597,0,0,1,0.00546659210375902
369,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004432027470412569,1,0,1,0.005031696420436066
370,KV320,Scavenging of heme from plasma,0.004815093032043597,0,0,1,0.00546659210375902
371,KV320,Scavenging of heme from plasma,0.004432027470412569,1,0,1,0.005031696420436066
372,LV151,Initial triggering of complement,0.00014431807953042865,0,0,1,0.00016384482475012007
373,LV151,Initial triggering of complement,0.0007751800225567063,1,0,1,0.0008800646139336859
374,LV151,Regulation of Complement cascade,0.00014431807953042865,0,0,1,0.00016384482475012007
375,LV151,Regulation of Complement cascade,0.0007751800225567063,1,0,1,0.0008800646139336859
376,LV151,FCGR activation,0.00014431807953042865,0,0,1,0.00016384482475012007
377,LV151,FCGR activation,0.0007751800225567063,1,0,1,0.0008800646139336859
378,LV151,Regulation of actin dynamics for phagocytic cup formation,0.00014431807953042865,0,0,1,0.00016384482475012007
379,LV151,Regulation of actin dynamics for phagocytic cup formation,0.0007751800225567063,1,0,1,0.0008800646139336859
380,LV151,Role of phospholipids in phagocytosis,0.00014431807953042865,0,0,1,0.00016384482475012007
381,LV151,Role of phospholipids in phagocytosis,0.0007751800225567063,1,0,1,0.0008800646139336859
382,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.00014431807953042865,0,0,1,0.00016384482475012007
383,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007751800225567063,1,0,1,0.0008800646139336859
384,LV151,FCERI mediated MAPK activation,0.00014431807953042865,0,0,1,0.00016384482475012007
385,LV151,FCERI mediated MAPK activation,0.0007751800225567063,1,0,1,0.0008800646139336859
386,LV151,FCERI mediated Ca+2 mobilization,0.00014431807953042865,0,0,1,0.00016384482475012007
387,LV151,FCERI mediated Ca+2 mobilization,0.0007751800225567063,1,0,1,0.0008800646139336859
388,LV151,FCERI mediated NF-kB activation,0.00014431807953042865,0,0,1,0.00016384482475012007
389,LV151,FCERI mediated NF-kB activation,0.0007751800225567063,1,0,1,0.0008800646139336859
390,LV151,Parasite infection,0.00014431807953042865,0,0,1,0.00016384482475012007
391,LV151,Parasite infection,0.0007751800225567063,1,0,1,0.0008800646139336859
392,LV151,Leishmania parasite growth and survival,0.00014431807953042865,0,0,1,0.00016384482475012007
393,LV151,Leishmania parasite growth and survival,0.0007751800225567063,1,0,1,0.0008800646139336859
394,LV151,Potential therapeutics for SARS,0.00014431807953042865,0,0,1,0.00016384482475012007
395,LV151,Potential therapeutics for SARS,0.0007751800225567063,1,0,1,0.0008800646139336859
396,LV151,CD22 mediated BCR regulation,0.00014431807953042865,0,0,1,0.00016384482475012007
397,LV151,CD22 mediated BCR regulation,0.0007751800225567063,1,0,1,0.0008800646139336859
398,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00014431807953042865,0,0,1,0.00016384482475012007
399,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007751800225567063,1,0,1,0.0008800646139336859
400,LV151,Cell surface interactions at the vascular wall,0.00014431807953042865,0,0,1,0.00016384482475012007
401,LV151,Cell surface interactions at the vascular wall,0.0007751800225567063,1,0,1,0.0008800646139336859
402,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00014431807953042865,0,0,1,0.00016384482475012007
403,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007751800225567063,1,0,1,0.0008800646139336859
404,LV151,Scavenging of heme from plasma,0.00014431807953042865,0,0,1,0.00016384482475012007
405,LV151,Scavenging of heme from plasma,0.0007751800225567063,1,0,1,0.0008800646139336859
406,LV140,Initial triggering of complement,0.0007853458549150374,0,0,1,0.0008916059192684666
407,LV140,Initial triggering of complement,0.001702487781802939,1,0,1,0.001932840383937547
408,LV140,Regulation of Complement cascade,0.0007853458549150374,0,0,1,0.0008916059192684666
409,LV140,Regulation of Complement cascade,0.001702487781802939,1,0,1,0.001932840383937547
410,LV140,FCGR activation,0.0007853458549150374,0,0,1,0.0008916059192684666
411,LV140,FCGR activation,0.001702487781802939,1,0,1,0.001932840383937547
412,LV140,Regulation of actin dynamics for phagocytic cup formation,0.0007853458549150374,0,0,1,0.0008916059192684666
413,LV140,Regulation of actin dynamics for phagocytic cup formation,0.001702487781802939,1,0,1,0.001932840383937547
414,LV140,Role of phospholipids in phagocytosis,0.0007853458549150374,0,0,1,0.0008916059192684666
415,LV140,Role of phospholipids in phagocytosis,0.001702487781802939,1,0,1,0.001932840383937547
416,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007853458549150374,0,0,1,0.0008916059192684666
417,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,0.001702487781802939,1,0,1,0.001932840383937547
418,LV140,FCERI mediated MAPK activation,0.0007853458549150374,0,0,1,0.0008916059192684666
419,LV140,FCERI mediated MAPK activation,0.001702487781802939,1,0,1,0.001932840383937547
420,LV140,FCERI mediated Ca+2 mobilization,0.0007853458549150374,0,0,1,0.0008916059192684666
421,LV140,FCERI mediated Ca+2 mobilization,0.001702487781802939,1,0,1,0.001932840383937547
422,LV140,FCERI mediated NF-kB activation,0.0007853458549150374,0,0,1,0.0008916059192684666
423,LV140,FCERI mediated NF-kB activation,0.001702487781802939,1,0,1,0.001932840383937547
424,LV140,Parasite infection,0.0007853458549150374,0,0,1,0.0008916059192684666
425,LV140,Parasite infection,0.001702487781802939,1,0,1,0.001932840383937547
426,LV140,Leishmania parasite growth and survival,0.0007853458549150374,0,0,1,0.0008916059192684666
427,LV140,Leishmania parasite growth and survival,0.001702487781802939,1,0,1,0.001932840383937547
428,LV140,Potential therapeutics for SARS,0.0007853458549150374,0,0,1,0.0008916059192684666
429,LV140,Potential therapeutics for SARS,0.001702487781802939,1,0,1,0.001932840383937547
430,LV140,CD22 mediated BCR regulation,0.0007853458549150374,0,0,1,0.0008916059192684666
431,LV140,CD22 mediated BCR regulation,0.001702487781802939,1,0,1,0.001932840383937547
432,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007853458549150374,0,0,1,0.0008916059192684666
433,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001702487781802939,1,0,1,0.001932840383937547
434,LV140,Cell surface interactions at the vascular wall,0.0007853458549150374,0,0,1,0.0008916059192684666
435,LV140,Cell surface interactions at the vascular wall,0.001702487781802939,1,0,1,0.001932840383937547
436,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007853458549150374,0,0,1,0.0008916059192684666
437,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001702487781802939,1,0,1,0.001932840383937547
438,LV140,Scavenging of heme from plasma,0.0007853458549150374,0,0,1,0.0008916059192684666
439,LV140,Scavenging of heme from plasma,0.001702487781802939,1,0,1,0.001932840383937547
440,LV214,Initial triggering of complement,0.0019243894120914865,0,0,1,0.002184766087527077
441,LV214,Initial triggering of complement,0.002387295627567966,1,0,1,0.0027103051467860643
442,LV214,Regulation of Complement cascade,0.0019243894120914865,0,0,1,0.002184766087527077
443,LV214,Regulation of Complement cascade,0.002387295627567966,1,0,1,0.0027103051467860643
444,LV214,FCGR activation,0.0019243894120914865,0,0,1,0.002184766087527077
445,LV214,FCGR activation,0.002387295627567966,1,0,1,0.0027103051467860643
446,LV214,Regulation of actin dynamics for phagocytic cup formation,0.0019243894120914865,0,0,1,0.002184766087527077
447,LV214,Regulation of actin dynamics for phagocytic cup formation,0.002387295627567966,1,0,1,0.0027103051467860643
448,LV214,Role of phospholipids in phagocytosis,0.0019243894120914865,0,0,1,0.002184766087527077
449,LV214,Role of phospholipids in phagocytosis,0.002387295627567966,1,0,1,0.0027103051467860643
450,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.0019243894120914865,0,0,1,0.002184766087527077
451,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,0.002387295627567966,1,0,1,0.0027103051467860643
452,LV214,FCERI mediated MAPK activation,0.0019243894120914865,0,0,1,0.002184766087527077
453,LV214,FCERI mediated MAPK activation,0.002387295627567966,1,0,1,0.0027103051467860643
454,LV214,FCERI mediated Ca+2 mobilization,0.0019243894120914865,0,0,1,0.002184766087527077
455,LV214,FCERI mediated Ca+2 mobilization,0.002387295627567966,1,0,1,0.0027103051467860643
456,LV214,FCERI mediated NF-kB activation,0.0019243894120914865,0,0,1,0.002184766087527077
457,LV214,FCERI mediated NF-kB activation,0.002387295627567966,1,0,1,0.0027103051467860643
458,LV214,Parasite infection,0.0019243894120914865,0,0,1,0.002184766087527077
459,LV214,Parasite infection,0.002387295627567966,1,0,1,0.0027103051467860643
460,LV214,Leishmania parasite growth and survival,0.0019243894120914865,0,0,1,0.002184766087527077
461,LV214,Leishmania parasite growth and survival,0.002387295627567966,1,0,1,0.0027103051467860643
462,LV214,Potential therapeutics for SARS,0.0019243894120914865,0,0,1,0.002184766087527077
463,LV214,Potential therapeutics for SARS,0.002387295627567966,1,0,1,0.0027103051467860643
464,LV214,CD22 mediated BCR regulation,0.0019243894120914865,0,0,1,0.002184766087527077
465,LV214,CD22 mediated BCR regulation,0.002387295627567966,1,0,1,0.0027103051467860643
466,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0019243894120914865,0,0,1,0.002184766087527077
467,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002387295627567966,1,0,1,0.0027103051467860643
468,LV214,Cell surface interactions at the vascular wall,0.0019243894120914865,0,0,1,0.002184766087527077
469,LV214,Cell surface interactions at the vascular wall,0.002387295627567966,1,0,1,0.0027103051467860643
470,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0019243894120914865,0,0,1,0.002184766087527077
471,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002387295627567966,1,0,1,0.0027103051467860643
472,LV214,Scavenging of heme from plasma,0.0019243894120914865,0,0,1,0.002184766087527077
473,LV214,Scavenging of heme from plasma,0.002387295627567966,1,0,1,0.0027103051467860643
474,LV211,Initial triggering of complement,0.0004337315041770128,0,0,1,0.0004924169066115175
475,LV211,Initial triggering of complement,0.0004583857585750826,1,0,1,0.0005204069685936333
476,LV211,Regulation of Complement cascade,0.0004337315041770128,0,0,1,0.0004924169066115175
477,LV211,Regulation of Complement cascade,0.0004583857585750826,1,0,1,0.0005204069685936333
478,LV211,FCGR activation,0.0004337315041770128,0,0,1,0.0004924169066115175
479,LV211,FCGR activation,0.0004583857585750826,1,0,1,0.0005204069685936333
480,LV211,Regulation of actin dynamics for phagocytic cup formation,0.0004337315041770128,0,0,1,0.0004924169066115175
481,LV211,Regulation of actin dynamics for phagocytic cup formation,0.0004583857585750826,1,0,1,0.0005204069685936333
482,LV211,Role of phospholipids in phagocytosis,0.0004337315041770128,0,0,1,0.0004924169066115175
483,LV211,Role of phospholipids in phagocytosis,0.0004583857585750826,1,0,1,0.0005204069685936333
484,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004337315041770128,0,0,1,0.0004924169066115175
485,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004583857585750826,1,0,1,0.0005204069685936333
486,LV211,FCERI mediated MAPK activation,0.0004337315041770128,0,0,1,0.0004924169066115175
487,LV211,FCERI mediated MAPK activation,0.0004583857585750826,1,0,1,0.0005204069685936333
488,LV211,FCERI mediated Ca+2 mobilization,0.0004337315041770128,0,0,1,0.0004924169066115175
489,LV211,FCERI mediated Ca+2 mobilization,0.0004583857585750826,1,0,1,0.0005204069685936333
490,LV211,FCERI mediated NF-kB activation,0.0004337315041770128,0,0,1,0.0004924169066115175
491,LV211,FCERI mediated NF-kB activation,0.0004583857585750826,1,0,1,0.0005204069685936333
492,LV211,Parasite infection,0.0004337315041770128,0,0,1,0.0004924169066115175
493,LV211,Parasite infection,0.0004583857585750826,1,0,1,0.0005204069685936333
494,LV211,Leishmania parasite growth and survival,0.0004337315041770128,0,0,1,0.0004924169066115175
495,LV211,Leishmania parasite growth and survival,0.0004583857585750826,1,0,1,0.0005204069685936333
496,LV211,Potential therapeutics for SARS,0.0004337315041770128,0,0,1,0.0004924169066115175
497,LV211,Potential therapeutics for SARS,0.0004583857585750826,1,0,1,0.0005204069685936333
498,LV211,CD22 mediated BCR regulation,0.0004337315041770128,0,0,1,0.0004924169066115175
499,LV211,CD22 mediated BCR regulation,0.0004583857585750826,1,0,1,0.0005204069685936333
500,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004337315041770128,0,0,1,0.0004924169066115175
501,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004583857585750826,1,0,1,0.0005204069685936333
502,LV211,Cell surface interactions at the vascular wall,0.0004337315041770128,0,0,1,0.0004924169066115175
503,LV211,Cell surface interactions at the vascular wall,0.0004583857585750826,1,0,1,0.0005204069685936333
504,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004337315041770128,0,0,1,0.0004924169066115175
505,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004583857585750826,1,0,1,0.0005204069685936333
506,LV211,Scavenging of heme from plasma,0.0004337315041770128,0,0,1,0.0004924169066115175
507,LV211,Scavenging of heme from plasma,0.0004583857585750826,1,0,1,0.0005204069685936333
508,LV208,Initial triggering of complement,0.0005183861496177718,0,0,1,0.000588525624186298
509,LV208,Initial triggering of complement,0.0017936489216924772,1,0,1,0.002036335947610658
510,LV208,Regulation of Complement cascade,0.0005183861496177718,0,0,1,0.000588525624186298
511,LV208,Regulation of Complement cascade,0.0017936489216924772,1,0,1,0.002036335947610658
512,LV208,FCGR activation,0.0005183861496177718,0,0,1,0.000588525624186298
513,LV208,FCGR activation,0.0017936489216924772,1,0,1,0.002036335947610658
514,LV208,Regulation of actin dynamics for phagocytic cup formation,0.0005183861496177718,0,0,1,0.000588525624186298
515,LV208,Regulation of actin dynamics for phagocytic cup formation,0.0017936489216924772,1,0,1,0.002036335947610658
516,LV208,Role of phospholipids in phagocytosis,0.0005183861496177718,0,0,1,0.000588525624186298
517,LV208,Role of phospholipids in phagocytosis,0.0017936489216924772,1,0,1,0.002036335947610658
518,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.0005183861496177718,0,0,1,0.000588525624186298
519,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,0.0017936489216924772,1,0,1,0.002036335947610658
520,LV208,FCERI mediated MAPK activation,0.0005183861496177718,0,0,1,0.000588525624186298
521,LV208,FCERI mediated MAPK activation,0.0017936489216924772,1,0,1,0.002036335947610658
522,LV208,FCERI mediated Ca+2 mobilization,0.0005183861496177718,0,0,1,0.000588525624186298
523,LV208,FCERI mediated Ca+2 mobilization,0.0017936489216924772,1,0,1,0.002036335947610658
524,LV208,FCERI mediated NF-kB activation,0.0005183861496177718,0,0,1,0.000588525624186298
525,LV208,FCERI mediated NF-kB activation,0.0017936489216924772,1,0,1,0.002036335947610658
526,LV208,Parasite infection,0.0005183861496177718,0,0,1,0.000588525624186298
527,LV208,Parasite infection,0.0017936489216924772,1,0,1,0.002036335947610658
528,LV208,Leishmania parasite growth and survival,0.0005183861496177718,0,0,1,0.000588525624186298
529,LV208,Leishmania parasite growth and survival,0.0017936489216924772,1,0,1,0.002036335947610658
530,LV208,Potential therapeutics for SARS,0.0005183861496177718,0,0,1,0.000588525624186298
531,LV208,Potential therapeutics for SARS,0.0017936489216924772,1,0,1,0.002036335947610658
532,LV208,CD22 mediated BCR regulation,0.0005183861496177718,0,0,1,0.000588525624186298
533,LV208,CD22 mediated BCR regulation,0.0017936489216924772,1,0,1,0.002036335947610658
534,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005183861496177718,0,0,1,0.000588525624186298
535,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0017936489216924772,1,0,1,0.002036335947610658
536,LV208,Cell surface interactions at the vascular wall,0.0005183861496177718,0,0,1,0.000588525624186298
537,LV208,Cell surface interactions at the vascular wall,0.0017936489216924772,1,0,1,0.002036335947610658
538,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005183861496177718,0,0,1,0.000588525624186298
539,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0017936489216924772,1,0,1,0.002036335947610658
540,LV208,Scavenging of heme from plasma,0.0005183861496177718,0,0,1,0.000588525624186298
541,LV208,Scavenging of heme from plasma,0.0017936489216924772,1,0,1,0.002036335947610658
542,LV319,Initial triggering of complement,0.0013708939445416506,0,0,1,0.0015563807308499348
543,LV319,Initial triggering of complement,0.0018733440596376133,1,0,1,0.002126814118831779
544,LV319,Regulation of Complement cascade,0.0013708939445416506,0,0,1,0.0015563807308499348
545,LV319,Regulation of Complement cascade,0.0018733440596376133,1,0,1,0.002126814118831779
546,LV319,FCGR activation,0.0013708939445416506,0,0,1,0.0015563807308499348
547,LV319,FCGR activation,0.0018733440596376133,1,0,1,0.002126814118831779
548,LV319,Regulation of actin dynamics for phagocytic cup formation,0.0013708939445416506,0,0,1,0.0015563807308499348
549,LV319,Regulation of actin dynamics for phagocytic cup formation,0.0018733440596376133,1,0,1,0.002126814118831779
550,LV319,Role of phospholipids in phagocytosis,0.0013708939445416506,0,0,1,0.0015563807308499348
551,LV319,Role of phospholipids in phagocytosis,0.0018733440596376133,1,0,1,0.002126814118831779
552,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013708939445416506,0,0,1,0.0015563807308499348
553,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.0018733440596376133,1,0,1,0.002126814118831779
554,LV319,FCERI mediated MAPK activation,0.0013708939445416506,0,0,1,0.0015563807308499348
555,LV319,FCERI mediated MAPK activation,0.0018733440596376133,1,0,1,0.002126814118831779
556,LV319,FCERI mediated Ca+2 mobilization,0.0013708939445416506,0,0,1,0.0015563807308499348
557,LV319,FCERI mediated Ca+2 mobilization,0.0018733440596376133,1,0,1,0.002126814118831779
558,LV319,FCERI mediated NF-kB activation,0.0013708939445416506,0,0,1,0.0015563807308499348
559,LV319,FCERI mediated NF-kB activation,0.0018733440596376133,1,0,1,0.002126814118831779
560,LV319,Parasite infection,0.0013708939445416506,0,0,1,0.0015563807308499348
561,LV319,Parasite infection,0.0018733440596376133,1,0,1,0.002126814118831779
562,LV319,Leishmania parasite growth and survival,0.0013708939445416506,0,0,1,0.0015563807308499348
563,LV319,Leishmania parasite growth and survival,0.0018733440596376133,1,0,1,0.002126814118831779
564,LV319,Potential therapeutics for SARS,0.0013708939445416506,0,0,1,0.0015563807308499348
565,LV319,Potential therapeutics for SARS,0.0018733440596376133,1,0,1,0.002126814118831779
566,LV319,CD22 mediated BCR regulation,0.0013708939445416506,0,0,1,0.0015563807308499348
567,LV319,CD22 mediated BCR regulation,0.0018733440596376133,1,0,1,0.002126814118831779
568,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013708939445416506,0,0,1,0.0015563807308499348
569,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0018733440596376133,1,0,1,0.002126814118831779
570,LV319,Cell surface interactions at the vascular wall,0.0013708939445416506,0,0,1,0.0015563807308499348
571,LV319,Cell surface interactions at the vascular wall,0.0018733440596376133,1,0,1,0.002126814118831779
572,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013708939445416506,0,0,1,0.0015563807308499348
573,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0018733440596376133,1,0,1,0.002126814118831779
574,LV319,Scavenging of heme from plasma,0.0013708939445416506,0,0,1,0.0015563807308499348
575,LV319,Scavenging of heme from plasma,0.0018733440596376133,1,0,1,0.002126814118831779
576,LV301,Initial triggering of complement,0.000712101653059321,0,0,1,0.0008084515185443217
577,LV301,Initial triggering of complement,0.0006145337803100861,1,0,1,0.0006976823684568592
578,LV301,Regulation of Complement cascade,0.000712101653059321,0,0,1,0.0008084515185443217
579,LV301,Regulation of Complement cascade,0.0006145337803100861,1,0,1,0.0006976823684568592
580,LV301,FCGR activation,0.000712101653059321,0,0,1,0.0008084515185443217
581,LV301,FCGR activation,0.0006145337803100861,1,0,1,0.0006976823684568592
582,LV301,Regulation of actin dynamics for phagocytic cup formation,0.000712101653059321,0,0,1,0.0008084515185443217
583,LV301,Regulation of actin dynamics for phagocytic cup formation,0.0006145337803100861,1,0,1,0.0006976823684568592
584,LV301,Role of phospholipids in phagocytosis,0.000712101653059321,0,0,1,0.0008084515185443217
585,LV301,Role of phospholipids in phagocytosis,0.0006145337803100861,1,0,1,0.0006976823684568592
586,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.000712101653059321,0,0,1,0.0008084515185443217
587,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006145337803100861,1,0,1,0.0006976823684568592
588,LV301,FCERI mediated MAPK activation,0.000712101653059321,0,0,1,0.0008084515185443217
589,LV301,FCERI mediated MAPK activation,0.0006145337803100861,1,0,1,0.0006976823684568592
590,LV301,FCERI mediated Ca+2 mobilization,0.000712101653059321,0,0,1,0.0008084515185443217
591,LV301,FCERI mediated Ca+2 mobilization,0.0006145337803100861,1,0,1,0.0006976823684568592
592,LV301,FCERI mediated NF-kB activation,0.000712101653059321,0,0,1,0.0008084515185443217
593,LV301,FCERI mediated NF-kB activation,0.0006145337803100861,1,0,1,0.0006976823684568592
594,LV301,Parasite infection,0.000712101653059321,0,0,1,0.0008084515185443217
595,LV301,Parasite infection,0.0006145337803100861,1,0,1,0.0006976823684568592
596,LV301,Leishmania parasite growth and survival,0.000712101653059321,0,0,1,0.0008084515185443217
597,LV301,Leishmania parasite growth and survival,0.0006145337803100861,1,0,1,0.0006976823684568592
598,LV301,Potential therapeutics for SARS,0.000712101653059321,0,0,1,0.0008084515185443217
599,LV301,Potential therapeutics for SARS,0.0006145337803100861,1,0,1,0.0006976823684568592
600,LV301,CD22 mediated BCR regulation,0.000712101653059321,0,0,1,0.0008084515185443217
601,LV301,CD22 mediated BCR regulation,0.0006145337803100861,1,0,1,0.0006976823684568592
602,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000712101653059321,0,0,1,0.0008084515185443217
603,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006145337803100861,1,0,1,0.0006976823684568592
604,LV301,Cell surface interactions at the vascular wall,0.000712101653059321,0,0,1,0.0008084515185443217
605,LV301,Cell surface interactions at the vascular wall,0.0006145337803100861,1,0,1,0.0006976823684568592
606,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000712101653059321,0,0,1,0.0008084515185443217
607,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006145337803100861,1,0,1,0.0006976823684568592
608,LV301,Scavenging of heme from plasma,0.000712101653059321,0,0,1,0.0008084515185443217
609,LV301,Scavenging of heme from plasma,0.0006145337803100861,1,0,1,0.0006976823684568592
610,LV325,Initial triggering of complement,0.006894404784153694,0,0,1,0.007827242070373303
611,LV325,Initial triggering of complement,0.007862485668293555,1,0,1,0.008926307712889657
612,LV325,Regulation of Complement cascade,0.006894404784153694,0,0,1,0.007827242070373303
613,LV325,Regulation of Complement cascade,0.007862485668293555,1,0,1,0.008926307712889657
614,LV325,FCGR activation,0.006894404784153694,0,0,1,0.007827242070373303
615,LV325,FCGR activation,0.007862485668293555,1,0,1,0.008926307712889657
616,LV325,Regulation of actin dynamics for phagocytic cup formation,0.006894404784153694,0,0,1,0.007827242070373303
617,LV325,Regulation of actin dynamics for phagocytic cup formation,0.007862485668293555,1,0,1,0.008926307712889657
618,LV325,Role of phospholipids in phagocytosis,0.006894404784153694,0,0,1,0.007827242070373303
619,LV325,Role of phospholipids in phagocytosis,0.007862485668293555,1,0,1,0.008926307712889657
620,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.006894404784153694,0,0,1,0.007827242070373303
621,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.007862485668293555,1,0,1,0.008926307712889657
622,LV325,FCERI mediated MAPK activation,0.006894404784153694,0,0,1,0.007827242070373303
623,LV325,FCERI mediated MAPK activation,0.007862485668293555,1,0,1,0.008926307712889657
624,LV325,FCERI mediated Ca+2 mobilization,0.006894404784153694,0,0,1,0.007827242070373303
625,LV325,FCERI mediated Ca+2 mobilization,0.007862485668293555,1,0,1,0.008926307712889657
626,LV325,FCERI mediated NF-kB activation,0.006894404784153694,0,0,1,0.007827242070373303
627,LV325,FCERI mediated NF-kB activation,0.007862485668293555,1,0,1,0.008926307712889657
628,LV325,Parasite infection,0.006894404784153694,0,0,1,0.007827242070373303
629,LV325,Parasite infection,0.007862485668293555,1,0,1,0.008926307712889657
630,LV325,Leishmania parasite growth and survival,0.006894404784153694,0,0,1,0.007827242070373303
631,LV325,Leishmania parasite growth and survival,0.007862485668293555,1,0,1,0.008926307712889657
632,LV325,Potential therapeutics for SARS,0.006894404784153694,0,0,1,0.007827242070373303
633,LV325,Potential therapeutics for SARS,0.007862485668293555,1,0,1,0.008926307712889657
634,LV325,CD22 mediated BCR regulation,0.006894404784153694,0,0,1,0.007827242070373303
635,LV325,CD22 mediated BCR regulation,0.007862485668293555,1,0,1,0.008926307712889657
636,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006894404784153694,0,0,1,0.007827242070373303
637,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007862485668293555,1,0,1,0.008926307712889657
638,LV325,Cell surface interactions at the vascular wall,0.006894404784153694,0,0,1,0.007827242070373303
639,LV325,Cell surface interactions at the vascular wall,0.007862485668293555,1,0,1,0.008926307712889657
640,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006894404784153694,0,0,1,0.007827242070373303
641,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007862485668293555,1,0,1,0.008926307712889657
642,LV325,Scavenging of heme from plasma,0.006894404784153694,0,0,1,0.007827242070373303
643,LV325,Scavenging of heme from plasma,0.007862485668293555,1,0,1,0.008926307712889657
644,LV327,Initial triggering of complement,0.004031236359354426,0,0,1,0.004576676858324433
645,LV327,Initial triggering of complement,0.0034753602983088067,1,0,1,0.003945588805454361
646,LV327,Regulation of Complement cascade,0.004031236359354426,0,0,1,0.004576676858324433
647,LV327,Regulation of Complement cascade,0.0034753602983088067,1,0,1,0.003945588805454361
648,LV327,FCGR activation,0.004031236359354426,0,0,1,0.004576676858324433
649,LV327,FCGR activation,0.0034753602983088067,1,0,1,0.003945588805454361
650,LV327,Regulation of actin dynamics for phagocytic cup formation,0.004031236359354426,0,0,1,0.004576676858324433
651,LV327,Regulation of actin dynamics for phagocytic cup formation,0.0034753602983088067,1,0,1,0.003945588805454361
652,LV327,Role of phospholipids in phagocytosis,0.004031236359354426,0,0,1,0.004576676858324433
653,LV327,Role of phospholipids in phagocytosis,0.0034753602983088067,1,0,1,0.003945588805454361
654,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.004031236359354426,0,0,1,0.004576676858324433
655,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,0.0034753602983088067,1,0,1,0.003945588805454361
656,LV327,FCERI mediated MAPK activation,0.004031236359354426,0,0,1,0.004576676858324433
657,LV327,FCERI mediated MAPK activation,0.0034753602983088067,1,0,1,0.003945588805454361
658,LV327,FCERI mediated Ca+2 mobilization,0.004031236359354426,0,0,1,0.004576676858324433
659,LV327,FCERI mediated Ca+2 mobilization,0.0034753602983088067,1,0,1,0.003945588805454361
660,LV327,FCERI mediated NF-kB activation,0.004031236359354426,0,0,1,0.004576676858324433
661,LV327,FCERI mediated NF-kB activation,0.0034753602983088067,1,0,1,0.003945588805454361
662,LV327,Parasite infection,0.004031236359354426,0,0,1,0.004576676858324433
663,LV327,Parasite infection,0.0034753602983088067,1,0,1,0.003945588805454361
664,LV327,Leishmania parasite growth and survival,0.004031236359354426,0,0,1,0.004576676858324433
665,LV327,Leishmania parasite growth and survival,0.0034753602983088067,1,0,1,0.003945588805454361
666,LV327,Potential therapeutics for SARS,0.004031236359354426,0,0,1,0.004576676858324433
667,LV327,Potential therapeutics for SARS,0.0034753602983088067,1,0,1,0.003945588805454361
668,LV327,CD22 mediated BCR regulation,0.004031236359354426,0,0,1,0.004576676858324433
669,LV327,CD22 mediated BCR regulation,0.0034753602983088067,1,0,1,0.003945588805454361
670,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004031236359354426,0,0,1,0.004576676858324433
671,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0034753602983088067,1,0,1,0.003945588805454361
672,LV327,Cell surface interactions at the vascular wall,0.004031236359354426,0,0,1,0.004576676858324433
673,LV327,Cell surface interactions at the vascular wall,0.0034753602983088067,1,0,1,0.003945588805454361
674,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004031236359354426,0,0,1,0.004576676858324433
675,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0034753602983088067,1,0,1,0.003945588805454361
676,LV327,Scavenging of heme from plasma,0.004031236359354426,0,0,1,0.004576676858324433
677,LV327,Scavenging of heme from plasma,0.0034753602983088067,1,0,1,0.003945588805454361
678,LV657,Initial triggering of complement,0.0013780525299717755,0,0,1,0.0015645078981395347
679,LV657,Initial triggering of complement,0.002170820396242384,1,0,1,0.0024645400530799535
680,LV657,Regulation of Complement cascade,0.0013780525299717755,0,0,1,0.0015645078981395347
681,LV657,Regulation of Complement cascade,0.002170820396242384,1,0,1,0.0024645400530799535
682,LV657,FCGR activation,0.0013780525299717755,0,0,1,0.0015645078981395347
683,LV657,FCGR activation,0.002170820396242384,1,0,1,0.0024645400530799535
684,LV657,Regulation of actin dynamics for phagocytic cup formation,0.0013780525299717755,0,0,1,0.0015645078981395347
685,LV657,Regulation of actin dynamics for phagocytic cup formation,0.002170820396242384,1,0,1,0.0024645400530799535
686,LV657,Role of phospholipids in phagocytosis,0.0013780525299717755,0,0,1,0.0015645078981395347
687,LV657,Role of phospholipids in phagocytosis,0.002170820396242384,1,0,1,0.0024645400530799535
688,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.0013780525299717755,0,0,1,0.0015645078981395347
689,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,0.002170820396242384,1,0,1,0.0024645400530799535
690,LV657,FCERI mediated MAPK activation,0.0013780525299717755,0,0,1,0.0015645078981395347
691,LV657,FCERI mediated MAPK activation,0.002170820396242384,1,0,1,0.0024645400530799535
692,LV657,FCERI mediated Ca+2 mobilization,0.0013780525299717755,0,0,1,0.0015645078981395347
693,LV657,FCERI mediated Ca+2 mobilization,0.002170820396242384,1,0,1,0.0024645400530799535
694,LV657,FCERI mediated NF-kB activation,0.0013780525299717755,0,0,1,0.0015645078981395347
695,LV657,FCERI mediated NF-kB activation,0.002170820396242384,1,0,1,0.0024645400530799535
696,LV657,Parasite infection,0.0013780525299717755,0,0,1,0.0015645078981395347
697,LV657,Parasite infection,0.002170820396242384,1,0,1,0.0024645400530799535
698,LV657,Leishmania parasite growth and survival,0.0013780525299717755,0,0,1,0.0015645078981395347
699,LV657,Leishmania parasite growth and survival,0.002170820396242384,1,0,1,0.0024645400530799535
700,LV657,Potential therapeutics for SARS,0.0013780525299717755,0,0,1,0.0015645078981395347
701,LV657,Potential therapeutics for SARS,0.002170820396242384,1,0,1,0.0024645400530799535
702,LV657,CD22 mediated BCR regulation,0.0013780525299717755,0,0,1,0.0015645078981395347
703,LV657,CD22 mediated BCR regulation,0.002170820396242384,1,0,1,0.0024645400530799535
704,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0013780525299717755,0,0,1,0.0015645078981395347
705,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002170820396242384,1,0,1,0.0024645400530799535
706,LV657,Cell surface interactions at the vascular wall,0.0013780525299717755,0,0,1,0.0015645078981395347
707,LV657,Cell surface interactions at the vascular wall,0.002170820396242384,1,0,1,0.0024645400530799535
708,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0013780525299717755,0,0,1,0.0015645078981395347
709,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002170820396242384,1,0,1,0.0024645400530799535
710,LV657,Scavenging of heme from plasma,0.0013780525299717755,0,0,1,0.0015645078981395347
711,LV657,Scavenging of heme from plasma,0.002170820396242384,1,0,1,0.0024645400530799535
712,HV169,Initial triggering of complement,0.0012195398653179115,0,0,1,0.0013845479108296219
713,HV169,Initial triggering of complement,0.00041270577598870653,1,0,1,0.00046854632323439907
714,HV169,Regulation of Complement cascade,0.0012195398653179115,0,0,1,0.0013845479108296219
715,HV169,Regulation of Complement cascade,0.00041270577598870653,1,0,1,0.00046854632323439907
716,HV169,FCGR activation,0.0012195398653179115,0,0,1,0.0013845479108296219
717,HV169,FCGR activation,0.00041270577598870653,1,0,1,0.00046854632323439907
718,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0012195398653179115,0,0,1,0.0013845479108296219
719,HV169,Regulation of actin dynamics for phagocytic cup formation,0.00041270577598870653,1,0,1,0.00046854632323439907
720,HV169,Role of phospholipids in phagocytosis,0.0012195398653179115,0,0,1,0.0013845479108296219
721,HV169,Role of phospholipids in phagocytosis,0.00041270577598870653,1,0,1,0.00046854632323439907
722,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0012195398653179115,0,0,1,0.0013845479108296219
723,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.00041270577598870653,1,0,1,0.00046854632323439907
724,HV169,FCERI mediated MAPK activation,0.0012195398653179115,0,0,1,0.0013845479108296219
725,HV169,FCERI mediated MAPK activation,0.00041270577598870653,1,0,1,0.00046854632323439907
726,HV169,FCERI mediated Ca+2 mobilization,0.0012195398653179115,0,0,1,0.0013845479108296219
727,HV169,FCERI mediated Ca+2 mobilization,0.00041270577598870653,1,0,1,0.00046854632323439907
728,HV169,FCERI mediated NF-kB activation,0.0012195398653179115,0,0,1,0.0013845479108296219
729,HV169,FCERI mediated NF-kB activation,0.00041270577598870653,1,0,1,0.00046854632323439907
730,HV169,Parasite infection,0.0012195398653179115,0,0,1,0.0013845479108296219
731,HV169,Parasite infection,0.00041270577598870653,1,0,1,0.00046854632323439907
732,HV169,Leishmania parasite growth and survival,0.0012195398653179115,0,0,1,0.0013845479108296219
733,HV169,Leishmania parasite growth and survival,0.00041270577598870653,1,0,1,0.00046854632323439907
734,HV169,Potential therapeutics for SARS,0.0012195398653179115,0,0,1,0.0013845479108296219
735,HV169,Potential therapeutics for SARS,0.00041270577598870653,1,0,1,0.00046854632323439907
736,HV169,CD22 mediated BCR regulation,0.0012195398653179115,0,0,1,0.0013845479108296219
737,HV169,CD22 mediated BCR regulation,0.00041270577598870653,1,0,1,0.00046854632323439907
738,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0012195398653179115,0,0,1,0.0013845479108296219
739,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00041270577598870653,1,0,1,0.00046854632323439907
740,HV169,Cell surface interactions at the vascular wall,0.0012195398653179115,0,0,1,0.0013845479108296219
741,HV169,Cell surface interactions at the vascular wall,0.00041270577598870653,1,0,1,0.00046854632323439907
742,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0012195398653179115,0,0,1,0.0013845479108296219
743,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00041270577598870653,1,0,1,0.00046854632323439907
744,HV169,Scavenging of heme from plasma,0.0012195398653179115,0,0,1,0.0013845479108296219
745,HV169,Scavenging of heme from plasma,0.00041270577598870653,1,0,1,0.00046854632323439907
746,HV146,Initial triggering of complement,0.005323477410627468,0,0,1,0.006043762682010863
747,HV146,Initial triggering of complement,0.004708186973939082,1,0,1,0.005345221278898734
748,HV146,Regulation of Complement cascade,0.005323477410627468,0,0,1,0.006043762682010863
749,HV146,Regulation of Complement cascade,0.004708186973939082,1,0,1,0.005345221278898734
750,HV146,FCGR activation,0.005323477410627468,0,0,1,0.006043762682010863
751,HV146,FCGR activation,0.004708186973939082,1,0,1,0.005345221278898734
752,HV146,Regulation of actin dynamics for phagocytic cup formation,0.005323477410627468,0,0,1,0.006043762682010863
753,HV146,Regulation of actin dynamics for phagocytic cup formation,0.004708186973939082,1,0,1,0.005345221278898734
754,HV146,Role of phospholipids in phagocytosis,0.005323477410627468,0,0,1,0.006043762682010863
755,HV146,Role of phospholipids in phagocytosis,0.004708186973939082,1,0,1,0.005345221278898734
756,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.005323477410627468,0,0,1,0.006043762682010863
757,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.004708186973939082,1,0,1,0.005345221278898734
758,HV146,FCERI mediated MAPK activation,0.005323477410627468,0,0,1,0.006043762682010863
759,HV146,FCERI mediated MAPK activation,0.004708186973939082,1,0,1,0.005345221278898734
760,HV146,FCERI mediated Ca+2 mobilization,0.005323477410627468,0,0,1,0.006043762682010863
761,HV146,FCERI mediated Ca+2 mobilization,0.004708186973939082,1,0,1,0.005345221278898734
762,HV146,FCERI mediated NF-kB activation,0.005323477410627468,0,0,1,0.006043762682010863
763,HV146,FCERI mediated NF-kB activation,0.004708186973939082,1,0,1,0.005345221278898734
764,HV146,Parasite infection,0.005323477410627468,0,0,1,0.006043762682010863
765,HV146,Parasite infection,0.004708186973939082,1,0,1,0.005345221278898734
766,HV146,Leishmania parasite growth and survival,0.005323477410627468,0,0,1,0.006043762682010863
767,HV146,Leishmania parasite growth and survival,0.004708186973939082,1,0,1,0.005345221278898734
768,HV146,Potential therapeutics for SARS,0.005323477410627468,0,0,1,0.006043762682010863
769,HV146,Potential therapeutics for SARS,0.004708186973939082,1,0,1,0.005345221278898734
770,HV146,CD22 mediated BCR regulation,0.005323477410627468,0,0,1,0.006043762682010863
771,HV146,CD22 mediated BCR regulation,0.004708186973939082,1,0,1,0.005345221278898734
772,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005323477410627468,0,0,1,0.006043762682010863
773,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004708186973939082,1,0,1,0.005345221278898734
774,HV146,Cell surface interactions at the vascular wall,0.005323477410627468,0,0,1,0.006043762682010863
775,HV146,Cell surface interactions at the vascular wall,0.004708186973939082,1,0,1,0.005345221278898734
776,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005323477410627468,0,0,1,0.006043762682010863
777,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004708186973939082,1,0,1,0.005345221278898734
778,HV146,Scavenging of heme from plasma,0.005323477410627468,0,0,1,0.006043762682010863
779,HV146,Scavenging of heme from plasma,0.004708186973939082,1,0,1,0.005345221278898734
780,HV348,Initial triggering of complement,0.000391319550359381,0,0,1,0.0004442664658408937
781,HV348,Initial triggering of complement,0.00021846585326515663,1,0,1,0.00024802505381571385
782,HV348,Regulation of Complement cascade,0.000391319550359381,0,0,1,0.0004442664658408937
783,HV348,Regulation of Complement cascade,0.00021846585326515663,1,0,1,0.00024802505381571385
784,HV348,FCGR activation,0.000391319550359381,0,0,1,0.0004442664658408937
785,HV348,FCGR activation,0.00021846585326515663,1,0,1,0.00024802505381571385
786,HV348,Regulation of actin dynamics for phagocytic cup formation,0.000391319550359381,0,0,1,0.0004442664658408937
787,HV348,Regulation of actin dynamics for phagocytic cup formation,0.00021846585326515663,1,0,1,0.00024802505381571385
788,HV348,Role of phospholipids in phagocytosis,0.000391319550359381,0,0,1,0.0004442664658408937
789,HV348,Role of phospholipids in phagocytosis,0.00021846585326515663,1,0,1,0.00024802505381571385
790,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.000391319550359381,0,0,1,0.0004442664658408937
791,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.00021846585326515663,1,0,1,0.00024802505381571385
792,HV348,FCERI mediated MAPK activation,0.000391319550359381,0,0,1,0.0004442664658408937
793,HV348,FCERI mediated MAPK activation,0.00021846585326515663,1,0,1,0.00024802505381571385
794,HV348,FCERI mediated Ca+2 mobilization,0.000391319550359381,0,0,1,0.0004442664658408937
795,HV348,FCERI mediated Ca+2 mobilization,0.00021846585326515663,1,0,1,0.00024802505381571385
796,HV348,FCERI mediated NF-kB activation,0.000391319550359381,0,0,1,0.0004442664658408937
797,HV348,FCERI mediated NF-kB activation,0.00021846585326515663,1,0,1,0.00024802505381571385
798,HV348,Parasite infection,0.000391319550359381,0,0,1,0.0004442664658408937
799,HV348,Parasite infection,0.00021846585326515663,1,0,1,0.00024802505381571385
800,HV348,Leishmania parasite growth and survival,0.000391319550359381,0,0,1,0.0004442664658408937
801,HV348,Leishmania parasite growth and survival,0.00021846585326515663,1,0,1,0.00024802505381571385
802,HV348,Potential therapeutics for SARS,0.000391319550359381,0,0,1,0.0004442664658408937
803,HV348,Potential therapeutics for SARS,0.00021846585326515663,1,0,1,0.00024802505381571385
804,HV348,CD22 mediated BCR regulation,0.000391319550359381,0,0,1,0.0004442664658408937
805,HV348,CD22 mediated BCR regulation,0.00021846585326515663,1,0,1,0.00024802505381571385
806,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000391319550359381,0,0,1,0.0004442664658408937
807,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00021846585326515663,1,0,1,0.00024802505381571385
808,HV348,Cell surface interactions at the vascular wall,0.000391319550359381,0,0,1,0.0004442664658408937
809,HV348,Cell surface interactions at the vascular wall,0.00021846585326515663,1,0,1,0.00024802505381571385
810,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000391319550359381,0,0,1,0.0004442664658408937
811,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00021846585326515663,1,0,1,0.00024802505381571385
812,HV348,Scavenging of heme from plasma,0.000391319550359381,0,0,1,0.0004442664658408937
813,HV348,Scavenging of heme from plasma,0.00021846585326515663,1,0,1,0.00024802505381571385
814,HV323,Initial triggering of complement,0.0031181172268500814,0,0,1,0.003540009486308777
815,HV323,Initial triggering of complement,0.004613950425166266,1,0,1,0.005238234192672418
816,HV323,Regulation of Complement cascade,0.0031181172268500814,0,0,1,0.003540009486308777
817,HV323,Regulation of Complement cascade,0.004613950425166266,1,0,1,0.005238234192672418
818,HV323,FCGR activation,0.0031181172268500814,0,0,1,0.003540009486308777
819,HV323,FCGR activation,0.004613950425166266,1,0,1,0.005238234192672418
820,HV323,Regulation of actin dynamics for phagocytic cup formation,0.0031181172268500814,0,0,1,0.003540009486308777
821,HV323,Regulation of actin dynamics for phagocytic cup formation,0.004613950425166266,1,0,1,0.005238234192672418
822,HV323,Role of phospholipids in phagocytosis,0.0031181172268500814,0,0,1,0.003540009486308777
823,HV323,Role of phospholipids in phagocytosis,0.004613950425166266,1,0,1,0.005238234192672418
824,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.0031181172268500814,0,0,1,0.003540009486308777
825,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.004613950425166266,1,0,1,0.005238234192672418
826,HV323,FCERI mediated MAPK activation,0.0031181172268500814,0,0,1,0.003540009486308777
827,HV323,FCERI mediated MAPK activation,0.004613950425166266,1,0,1,0.005238234192672418
828,HV323,FCERI mediated Ca+2 mobilization,0.0031181172268500814,0,0,1,0.003540009486308777
829,HV323,FCERI mediated Ca+2 mobilization,0.004613950425166266,1,0,1,0.005238234192672418
830,HV323,FCERI mediated NF-kB activation,0.0031181172268500814,0,0,1,0.003540009486308777
831,HV323,FCERI mediated NF-kB activation,0.004613950425166266,1,0,1,0.005238234192672418
832,HV323,Parasite infection,0.0031181172268500814,0,0,1,0.003540009486308777
833,HV323,Parasite infection,0.004613950425166266,1,0,1,0.005238234192672418
834,HV323,Leishmania parasite growth and survival,0.0031181172268500814,0,0,1,0.003540009486308777
835,HV323,Leishmania parasite growth and survival,0.004613950425166266,1,0,1,0.005238234192672418
836,HV323,Potential therapeutics for SARS,0.0031181172268500814,0,0,1,0.003540009486308777
837,HV323,Potential therapeutics for SARS,0.004613950425166266,1,0,1,0.005238234192672418
838,HV323,CD22 mediated BCR regulation,0.0031181172268500814,0,0,1,0.003540009486308777
839,HV323,CD22 mediated BCR regulation,0.004613950425166266,1,0,1,0.005238234192672418
840,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0031181172268500814,0,0,1,0.003540009486308777
841,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004613950425166266,1,0,1,0.005238234192672418
842,HV323,Cell surface interactions at the vascular wall,0.0031181172268500814,0,0,1,0.003540009486308777
843,HV323,Cell surface interactions at the vascular wall,0.004613950425166266,1,0,1,0.005238234192672418
844,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031181172268500814,0,0,1,0.003540009486308777
845,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004613950425166266,1,0,1,0.005238234192672418
846,HV323,Scavenging of heme from plasma,0.0031181172268500814,0,0,1,0.003540009486308777
847,HV323,Scavenging of heme from plasma,0.004613950425166266,1,0,1,0.005238234192672418
848,HV313,Initial triggering of complement,0.0010472408240729484,0,0,1,0.0011889362015465694
849,HV313,Initial triggering of complement,0.001046258829641774,1,0,1,0.0011878213398050267
850,HV313,Regulation of Complement cascade,0.0010472408240729484,0,0,1,0.0011889362015465694
851,HV313,Regulation of Complement cascade,0.001046258829641774,1,0,1,0.0011878213398050267
852,HV313,FCGR activation,0.0010472408240729484,0,0,1,0.0011889362015465694
853,HV313,FCGR activation,0.001046258829641774,1,0,1,0.0011878213398050267
854,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0010472408240729484,0,0,1,0.0011889362015465694
855,HV313,Regulation of actin dynamics for phagocytic cup formation,0.001046258829641774,1,0,1,0.0011878213398050267
856,HV313,Role of phospholipids in phagocytosis,0.0010472408240729484,0,0,1,0.0011889362015465694
857,HV313,Role of phospholipids in phagocytosis,0.001046258829641774,1,0,1,0.0011878213398050267
858,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0010472408240729484,0,0,1,0.0011889362015465694
859,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.001046258829641774,1,0,1,0.0011878213398050267
860,HV313,FCERI mediated MAPK activation,0.0010472408240729484,0,0,1,0.0011889362015465694
861,HV313,FCERI mediated MAPK activation,0.001046258829641774,1,0,1,0.0011878213398050267
862,HV313,FCERI mediated Ca+2 mobilization,0.0010472408240729484,0,0,1,0.0011889362015465694
863,HV313,FCERI mediated Ca+2 mobilization,0.001046258829641774,1,0,1,0.0011878213398050267
864,HV313,FCERI mediated NF-kB activation,0.0010472408240729484,0,0,1,0.0011889362015465694
865,HV313,FCERI mediated NF-kB activation,0.001046258829641774,1,0,1,0.0011878213398050267
866,HV313,Parasite infection,0.0010472408240729484,0,0,1,0.0011889362015465694
867,HV313,Parasite infection,0.001046258829641774,1,0,1,0.0011878213398050267
868,HV313,Leishmania parasite growth and survival,0.0010472408240729484,0,0,1,0.0011889362015465694
869,HV313,Leishmania parasite growth and survival,0.001046258829641774,1,0,1,0.0011878213398050267
870,HV313,Potential therapeutics for SARS,0.0010472408240729484,0,0,1,0.0011889362015465694
871,HV313,Potential therapeutics for SARS,0.001046258829641774,1,0,1,0.0011878213398050267
872,HV313,CD22 mediated BCR regulation,0.0010472408240729484,0,0,1,0.0011889362015465694
873,HV313,CD22 mediated BCR regulation,0.001046258829641774,1,0,1,0.0011878213398050267
874,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0010472408240729484,0,0,1,0.0011889362015465694
875,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001046258829641774,1,0,1,0.0011878213398050267
876,HV313,Cell surface interactions at the vascular wall,0.0010472408240729484,0,0,1,0.0011889362015465694
877,HV313,Cell surface interactions at the vascular wall,0.001046258829641774,1,0,1,0.0011878213398050267
878,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010472408240729484,0,0,1,0.0011889362015465694
879,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001046258829641774,1,0,1,0.0011878213398050267
880,HV313,Scavenging of heme from plasma,0.0010472408240729484,0,0,1,0.0011889362015465694
881,HV313,Scavenging of heme from plasma,0.001046258829641774,1,0,1,0.0011878213398050267
882,HV353,Initial triggering of complement,0.0007403718238500672,0,0,1,0.0008405467431616171
883,HV353,Initial triggering of complement,0.000235877687913237,1,0,1,0.00026779277110917525
884,HV353,Regulation of Complement cascade,0.0007403718238500672,0,0,1,0.0008405467431616171
885,HV353,Regulation of Complement cascade,0.000235877687913237,1,0,1,0.00026779277110917525
886,HV353,FCGR activation,0.0007403718238500672,0,0,1,0.0008405467431616171
887,HV353,FCGR activation,0.000235877687913237,1,0,1,0.00026779277110917525
888,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0007403718238500672,0,0,1,0.0008405467431616171
889,HV353,Regulation of actin dynamics for phagocytic cup formation,0.000235877687913237,1,0,1,0.00026779277110917525
890,HV353,Role of phospholipids in phagocytosis,0.0007403718238500672,0,0,1,0.0008405467431616171
891,HV353,Role of phospholipids in phagocytosis,0.000235877687913237,1,0,1,0.00026779277110917525
892,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007403718238500672,0,0,1,0.0008405467431616171
893,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.000235877687913237,1,0,1,0.00026779277110917525
894,HV353,FCERI mediated MAPK activation,0.0007403718238500672,0,0,1,0.0008405467431616171
895,HV353,FCERI mediated MAPK activation,0.000235877687913237,1,0,1,0.00026779277110917525
896,HV353,FCERI mediated Ca+2 mobilization,0.0007403718238500672,0,0,1,0.0008405467431616171
897,HV353,FCERI mediated Ca+2 mobilization,0.000235877687913237,1,0,1,0.00026779277110917525
898,HV353,FCERI mediated NF-kB activation,0.0007403718238500672,0,0,1,0.0008405467431616171
899,HV353,FCERI mediated NF-kB activation,0.000235877687913237,1,0,1,0.00026779277110917525
900,HV353,Parasite infection,0.0007403718238500672,0,0,1,0.0008405467431616171
901,HV353,Parasite infection,0.000235877687913237,1,0,1,0.00026779277110917525
902,HV353,Leishmania parasite growth and survival,0.0007403718238500672,0,0,1,0.0008405467431616171
903,HV353,Leishmania parasite growth and survival,0.000235877687913237,1,0,1,0.00026779277110917525
904,HV353,Potential therapeutics for SARS,0.0007403718238500672,0,0,1,0.0008405467431616171
905,HV353,Potential therapeutics for SARS,0.000235877687913237,1,0,1,0.00026779277110917525
906,HV353,CD22 mediated BCR regulation,0.0007403718238500672,0,0,1,0.0008405467431616171
907,HV353,CD22 mediated BCR regulation,0.000235877687913237,1,0,1,0.00026779277110917525
908,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007403718238500672,0,0,1,0.0008405467431616171
909,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000235877687913237,1,0,1,0.00026779277110917525
910,HV353,Cell surface interactions at the vascular wall,0.0007403718238500672,0,0,1,0.0008405467431616171
911,HV353,Cell surface interactions at the vascular wall,0.000235877687913237,1,0,1,0.00026779277110917525
912,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007403718238500672,0,0,1,0.0008405467431616171
913,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000235877687913237,1,0,1,0.00026779277110917525
914,HV353,Scavenging of heme from plasma,0.0007403718238500672,0,0,1,0.0008405467431616171
915,HV353,Scavenging of heme from plasma,0.000235877687913237,1,0,1,0.00026779277110917525
916,HV307,Initial triggering of complement,0.003962713385655708,0,0,1,0.004498882484580316
917,HV307,Initial triggering of complement,0.004825600256248266,1,0,1,0.005478520992461153
918,HV307,Regulation of Complement cascade,0.003962713385655708,0,0,1,0.004498882484580316
919,HV307,Regulation of Complement cascade,0.004825600256248266,1,0,1,0.005478520992461153
920,HV307,FCGR activation,0.003962713385655708,0,0,1,0.004498882484580316
921,HV307,FCGR activation,0.004825600256248266,1,0,1,0.005478520992461153
922,HV307,Regulation of actin dynamics for phagocytic cup formation,0.003962713385655708,0,0,1,0.004498882484580316
923,HV307,Regulation of actin dynamics for phagocytic cup formation,0.004825600256248266,1,0,1,0.005478520992461153
924,HV307,Role of phospholipids in phagocytosis,0.003962713385655708,0,0,1,0.004498882484580316
925,HV307,Role of phospholipids in phagocytosis,0.004825600256248266,1,0,1,0.005478520992461153
926,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.003962713385655708,0,0,1,0.004498882484580316
927,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.004825600256248266,1,0,1,0.005478520992461153
928,HV307,FCERI mediated MAPK activation,0.003962713385655708,0,0,1,0.004498882484580316
929,HV307,FCERI mediated MAPK activation,0.004825600256248266,1,0,1,0.005478520992461153
930,HV307,FCERI mediated Ca+2 mobilization,0.003962713385655708,0,0,1,0.004498882484580316
931,HV307,FCERI mediated Ca+2 mobilization,0.004825600256248266,1,0,1,0.005478520992461153
932,HV307,FCERI mediated NF-kB activation,0.003962713385655708,0,0,1,0.004498882484580316
933,HV307,FCERI mediated NF-kB activation,0.004825600256248266,1,0,1,0.005478520992461153
934,HV307,Parasite infection,0.003962713385655708,0,0,1,0.004498882484580316
935,HV307,Parasite infection,0.004825600256248266,1,0,1,0.005478520992461153
936,HV307,Leishmania parasite growth and survival,0.003962713385655708,0,0,1,0.004498882484580316
937,HV307,Leishmania parasite growth and survival,0.004825600256248266,1,0,1,0.005478520992461153
938,HV307,Potential therapeutics for SARS,0.003962713385655708,0,0,1,0.004498882484580316
939,HV307,Potential therapeutics for SARS,0.004825600256248266,1,0,1,0.005478520992461153
940,HV307,CD22 mediated BCR regulation,0.003962713385655708,0,0,1,0.004498882484580316
941,HV307,CD22 mediated BCR regulation,0.004825600256248266,1,0,1,0.005478520992461153
942,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003962713385655708,0,0,1,0.004498882484580316
943,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004825600256248266,1,0,1,0.005478520992461153
944,HV307,Cell surface interactions at the vascular wall,0.003962713385655708,0,0,1,0.004498882484580316
945,HV307,Cell surface interactions at the vascular wall,0.004825600256248266,1,0,1,0.005478520992461153
946,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003962713385655708,0,0,1,0.004498882484580316
947,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004825600256248266,1,0,1,0.005478520992461153
948,HV307,Scavenging of heme from plasma,0.003962713385655708,0,0,1,0.004498882484580316
949,HV307,Scavenging of heme from plasma,0.004825600256248266,1,0,1,0.005478520992461153
950,HV205,Initial triggering of complement,0.0028836317783190422,0,0,1,0.0032737973294811153
951,HV205,Initial triggering of complement,0.001689379613243621,1,0,1,0.00191795863393516
952,HV205,Regulation of Complement cascade,0.0028836317783190422,0,0,1,0.0032737973294811153
953,HV205,Regulation of Complement cascade,0.001689379613243621,1,0,1,0.00191795863393516
954,HV205,FCGR activation,0.0028836317783190422,0,0,1,0.0032737973294811153
955,HV205,FCGR activation,0.001689379613243621,1,0,1,0.00191795863393516
956,HV205,Regulation of actin dynamics for phagocytic cup formation,0.0028836317783190422,0,0,1,0.0032737973294811153
957,HV205,Regulation of actin dynamics for phagocytic cup formation,0.001689379613243621,1,0,1,0.00191795863393516
958,HV205,Role of phospholipids in phagocytosis,0.0028836317783190422,0,0,1,0.0032737973294811153
959,HV205,Role of phospholipids in phagocytosis,0.001689379613243621,1,0,1,0.00191795863393516
960,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.0028836317783190422,0,0,1,0.0032737973294811153
961,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,0.001689379613243621,1,0,1,0.00191795863393516
962,HV205,FCERI mediated MAPK activation,0.0028836317783190422,0,0,1,0.0032737973294811153
963,HV205,FCERI mediated MAPK activation,0.001689379613243621,1,0,1,0.00191795863393516
964,HV205,FCERI mediated Ca+2 mobilization,0.0028836317783190422,0,0,1,0.0032737973294811153
965,HV205,FCERI mediated Ca+2 mobilization,0.001689379613243621,1,0,1,0.00191795863393516
966,HV205,FCERI mediated NF-kB activation,0.0028836317783190422,0,0,1,0.0032737973294811153
967,HV205,FCERI mediated NF-kB activation,0.001689379613243621,1,0,1,0.00191795863393516
968,HV205,Parasite infection,0.0028836317783190422,0,0,1,0.0032737973294811153
969,HV205,Parasite infection,0.001689379613243621,1,0,1,0.00191795863393516
970,HV205,Leishmania parasite growth and survival,0.0028836317783190422,0,0,1,0.0032737973294811153
971,HV205,Leishmania parasite growth and survival,0.001689379613243621,1,0,1,0.00191795863393516
972,HV205,Potential therapeutics for SARS,0.0028836317783190422,0,0,1,0.0032737973294811153
973,HV205,Potential therapeutics for SARS,0.001689379613243621,1,0,1,0.00191795863393516
974,HV205,CD22 mediated BCR regulation,0.0028836317783190422,0,0,1,0.0032737973294811153
975,HV205,CD22 mediated BCR regulation,0.001689379613243621,1,0,1,0.00191795863393516
976,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0028836317783190422,0,0,1,0.0032737973294811153
977,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001689379613243621,1,0,1,0.00191795863393516
978,HV205,Cell surface interactions at the vascular wall,0.0028836317783190422,0,0,1,0.0032737973294811153
979,HV205,Cell surface interactions at the vascular wall,0.001689379613243621,1,0,1,0.00191795863393516
980,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0028836317783190422,0,0,1,0.0032737973294811153
981,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001689379613243621,1,0,1,0.00191795863393516
982,HV205,Scavenging of heme from plasma,0.0028836317783190422,0,0,1,0.0032737973294811153
983,HV205,Scavenging of heme from plasma,0.001689379613243621,1,0,1,0.00191795863393516
984,PIGR,Neutrophil degranulation,0.00017918019409158718,0,0,1,0.0002034239063820045
985,PIGR,Neutrophil degranulation,0.00021991432198138303,1,0,1,0.0002496695054584902
986,IGKC,Initial triggering of complement,0.0004988712326905566,0,0,1,0.0005663702701630445
987,IGKC,Initial triggering of complement,0.002009717981224397,1,0,1,0.002281639913046717
988,IGKC,Regulation of Complement cascade,0.0004988712326905566,0,0,1,0.0005663702701630445
989,IGKC,Regulation of Complement cascade,0.002009717981224397,1,0,1,0.002281639913046717
990,IGKC,FCGR activation,0.0004988712326905566,0,0,1,0.0005663702701630445
991,IGKC,FCGR activation,0.002009717981224397,1,0,1,0.002281639913046717
992,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0004988712326905566,0,0,1,0.0005663702701630445
993,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.002009717981224397,1,0,1,0.002281639913046717
994,IGKC,Role of phospholipids in phagocytosis,0.0004988712326905566,0,0,1,0.0005663702701630445
995,IGKC,Role of phospholipids in phagocytosis,0.002009717981224397,1,0,1,0.002281639913046717
996,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004988712326905566,0,0,1,0.0005663702701630445
997,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.002009717981224397,1,0,1,0.002281639913046717
998,IGKC,FCERI mediated MAPK activation,0.0004988712326905566,0,0,1,0.0005663702701630445
999,IGKC,FCERI mediated MAPK activation,0.002009717981224397,1,0,1,0.002281639913046717
1000,IGKC,FCERI mediated Ca+2 mobilization,0.0004988712326905566,0,0,1,0.0005663702701630445
1001,IGKC,FCERI mediated Ca+2 mobilization,0.002009717981224397,1,0,1,0.002281639913046717
1002,IGKC,FCERI mediated NF-kB activation,0.0004988712326905566,0,0,1,0.0005663702701630445
1003,IGKC,FCERI mediated NF-kB activation,0.002009717981224397,1,0,1,0.002281639913046717
1004,IGKC,Parasite infection,0.0004988712326905566,0,0,1,0.0005663702701630445
1005,IGKC,Parasite infection,0.002009717981224397,1,0,1,0.002281639913046717
1006,IGKC,Leishmania parasite growth and survival,0.0004988712326905566,0,0,1,0.0005663702701630445
1007,IGKC,Leishmania parasite growth and survival,0.002009717981224397,1,0,1,0.002281639913046717
1008,IGKC,Potential therapeutics for SARS,0.0004988712326905566,0,0,1,0.0005663702701630445
1009,IGKC,Potential therapeutics for SARS,0.002009717981224397,1,0,1,0.002281639913046717
1010,IGKC,CD22 mediated BCR regulation,0.0004988712326905566,0,0,1,0.0005663702701630445
1011,IGKC,CD22 mediated BCR regulation,0.002009717981224397,1,0,1,0.002281639913046717
1012,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004988712326905566,0,0,1,0.0005663702701630445
1013,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002009717981224397,1,0,1,0.002281639913046717
1014,IGKC,Cell surface interactions at the vascular wall,0.0004988712326905566,0,0,1,0.0005663702701630445
1015,IGKC,Cell surface interactions at the vascular wall,0.002009717981224397,1,0,1,0.002281639913046717
1016,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004988712326905566,0,0,1,0.0005663702701630445
1017,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002009717981224397,1,0,1,0.002281639913046717
1018,IGKC,Scavenging of heme from plasma,0.0004988712326905566,0,0,1,0.0005663702701630445
1019,IGKC,Scavenging of heme from plasma,0.002009717981224397,1,0,1,0.002281639913046717
1020,IGHM,Potential therapeutics for SARS,0.0004964509897167785,0,0,1,0.0005636225597778895
1021,IGHM,Potential therapeutics for SARS,0.00019471394150774466,1,0,1,0.00022105942461640788
1022,IGHM,CD22 mediated BCR regulation,0.0004964509897167785,0,0,1,0.0005636225597778895
1023,IGHM,CD22 mediated BCR regulation,0.00019471394150774466,1,0,1,0.00022105942461640788
1024,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004964509897167785,0,0,1,0.0005636225597778895
1025,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00019471394150774466,1,0,1,0.00022105942461640788
1026,IGHM,Cell surface interactions at the vascular wall,0.0004964509897167785,0,0,1,0.0005636225597778895
1027,IGHM,Cell surface interactions at the vascular wall,0.00019471394150774466,1,0,1,0.00022105942461640788
1028,IGHD,Potential therapeutics for SARS,0.000652103439064551,0,0,1,0.0007403353345618388
1029,IGHD,Potential therapeutics for SARS,0.0004492794884550528,1,0,1,0.0005100685880054343
1030,IGHD,CD22 mediated BCR regulation,0.000652103439064551,0,0,1,0.0007403353345618388
1031,IGHD,CD22 mediated BCR regulation,0.0004492794884550528,1,0,1,0.0005100685880054343
1032,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000652103439064551,0,0,1,0.0007403353345618388
1033,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004492794884550528,1,0,1,0.0005100685880054343
1034,HBD,Factors involved in megakaryocyte development and platelet production,0.004111247134885305,0,0,1,0.004667513374010011
1035,HBD,Factors involved in megakaryocyte development and platelet production,0.004023716131928963,1,0,1,0.0045681391176018915
1036,APOA1,PPARA activates gene expression,0.03266148318038722,0,0,1,0.037080697062915266
1037,APOA1,PPARA activates gene expression,0.027236633814233822,1,0,1,0.030921846442222265
1038,APOA1,Defective ABCA1 causes TGD,0.03266148318038722,0,0,1,0.037080697062915266
1039,APOA1,Defective ABCA1 causes TGD,0.027236633814233822,1,0,1,0.030921846442222265
1040,APOA1,Platelet degranulation ,0.03266148318038722,0,0,1,0.037080697062915266
1041,APOA1,Platelet degranulation ,0.027236633814233822,1,0,1,0.030921846442222265
1042,APOA1,Chylomicron assembly,0.03266148318038722,0,0,1,0.037080697062915266
1043,APOA1,Chylomicron assembly,0.027236633814233822,1,0,1,0.030921846442222265
1044,APOA1,HDL assembly,0.03266148318038722,0,0,1,0.037080697062915266
1045,APOA1,HDL assembly,0.027236633814233822,1,0,1,0.030921846442222265
1046,APOA1,Chylomicron remodeling,0.03266148318038722,0,0,1,0.037080697062915266
1047,APOA1,Chylomicron remodeling,0.027236633814233822,1,0,1,0.030921846442222265
1048,APOA1,HDL remodeling,0.03266148318038722,0,0,1,0.037080697062915266
1049,APOA1,HDL remodeling,0.027236633814233822,1,0,1,0.030921846442222265
1050,APOA1,HDL clearance,0.03266148318038722,0,0,1,0.037080697062915266
1051,APOA1,HDL clearance,0.027236633814233822,1,0,1,0.030921846442222265
1052,APOA1,Scavenging of heme from plasma,0.03266148318038722,0,0,1,0.037080697062915266
1053,APOA1,Scavenging of heme from plasma,0.027236633814233822,1,0,1,0.030921846442222265
1054,APOA1,Scavenging by Class B Receptors,0.03266148318038722,0,0,1,0.037080697062915266
1055,APOA1,Scavenging by Class B Receptors,0.027236633814233822,1,0,1,0.030921846442222265
1056,APOA1,Scavenging by Class A Receptors,0.03266148318038722,0,0,1,0.037080697062915266
1057,APOA1,Scavenging by Class A Receptors,0.027236633814233822,1,0,1,0.030921846442222265
1058,APOA1,Retinoid metabolism and transport,0.03266148318038722,0,0,1,0.037080697062915266
1059,APOA1,Retinoid metabolism and transport,0.027236633814233822,1,0,1,0.030921846442222265
1060,APOA1,Heme signaling,0.03266148318038722,0,0,1,0.037080697062915266
1061,APOA1,Heme signaling,0.027236633814233822,1,0,1,0.030921846442222265
1062,APOA1,ABC transporters in lipid homeostasis,0.03266148318038722,0,0,1,0.037080697062915266
1063,APOA1,ABC transporters in lipid homeostasis,0.027236633814233822,1,0,1,0.030921846442222265
1064,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03266148318038722,0,0,1,0.037080697062915266
1065,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.027236633814233822,1,0,1,0.030921846442222265
1066,APOA1,Amyloid fiber formation,0.03266148318038722,0,0,1,0.037080697062915266
1067,APOA1,Amyloid fiber formation,0.027236633814233822,1,0,1,0.030921846442222265
1068,APOA1,Post-translational protein phosphorylation,0.03266148318038722,0,0,1,0.037080697062915266
1069,APOA1,Post-translational protein phosphorylation,0.027236633814233822,1,0,1,0.030921846442222265
1070,APOE,Nuclear signaling by ERBB4,0.06246917830125037,0,0,1,0.07092147847556637
1071,APOE,Nuclear signaling by ERBB4,0.029372812254061877,1,0,1,0.033347057359991
1072,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.06246917830125037,0,0,1,0.07092147847556637
1073,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.029372812254061877,1,0,1,0.033347057359991
1074,APOE,Chylomicron assembly,0.06246917830125037,0,0,1,0.07092147847556637
1075,APOE,Chylomicron assembly,0.029372812254061877,1,0,1,0.033347057359991
1076,APOE,Chylomicron remodeling,0.06246917830125037,0,0,1,0.07092147847556637
1077,APOE,Chylomicron remodeling,0.029372812254061877,1,0,1,0.033347057359991
1078,APOE,HDL remodeling,0.06246917830125037,0,0,1,0.07092147847556637
1079,APOE,HDL remodeling,0.029372812254061877,1,0,1,0.033347057359991
1080,APOE,Chylomicron clearance,0.06246917830125037,0,0,1,0.07092147847556637
1081,APOE,Chylomicron clearance,0.029372812254061877,1,0,1,0.033347057359991
1082,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.06246917830125037,0,0,1,0.07092147847556637
1083,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.029372812254061877,1,0,1,0.033347057359991
1084,APOE,Scavenging by Class A Receptors,0.06246917830125037,0,0,1,0.07092147847556637
1085,APOE,Scavenging by Class A Receptors,0.029372812254061877,1,0,1,0.033347057359991
1086,APOE,Retinoid metabolism and transport,0.06246917830125037,0,0,1,0.07092147847556637
1087,APOE,Retinoid metabolism and transport,0.029372812254061877,1,0,1,0.033347057359991
1088,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.06246917830125037,0,0,1,0.07092147847556637
1089,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.029372812254061877,1,0,1,0.033347057359991
1090,APOE,Amyloid fiber formation,0.06246917830125037,0,0,1,0.07092147847556637
1091,APOE,Amyloid fiber formation,0.029372812254061877,1,0,1,0.033347057359991
1092,APOE,Post-translational protein phosphorylation,0.06246917830125037,0,0,1,0.07092147847556637
1093,APOE,Post-translational protein phosphorylation,0.029372812254061877,1,0,1,0.033347057359991
1094,FIBA,Antigen processing-Cross presentation,0.04527007842077528,0,0,1,0.05139527971415549
1095,FIBA,Antigen processing-Cross presentation,0.03157267869288418,1,0,1,0.035844573487667265
1096,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.04527007842077528,0,0,1,0.05139527971415549
1097,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.03157267869288418,1,0,1,0.035844573487667265
1098,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.04527007842077528,0,0,1,0.05139527971415549
1099,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.03157267869288418,1,0,1,0.035844573487667265
1100,FIBA,Regulation of TLR by endogenous ligand,0.04527007842077528,0,0,1,0.05139527971415549
1101,FIBA,Regulation of TLR by endogenous ligand,0.03157267869288418,1,0,1,0.035844573487667265
1102,FIBA,MyD88 deficiency (TLR2/4),0.04527007842077528,0,0,1,0.05139527971415549
1103,FIBA,MyD88 deficiency (TLR2/4),0.03157267869288418,1,0,1,0.035844573487667265
1104,FIBA,IRAK4 deficiency (TLR2/4),0.04527007842077528,0,0,1,0.05139527971415549
1105,FIBA,IRAK4 deficiency (TLR2/4),0.03157267869288418,1,0,1,0.035844573487667265
1106,FIBA,RAF/MAP kinase cascade,0.04527007842077528,0,0,1,0.05139527971415549
1107,FIBA,RAF/MAP kinase cascade,0.03157267869288418,1,0,1,0.035844573487667265
1108,FIBA,Signaling by RAS mutants,0.04527007842077528,0,0,1,0.05139527971415549
1109,FIBA,Signaling by RAS mutants,0.03157267869288418,1,0,1,0.035844573487667265
1110,FIBA,Signaling by moderate kinase activity BRAF mutants,0.04527007842077528,0,0,1,0.05139527971415549
1111,FIBA,Signaling by moderate kinase activity BRAF mutants,0.03157267869288418,1,0,1,0.035844573487667265
1112,FIBA,Signaling by high-kinase activity BRAF mutants,0.04527007842077528,0,0,1,0.05139527971415549
1113,FIBA,Signaling by high-kinase activity BRAF mutants,0.03157267869288418,1,0,1,0.035844573487667265
1114,FIBA,Signaling by BRAF and RAF1 fusions,0.04527007842077528,0,0,1,0.05139527971415549
1115,FIBA,Signaling by BRAF and RAF1 fusions,0.03157267869288418,1,0,1,0.035844573487667265
1116,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.04527007842077528,0,0,1,0.05139527971415549
1117,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.03157267869288418,1,0,1,0.035844573487667265
1118,FIBA,Signaling by RAF1 mutants,0.04527007842077528,0,0,1,0.05139527971415549
1119,FIBA,Signaling by RAF1 mutants,0.03157267869288418,1,0,1,0.035844573487667265
1120,FIBA,Platelet degranulation ,0.04527007842077528,0,0,1,0.05139527971415549
1121,FIBA,Platelet degranulation ,0.03157267869288418,1,0,1,0.035844573487667265
1122,FIBA,Common Pathway of Fibrin Clot Formation,0.04527007842077528,0,0,1,0.05139527971415549
1123,FIBA,Common Pathway of Fibrin Clot Formation,0.03157267869288418,1,0,1,0.035844573487667265
1124,FIBA,Integrin cell surface interactions,0.04527007842077528,0,0,1,0.05139527971415549
1125,FIBA,Integrin cell surface interactions,0.03157267869288418,1,0,1,0.035844573487667265
1126,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.04527007842077528,0,0,1,0.05139527971415549
1127,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.03157267869288418,1,0,1,0.035844573487667265
1128,FIBA,p130Cas linkage to MAPK signaling for integrins,0.04527007842077528,0,0,1,0.05139527971415549
1129,FIBA,p130Cas linkage to MAPK signaling for integrins,0.03157267869288418,1,0,1,0.035844573487667265
1130,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04527007842077528,0,0,1,0.05139527971415549
1131,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03157267869288418,1,0,1,0.035844573487667265
1132,FIBA,Amyloid fiber formation,0.04527007842077528,0,0,1,0.05139527971415549
1133,FIBA,Amyloid fiber formation,0.03157267869288418,1,0,1,0.035844573487667265
1134,FIBA,Post-translational protein phosphorylation,0.04527007842077528,0,0,1,0.05139527971415549
1135,FIBA,Post-translational protein phosphorylation,0.03157267869288418,1,0,1,0.035844573487667265
1136,FIBB,Antigen processing-Cross presentation,0.026124834969022095,0,0,1,0.02965961729155862
1137,FIBB,Antigen processing-Cross presentation,0.015594307946497821,1,0,1,0.017704272818116477
1138,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.026124834969022095,0,0,1,0.02965961729155862
1139,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.015594307946497821,1,0,1,0.017704272818116477
1140,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.026124834969022095,0,0,1,0.02965961729155862
1141,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.015594307946497821,1,0,1,0.017704272818116477
1142,FIBB,Regulation of TLR by endogenous ligand,0.026124834969022095,0,0,1,0.02965961729155862
1143,FIBB,Regulation of TLR by endogenous ligand,0.015594307946497821,1,0,1,0.017704272818116477
1144,FIBB,MyD88 deficiency (TLR2/4),0.026124834969022095,0,0,1,0.02965961729155862
1145,FIBB,MyD88 deficiency (TLR2/4),0.015594307946497821,1,0,1,0.017704272818116477
1146,FIBB,IRAK4 deficiency (TLR2/4),0.026124834969022095,0,0,1,0.02965961729155862
1147,FIBB,IRAK4 deficiency (TLR2/4),0.015594307946497821,1,0,1,0.017704272818116477
1148,FIBB,RAF/MAP kinase cascade,0.026124834969022095,0,0,1,0.02965961729155862
1149,FIBB,RAF/MAP kinase cascade,0.015594307946497821,1,0,1,0.017704272818116477
1150,FIBB,Signaling by RAS mutants,0.026124834969022095,0,0,1,0.02965961729155862
1151,FIBB,Signaling by RAS mutants,0.015594307946497821,1,0,1,0.017704272818116477
1152,FIBB,Signaling by moderate kinase activity BRAF mutants,0.026124834969022095,0,0,1,0.02965961729155862
1153,FIBB,Signaling by moderate kinase activity BRAF mutants,0.015594307946497821,1,0,1,0.017704272818116477
1154,FIBB,Signaling by high-kinase activity BRAF mutants,0.026124834969022095,0,0,1,0.02965961729155862
1155,FIBB,Signaling by high-kinase activity BRAF mutants,0.015594307946497821,1,0,1,0.017704272818116477
1156,FIBB,Signaling by BRAF and RAF1 fusions,0.026124834969022095,0,0,1,0.02965961729155862
1157,FIBB,Signaling by BRAF and RAF1 fusions,0.015594307946497821,1,0,1,0.017704272818116477
1158,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.026124834969022095,0,0,1,0.02965961729155862
1159,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.015594307946497821,1,0,1,0.017704272818116477
1160,FIBB,Signaling by RAF1 mutants,0.026124834969022095,0,0,1,0.02965961729155862
1161,FIBB,Signaling by RAF1 mutants,0.015594307946497821,1,0,1,0.017704272818116477
1162,FIBB,Platelet degranulation ,0.026124834969022095,0,0,1,0.02965961729155862
1163,FIBB,Platelet degranulation ,0.015594307946497821,1,0,1,0.017704272818116477
1164,FIBB,Common Pathway of Fibrin Clot Formation,0.026124834969022095,0,0,1,0.02965961729155862
1165,FIBB,Common Pathway of Fibrin Clot Formation,0.015594307946497821,1,0,1,0.017704272818116477
1166,FIBB,Integrin cell surface interactions,0.026124834969022095,0,0,1,0.02965961729155862
1167,FIBB,Integrin cell surface interactions,0.015594307946497821,1,0,1,0.017704272818116477
1168,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.026124834969022095,0,0,1,0.02965961729155862
1169,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.015594307946497821,1,0,1,0.017704272818116477
1170,FIBB,p130Cas linkage to MAPK signaling for integrins,0.026124834969022095,0,0,1,0.02965961729155862
1171,FIBB,p130Cas linkage to MAPK signaling for integrins,0.015594307946497821,1,0,1,0.017704272818116477
1172,CRP,Initial triggering of complement,0.00018679441874741245,0,0,1,0.00021206836249173744
1173,CRP,Initial triggering of complement,0.00018131342590884655,1,0,1,0.00020584577198877728
1174,SAMP,Amyloid fiber formation,0.0012389278640677686,0,0,1,0.0014065591741984375
1175,SAMP,Amyloid fiber formation,0.0011599405904103965,1,0,1,0.0013168846438000943
1176,C1QA,Initial triggering of complement,0.0011154061199282982,0,0,1,0.0012663245023734593
1177,C1QA,Initial triggering of complement,0.0011683364520060325,1,0,1,0.001326416495084695
1178,C1QA,Regulation of Complement cascade,0.0011154061199282982,0,0,1,0.0012663245023734593
1179,C1QA,Regulation of Complement cascade,0.0011683364520060325,1,0,1,0.001326416495084695
1180,C1QC,Initial triggering of complement,0.0013713694430881429,0,0,1,0.0015569205660270135
1181,C1QC,Initial triggering of complement,0.0014088888556375125,1,0,1,0.001599516487438113
1182,C1QC,Regulation of Complement cascade,0.0013713694430881429,0,0,1,0.0015569205660270135
1183,C1QC,Regulation of Complement cascade,0.0014088888556375125,1,0,1,0.001599516487438113
1184,CO9,Terminal pathway of complement,0.0019834515933140405,0,0,1,0.002251819590201556
1185,CO9,Terminal pathway of complement,0.0037202531283208433,1,0,1,0.004223616499187793
1186,CO9,Regulation of Complement cascade,0.0019834515933140405,0,0,1,0.002251819590201556
1187,CO9,Regulation of Complement cascade,0.0037202531283208433,1,0,1,0.004223616499187793
1188,APOH,Platelet degranulation ,0.0018711606373155618,0,0,1,0.0021243352717678766
1189,APOH,Platelet degranulation ,0.002340649024969353,1,0,1,0.002657347094317338
1190,A2GL,Neutrophil degranulation,0.00015758874406353166,0,0,1,0.0001789110570047244
1191,A2GL,Neutrophil degranulation,0.00019575318335535543,1,0,1,0.00022223927955176184
1192,AMBP,Scavenging of heme from plasma,5.609767682787918e-05,0,0,1,6.368789037838325e-05
1193,AMBP,Scavenging of heme from plasma,2.4051693503805598e-05,1,0,1,2.730597247341935e-05
1194,A1AG1,Platelet degranulation ,0.0016846625940379614,0,0,1,0.0019126033853924345
1195,A1AG1,Platelet degranulation ,0.0021050478000683302,1,0,1,0.0023898681926411086
1196,A1AG1,Neutrophil degranulation,0.0016846625940379614,0,0,1,0.0019126033853924345
1197,A1AG1,Neutrophil degranulation,0.0021050478000683302,1,0,1,0.0023898681926411086
1198,FETUA,Platelet degranulation ,0.004968054980439393,0,0,1,0.005640250343321873
1199,FETUA,Platelet degranulation ,0.003928266112597272,1,0,1,0.00445977437396976
1200,FETUA,Neutrophil degranulation,0.004968054980439393,0,0,1,0.005640250343321873
1201,FETUA,Neutrophil degranulation,0.003928266112597272,1,0,1,0.00445977437396976
1202,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004968054980439393,0,0,1,0.005640250343321873
1203,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003928266112597272,1,0,1,0.00445977437396976
1204,FETUA,Post-translational protein phosphorylation,0.004968054980439393,0,0,1,0.005640250343321873
1205,FETUA,Post-translational protein phosphorylation,0.003928266112597272,1,0,1,0.00445977437396976
1206,CXCL7,Class A/1 (Rhodopsin-like receptors),0.005013469751571959,0,0,1,0.005691809893182104
1207,CXCL7,Class A/1 (Rhodopsin-like receptors),0.006024272693196467,1,0,1,0.006839378038256086
1208,CXCL7,G alpha (i) signalling events,0.005013469751571959,0,0,1,0.005691809893182104
1209,CXCL7,G alpha (i) signalling events,0.006024272693196467,1,0,1,0.006839378038256086
1210,CXCL7,Platelet degranulation ,0.005013469751571959,0,0,1,0.005691809893182104
1211,CXCL7,Platelet degranulation ,0.006024272693196467,1,0,1,0.006839378038256086
1212,CXCL7,Neutrophil degranulation,0.005013469751571959,0,0,1,0.005691809893182104
1213,CXCL7,Neutrophil degranulation,0.006024272693196467,1,0,1,0.006839378038256086
1214,PLF4,Transcriptional regulation by RUNX1,0.015409267492528534,0,0,1,0.01749419573802418
1215,PLF4,Transcriptional regulation by RUNX1,0.01921264510801292,1,0,1,0.021812183760697237
1216,PLF4,Class A/1 (Rhodopsin-like receptors),0.015409267492528534,0,0,1,0.01749419573802418
1217,PLF4,Class A/1 (Rhodopsin-like receptors),0.01921264510801292,1,0,1,0.021812183760697237
1218,PLF4,G alpha (i) signalling events,0.015409267492528534,0,0,1,0.01749419573802418
1219,PLF4,G alpha (i) signalling events,0.01921264510801292,1,0,1,0.021812183760697237
1220,PLF4,Platelet degranulation ,0.015409267492528534,0,0,1,0.01749419573802418
1221,PLF4,Platelet degranulation ,0.01921264510801292,1,0,1,0.021812183760697237
1222,PLF4,Cell surface interactions at the vascular wall,0.015409267492528534,0,0,1,0.01749419573802418
1223,PLF4,Cell surface interactions at the vascular wall,0.01921264510801292,1,0,1,0.021812183760697237
1224,PLF4,Common Pathway of Fibrin Clot Formation,0.015409267492528534,0,0,1,0.01749419573802418
1225,PLF4,Common Pathway of Fibrin Clot Formation,0.01921264510801292,1,0,1,0.021812183760697237
1226,TRFE,Platelet degranulation ,0.005712503798643542,0,0,1,0.006485425712554632
1227,TRFE,Platelet degranulation ,0.004080778685522165,1,0,1,0.004632922435975397
1228,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.005712503798643542,0,0,1,0.006485425712554632
1229,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.004080778685522165,1,0,1,0.004632922435975397
1230,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005712503798643542,0,0,1,0.006485425712554632
1231,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004080778685522165,1,0,1,0.004632922435975397
1232,TRFE,Post-translational protein phosphorylation,0.005712503798643542,0,0,1,0.006485425712554632
1233,TRFE,Post-translational protein phosphorylation,0.004080778685522165,1,0,1,0.004632922435975397
1234,TRFE,Transferrin endocytosis and recycling,0.005712503798643542,0,0,1,0.006485425712554632
1235,TRFE,Transferrin endocytosis and recycling,0.004080778685522165,1,0,1,0.004632922435975397
1236,HEMO,Scavenging of heme from plasma,0.0005995778758225816,0,0,1,0.0006807028773376053
1237,HEMO,Scavenging of heme from plasma,0.00025333589875574863,1,0,1,0.0002876131394597592
1238,ANGI,Adherens junctions interactions,0.0019329594217919984,0,0,1,0.0021944956497694235
1239,ANGI,Adherens junctions interactions,0.0002725587940045017,1,0,1,0.00030943696024139444
1240,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0019329594217919984,0,0,1,0.0021944956497694235
1241,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0002725587940045017,1,0,1,0.00030943696024139444
1242,C4BPA,Regulation of Complement cascade,0.0009638498092543026,0,0,1,0.0010942620882743311
1243,C4BPA,Regulation of Complement cascade,0.0010101826778343222,1,0,1,0.001146863957405101
1244,VTNC,Regulation of Complement cascade,0.020381351090120254,0,0,1,0.023139019784609402
1245,VTNC,Regulation of Complement cascade,0.007979874741157784,1,0,1,0.009059579941383823
1246,VTNC,Integrin cell surface interactions,0.020381351090120254,0,0,1,0.023139019784609402
1247,VTNC,Integrin cell surface interactions,0.007979874741157784,1,0,1,0.009059579941383823
1248,VTNC,ECM proteoglycans,0.020381351090120254,0,0,1,0.023139019784609402
1249,VTNC,ECM proteoglycans,0.007979874741157784,1,0,1,0.009059579941383823
1250,VTNC,Molecules associated with elastic fibres,0.020381351090120254,0,0,1,0.023139019784609402
1251,VTNC,Molecules associated with elastic fibres,0.007979874741157784,1,0,1,0.009059579941383823
1252,VTNC,Syndecan interactions,0.020381351090120254,0,0,1,0.023139019784609402
1253,VTNC,Syndecan interactions,0.007979874741157784,1,0,1,0.009059579941383823
1254,CATA,FOXO-mediated transcription,0.002367212883267264,0,0,1,0.0026875051363427693
1255,CATA,FOXO-mediated transcription,0.004888108437691084,1,0,1,0.005549486751340919
1256,CATA,Detoxification of Reactive Oxygen Species,0.002367212883267264,0,0,1,0.0026875051363427693
1257,CATA,Detoxification of Reactive Oxygen Species,0.004888108437691084,1,0,1,0.005549486751340919
1258,CATA,Neutrophil degranulation,0.002367212883267264,0,0,1,0.0026875051363427693
1259,CATA,Neutrophil degranulation,0.004888108437691084,1,0,1,0.005549486751340919
1260,CATA,Peroxisomal protein import,0.002367212883267264,0,0,1,0.0026875051363427693
1261,CATA,Peroxisomal protein import,0.004888108437691084,1,0,1,0.005549486751340919
1262,APOB,Regulation of TLR by endogenous ligand,0.04443221126510933,0,0,1,0.05044404617688392
1263,APOB,Regulation of TLR by endogenous ligand,0.03573967458376652,1,0,1,0.04057537862100563
1264,APOB,Cargo recognition for clathrin-mediated endocytosis,0.04443221126510933,0,0,1,0.05044404617688392
1265,APOB,Cargo recognition for clathrin-mediated endocytosis,0.03573967458376652,1,0,1,0.04057537862100563
1266,APOB,VLDL assembly,0.04443221126510933,0,0,1,0.05044404617688392
1267,APOB,VLDL assembly,0.03573967458376652,1,0,1,0.04057537862100563
1268,APOB,Chylomicron assembly,0.04443221126510933,0,0,1,0.05044404617688392
1269,APOB,Chylomicron assembly,0.03573967458376652,1,0,1,0.04057537862100563
1270,APOB,Chylomicron remodeling,0.04443221126510933,0,0,1,0.05044404617688392
1271,APOB,Chylomicron remodeling,0.03573967458376652,1,0,1,0.04057537862100563
1272,APOB,LDL remodeling,0.04443221126510933,0,0,1,0.05044404617688392
1273,APOB,LDL remodeling,0.03573967458376652,1,0,1,0.04057537862100563
1274,APOB,Chylomicron clearance,0.04443221126510933,0,0,1,0.05044404617688392
1275,APOB,Chylomicron clearance,0.03573967458376652,1,0,1,0.04057537862100563
1276,APOB,LDL clearance,0.04443221126510933,0,0,1,0.05044404617688392
1277,APOB,LDL clearance,0.03573967458376652,1,0,1,0.04057537862100563
1278,APOB,VLDL clearance,0.04443221126510933,0,0,1,0.05044404617688392
1279,APOB,VLDL clearance,0.03573967458376652,1,0,1,0.04057537862100563
1280,APOB,Cell surface interactions at the vascular wall,0.04443221126510933,0,0,1,0.05044404617688392
1281,APOB,Cell surface interactions at the vascular wall,0.03573967458376652,1,0,1,0.04057537862100563
1282,APOB,Scavenging by Class B Receptors,0.04443221126510933,0,0,1,0.05044404617688392
1283,APOB,Scavenging by Class B Receptors,0.03573967458376652,1,0,1,0.04057537862100563
1284,APOB,Scavenging by Class A Receptors,0.04443221126510933,0,0,1,0.05044404617688392
1285,APOB,Scavenging by Class A Receptors,0.03573967458376652,1,0,1,0.04057537862100563
1286,APOB,Scavenging by Class F Receptors,0.04443221126510933,0,0,1,0.05044404617688392
1287,APOB,Scavenging by Class F Receptors,0.03573967458376652,1,0,1,0.04057537862100563
1288,APOB,Scavenging by Class H Receptors,0.04443221126510933,0,0,1,0.05044404617688392
1289,APOB,Scavenging by Class H Receptors,0.03573967458376652,1,0,1,0.04057537862100563
1290,APOB,Retinoid metabolism and transport,0.04443221126510933,0,0,1,0.05044404617688392
1291,APOB,Retinoid metabolism and transport,0.03573967458376652,1,0,1,0.04057537862100563
1292,APOB,Heme signaling,0.04443221126510933,0,0,1,0.05044404617688392
1293,APOB,Heme signaling,0.03573967458376652,1,0,1,0.04057537862100563
1294,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04443221126510933,0,0,1,0.05044404617688392
1295,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03573967458376652,1,0,1,0.04057537862100563
1296,APOB,Platelet sensitization by LDL,0.04443221126510933,0,0,1,0.05044404617688392
1297,APOB,Platelet sensitization by LDL,0.03573967458376652,1,0,1,0.04057537862100563
1298,APOB,Post-translational protein phosphorylation,0.04443221126510933,0,0,1,0.05044404617688392
1299,APOB,Post-translational protein phosphorylation,0.03573967458376652,1,0,1,0.04057537862100563
1300,LCAT,HDL remodeling,0.000928268936171016,0,0,1,0.0010538669975569677
1301,LCAT,HDL remodeling,0.0005342943904673529,1,0,1,0.0006065863061366338
1302,HRG,Platelet degranulation ,0.0004699149567606577,0,0,1,0.0005334961079611418
1303,HRG,Platelet degranulation ,0.004495720986533462,1,0,1,0.00510400789395693
1304,HRG,Dissolution of Fibrin Clot,0.0004699149567606577,0,0,1,0.0005334961079611418
1305,HRG,Dissolution of Fibrin Clot,0.004495720986533462,1,0,1,0.00510400789395693
1306,LV743,Initial triggering of complement,0.0005757877736544548,0,0,1,0.000653693890430304
1307,LV743,Initial triggering of complement,0.0010377679341198169,1,0,1,0.0011781815961686565
1308,LV743,Regulation of Complement cascade,0.0005757877736544548,0,0,1,0.000653693890430304
1309,LV743,Regulation of Complement cascade,0.0010377679341198169,1,0,1,0.0011781815961686565
1310,LV743,FCGR activation,0.0005757877736544548,0,0,1,0.000653693890430304
1311,LV743,FCGR activation,0.0010377679341198169,1,0,1,0.0011781815961686565
1312,LV743,Regulation of actin dynamics for phagocytic cup formation,0.0005757877736544548,0,0,1,0.000653693890430304
1313,LV743,Regulation of actin dynamics for phagocytic cup formation,0.0010377679341198169,1,0,1,0.0011781815961686565
1314,LV743,Role of phospholipids in phagocytosis,0.0005757877736544548,0,0,1,0.000653693890430304
1315,LV743,Role of phospholipids in phagocytosis,0.0010377679341198169,1,0,1,0.0011781815961686565
1316,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.0005757877736544548,0,0,1,0.000653693890430304
1317,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.0010377679341198169,1,0,1,0.0011781815961686565
1318,LV743,FCERI mediated MAPK activation,0.0005757877736544548,0,0,1,0.000653693890430304
1319,LV743,FCERI mediated MAPK activation,0.0010377679341198169,1,0,1,0.0011781815961686565
1320,LV743,FCERI mediated Ca+2 mobilization,0.0005757877736544548,0,0,1,0.000653693890430304
1321,LV743,FCERI mediated Ca+2 mobilization,0.0010377679341198169,1,0,1,0.0011781815961686565
1322,LV743,FCERI mediated NF-kB activation,0.0005757877736544548,0,0,1,0.000653693890430304
1323,LV743,FCERI mediated NF-kB activation,0.0010377679341198169,1,0,1,0.0011781815961686565
1324,LV743,Parasite infection,0.0005757877736544548,0,0,1,0.000653693890430304
1325,LV743,Parasite infection,0.0010377679341198169,1,0,1,0.0011781815961686565
1326,LV743,Leishmania parasite growth and survival,0.0005757877736544548,0,0,1,0.000653693890430304
1327,LV743,Leishmania parasite growth and survival,0.0010377679341198169,1,0,1,0.0011781815961686565
1328,LV743,Potential therapeutics for SARS,0.0005757877736544548,0,0,1,0.000653693890430304
1329,LV743,Potential therapeutics for SARS,0.0010377679341198169,1,0,1,0.0011781815961686565
1330,LV743,CD22 mediated BCR regulation,0.0005757877736544548,0,0,1,0.000653693890430304
1331,LV743,CD22 mediated BCR regulation,0.0010377679341198169,1,0,1,0.0011781815961686565
1332,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005757877736544548,0,0,1,0.000653693890430304
1333,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0010377679341198169,1,0,1,0.0011781815961686565
1334,LV743,Cell surface interactions at the vascular wall,0.0005757877736544548,0,0,1,0.000653693890430304
1335,LV743,Cell surface interactions at the vascular wall,0.0010377679341198169,1,0,1,0.0011781815961686565
1336,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005757877736544548,0,0,1,0.000653693890430304
1337,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010377679341198169,1,0,1,0.0011781815961686565
1338,LV743,Scavenging of heme from plasma,0.0005757877736544548,0,0,1,0.000653693890430304
1339,LV743,Scavenging of heme from plasma,0.0010377679341198169,1,0,1,0.0011781815961686565
1340,K2C1,Neutrophil degranulation,1.1231951241460289e-05,0,0,1,1.275167386336331e-05
1341,K2C1,Neutrophil degranulation,2.5512781144673748e-05,1,0,1,2.8964750425852774e-05
1342,K2C1,Formation of the cornified envelope,1.1231951241460289e-05,0,0,1,1.275167386336331e-05
1343,K2C1,Formation of the cornified envelope,2.5512781144673748e-05,1,0,1,2.8964750425852774e-05
1344,VWF,RAF/MAP kinase cascade,0.011261104865568035,0,0,1,0.012784772075647637
1345,VWF,RAF/MAP kinase cascade,0.010156746901424905,1,0,1,0.011530990583507702
1346,VWF,Signaling by RAS mutants,0.011261104865568035,0,0,1,0.012784772075647637
1347,VWF,Signaling by RAS mutants,0.010156746901424905,1,0,1,0.011530990583507702
1348,VWF,Signaling by moderate kinase activity BRAF mutants,0.011261104865568035,0,0,1,0.012784772075647637
1349,VWF,Signaling by moderate kinase activity BRAF mutants,0.010156746901424905,1,0,1,0.011530990583507702
1350,VWF,Signaling by high-kinase activity BRAF mutants,0.011261104865568035,0,0,1,0.012784772075647637
1351,VWF,Signaling by high-kinase activity BRAF mutants,0.010156746901424905,1,0,1,0.011530990583507702
1352,VWF,Signaling by BRAF and RAF1 fusions,0.011261104865568035,0,0,1,0.012784772075647637
1353,VWF,Signaling by BRAF and RAF1 fusions,0.010156746901424905,1,0,1,0.011530990583507702
1354,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.011261104865568035,0,0,1,0.012784772075647637
1355,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.010156746901424905,1,0,1,0.011530990583507702
1356,VWF,Signaling by RAF1 mutants,0.011261104865568035,0,0,1,0.012784772075647637
1357,VWF,Signaling by RAF1 mutants,0.010156746901424905,1,0,1,0.011530990583507702
1358,VWF,Platelet degranulation ,0.011261104865568035,0,0,1,0.012784772075647637
1359,VWF,Platelet degranulation ,0.010156746901424905,1,0,1,0.011530990583507702
1360,VWF,Defective factor VIII causes hemophilia A,0.011261104865568035,0,0,1,0.012784772075647637
1361,VWF,Defective factor VIII causes hemophilia A,0.010156746901424905,1,0,1,0.011530990583507702
1362,VWF,Platelet Adhesion to exposed collagen,0.011261104865568035,0,0,1,0.012784772075647637
1363,VWF,Platelet Adhesion to exposed collagen,0.010156746901424905,1,0,1,0.011530990583507702
1364,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.011261104865568035,0,0,1,0.012784772075647637
1365,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.010156746901424905,1,0,1,0.011530990583507702
1366,VWF,Integrin cell surface interactions,0.011261104865568035,0,0,1,0.012784772075647637
1367,VWF,Integrin cell surface interactions,0.010156746901424905,1,0,1,0.011530990583507702
1368,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.011261104865568035,0,0,1,0.012784772075647637
1369,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.010156746901424905,1,0,1,0.011530990583507702
1370,VWF,p130Cas linkage to MAPK signaling for integrins,0.011261104865568035,0,0,1,0.012784772075647637
1371,VWF,p130Cas linkage to MAPK signaling for integrins,0.010156746901424905,1,0,1,0.011530990583507702
1372,VWF,GP1b-IX-V activation signalling,0.011261104865568035,0,0,1,0.012784772075647637
1373,VWF,GP1b-IX-V activation signalling,0.010156746901424905,1,0,1,0.011530990583507702
1374,KV116,Initial triggering of complement,0.0033977679444833113,0,0,1,0.0038574979324615065
1375,KV116,Initial triggering of complement,0.0023967560252941378,1,0,1,0.002721045569694645
1376,KV116,Regulation of Complement cascade,0.0033977679444833113,0,0,1,0.0038574979324615065
1377,KV116,Regulation of Complement cascade,0.0023967560252941378,1,0,1,0.002721045569694645
1378,KV116,FCGR activation,0.0033977679444833113,0,0,1,0.0038574979324615065
1379,KV116,FCGR activation,0.0023967560252941378,1,0,1,0.002721045569694645
1380,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0033977679444833113,0,0,1,0.0038574979324615065
1381,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0023967560252941378,1,0,1,0.002721045569694645
1382,KV116,Role of phospholipids in phagocytosis,0.0033977679444833113,0,0,1,0.0038574979324615065
1383,KV116,Role of phospholipids in phagocytosis,0.0023967560252941378,1,0,1,0.002721045569694645
1384,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0033977679444833113,0,0,1,0.0038574979324615065
1385,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023967560252941378,1,0,1,0.002721045569694645
1386,KV116,FCERI mediated MAPK activation,0.0033977679444833113,0,0,1,0.0038574979324615065
1387,KV116,FCERI mediated MAPK activation,0.0023967560252941378,1,0,1,0.002721045569694645
1388,KV116,FCERI mediated Ca+2 mobilization,0.0033977679444833113,0,0,1,0.0038574979324615065
1389,KV116,FCERI mediated Ca+2 mobilization,0.0023967560252941378,1,0,1,0.002721045569694645
1390,KV116,FCERI mediated NF-kB activation,0.0033977679444833113,0,0,1,0.0038574979324615065
1391,KV116,FCERI mediated NF-kB activation,0.0023967560252941378,1,0,1,0.002721045569694645
1392,KV116,Parasite infection,0.0033977679444833113,0,0,1,0.0038574979324615065
1393,KV116,Parasite infection,0.0023967560252941378,1,0,1,0.002721045569694645
1394,KV116,Leishmania parasite growth and survival,0.0033977679444833113,0,0,1,0.0038574979324615065
1395,KV116,Leishmania parasite growth and survival,0.0023967560252941378,1,0,1,0.002721045569694645
1396,KV116,Potential therapeutics for SARS,0.0033977679444833113,0,0,1,0.0038574979324615065
1397,KV116,Potential therapeutics for SARS,0.0023967560252941378,1,0,1,0.002721045569694645
1398,KV116,CD22 mediated BCR regulation,0.0033977679444833113,0,0,1,0.0038574979324615065
1399,KV116,CD22 mediated BCR regulation,0.0023967560252941378,1,0,1,0.002721045569694645
1400,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0033977679444833113,0,0,1,0.0038574979324615065
1401,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023967560252941378,1,0,1,0.002721045569694645
1402,KV116,Cell surface interactions at the vascular wall,0.0033977679444833113,0,0,1,0.0038574979324615065
1403,KV116,Cell surface interactions at the vascular wall,0.0023967560252941378,1,0,1,0.002721045569694645
1404,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0033977679444833113,0,0,1,0.0038574979324615065
1405,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023967560252941378,1,0,1,0.002721045569694645
1406,KV116,Scavenging of heme from plasma,0.0033977679444833113,0,0,1,0.0038574979324615065
1407,KV116,Scavenging of heme from plasma,0.0023967560252941378,1,0,1,0.002721045569694645
1408,S10A8,Antigen processing-Cross presentation,0.01554028428176769,0,0,1,0.01764293956098842
1409,S10A8,Antigen processing-Cross presentation,0.017961721608226813,1,0,1,0.02039200589895506
1410,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.01554028428176769,0,0,1,0.01764293956098842
1411,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.017961721608226813,1,0,1,0.02039200589895506
1412,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.01554028428176769,0,0,1,0.01764293956098842
1413,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.017961721608226813,1,0,1,0.02039200589895506
1414,S10A8,Regulation of TLR by endogenous ligand,0.01554028428176769,0,0,1,0.01764293956098842
1415,S10A8,Regulation of TLR by endogenous ligand,0.017961721608226813,1,0,1,0.02039200589895506
1416,S10A8,RHO GTPase Effectors,0.01554028428176769,0,0,1,0.01764293956098842
1417,S10A8,RHO GTPase Effectors,0.017961721608226813,1,0,1,0.02039200589895506
1418,S10A8,MyD88 deficiency (TLR2/4),0.01554028428176769,0,0,1,0.01764293956098842
1419,S10A8,MyD88 deficiency (TLR2/4),0.017961721608226813,1,0,1,0.02039200589895506
1420,S10A8,IRAK4 deficiency (TLR2/4),0.01554028428176769,0,0,1,0.01764293956098842
1421,S10A8,IRAK4 deficiency (TLR2/4),0.017961721608226813,1,0,1,0.02039200589895506
1422,S10A8,Metal sequestration by antimicrobial proteins,0.01554028428176769,0,0,1,0.01764293956098842
1423,S10A8,Metal sequestration by antimicrobial proteins,0.017961721608226813,1,0,1,0.02039200589895506
1424,S10A8,Neutrophil degranulation,0.01554028428176769,0,0,1,0.01764293956098842
1425,S10A8,Neutrophil degranulation,0.017961721608226813,1,0,1,0.02039200589895506
1426,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0004743289594849687,0,0,1,0.0005385073408237492
1427,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.00011702375900098073,1,0,1,0.00013285748637663445
1428,IPSP,Common Pathway of Fibrin Clot Formation,0.0004743289594849687,0,0,1,0.0005385073408237492
1429,IPSP,Common Pathway of Fibrin Clot Formation,0.00011702375900098073,1,0,1,0.00013285748637663445
1430,F13B,Common Pathway of Fibrin Clot Formation,0.0002794475464757876,0,0,1,0.0003172577852210313
1431,F13B,Common Pathway of Fibrin Clot Formation,0.0002342744605461362,1,0,1,0.00026597262142417444
1432,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.004854107339150683,0,0,1,0.005510885184234498
1433,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.004128321257045051,1,0,1,0.004686897685124238
1434,HEP2,Common Pathway of Fibrin Clot Formation,0.004854107339150683,0,0,1,0.005510885184234498
1435,HEP2,Common Pathway of Fibrin Clot Formation,0.004128321257045051,1,0,1,0.004686897685124238
1436,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004854107339150683,0,0,1,0.005510885184234498
1437,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004128321257045051,1,0,1,0.004686897685124238
1438,HEP2,Post-translational protein phosphorylation,0.004854107339150683,0,0,1,0.005510885184234498
1439,HEP2,Post-translational protein phosphorylation,0.004128321257045051,1,0,1,0.004686897685124238
1440,KV230,Initial triggering of complement,0.0024423131470988537,0,0,1,0.0027727667307750887
1441,KV230,Initial triggering of complement,0.0022512955548899625,1,0,1,0.0025559037845559575
1442,KV230,Regulation of Complement cascade,0.0024423131470988537,0,0,1,0.0027727667307750887
1443,KV230,Regulation of Complement cascade,0.0022512955548899625,1,0,1,0.0025559037845559575
1444,KV230,FCGR activation,0.0024423131470988537,0,0,1,0.0027727667307750887
1445,KV230,FCGR activation,0.0022512955548899625,1,0,1,0.0025559037845559575
1446,KV230,Regulation of actin dynamics for phagocytic cup formation,0.0024423131470988537,0,0,1,0.0027727667307750887
1447,KV230,Regulation of actin dynamics for phagocytic cup formation,0.0022512955548899625,1,0,1,0.0025559037845559575
1448,KV230,Role of phospholipids in phagocytosis,0.0024423131470988537,0,0,1,0.0027727667307750887
1449,KV230,Role of phospholipids in phagocytosis,0.0022512955548899625,1,0,1,0.0025559037845559575
1450,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.0024423131470988537,0,0,1,0.0027727667307750887
1451,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.0022512955548899625,1,0,1,0.0025559037845559575
1452,KV230,FCERI mediated MAPK activation,0.0024423131470988537,0,0,1,0.0027727667307750887
1453,KV230,FCERI mediated MAPK activation,0.0022512955548899625,1,0,1,0.0025559037845559575
1454,KV230,FCERI mediated Ca+2 mobilization,0.0024423131470988537,0,0,1,0.0027727667307750887
1455,KV230,FCERI mediated Ca+2 mobilization,0.0022512955548899625,1,0,1,0.0025559037845559575
1456,KV230,FCERI mediated NF-kB activation,0.0024423131470988537,0,0,1,0.0027727667307750887
1457,KV230,FCERI mediated NF-kB activation,0.0022512955548899625,1,0,1,0.0025559037845559575
1458,KV230,Parasite infection,0.0024423131470988537,0,0,1,0.0027727667307750887
1459,KV230,Parasite infection,0.0022512955548899625,1,0,1,0.0025559037845559575
1460,KV230,Leishmania parasite growth and survival,0.0024423131470988537,0,0,1,0.0027727667307750887
1461,KV230,Leishmania parasite growth and survival,0.0022512955548899625,1,0,1,0.0025559037845559575
1462,KV230,Potential therapeutics for SARS,0.0024423131470988537,0,0,1,0.0027727667307750887
1463,KV230,Potential therapeutics for SARS,0.0022512955548899625,1,0,1,0.0025559037845559575
1464,KV230,CD22 mediated BCR regulation,0.0024423131470988537,0,0,1,0.0027727667307750887
1465,KV230,CD22 mediated BCR regulation,0.0022512955548899625,1,0,1,0.0025559037845559575
1466,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0024423131470988537,0,0,1,0.0027727667307750887
1467,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0022512955548899625,1,0,1,0.0025559037845559575
1468,KV230,Cell surface interactions at the vascular wall,0.0024423131470988537,0,0,1,0.0027727667307750887
1469,KV230,Cell surface interactions at the vascular wall,0.0022512955548899625,1,0,1,0.0025559037845559575
1470,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0024423131470988537,0,0,1,0.0027727667307750887
1471,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0022512955548899625,1,0,1,0.0025559037845559575
1472,KV230,Scavenging of heme from plasma,0.0024423131470988537,0,0,1,0.0027727667307750887
1473,KV230,Scavenging of heme from plasma,0.0022512955548899625,1,0,1,0.0025559037845559575
1474,KV401,Initial triggering of complement,0.0034056948852051573,0,0,1,0.0038664974162240496
1475,KV401,Initial triggering of complement,0.004596244779234935,1,0,1,0.0052181329103927095
1476,KV401,Regulation of Complement cascade,0.0034056948852051573,0,0,1,0.0038664974162240496
1477,KV401,Regulation of Complement cascade,0.004596244779234935,1,0,1,0.0052181329103927095
1478,KV401,FCGR activation,0.0034056948852051573,0,0,1,0.0038664974162240496
1479,KV401,FCGR activation,0.004596244779234935,1,0,1,0.0052181329103927095
1480,KV401,Regulation of actin dynamics for phagocytic cup formation,0.0034056948852051573,0,0,1,0.0038664974162240496
1481,KV401,Regulation of actin dynamics for phagocytic cup formation,0.004596244779234935,1,0,1,0.0052181329103927095
1482,KV401,Role of phospholipids in phagocytosis,0.0034056948852051573,0,0,1,0.0038664974162240496
1483,KV401,Role of phospholipids in phagocytosis,0.004596244779234935,1,0,1,0.0052181329103927095
1484,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.0034056948852051573,0,0,1,0.0038664974162240496
1485,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.004596244779234935,1,0,1,0.0052181329103927095
1486,KV401,FCERI mediated MAPK activation,0.0034056948852051573,0,0,1,0.0038664974162240496
1487,KV401,FCERI mediated MAPK activation,0.004596244779234935,1,0,1,0.0052181329103927095
1488,KV401,FCERI mediated Ca+2 mobilization,0.0034056948852051573,0,0,1,0.0038664974162240496
1489,KV401,FCERI mediated Ca+2 mobilization,0.004596244779234935,1,0,1,0.0052181329103927095
1490,KV401,FCERI mediated NF-kB activation,0.0034056948852051573,0,0,1,0.0038664974162240496
1491,KV401,FCERI mediated NF-kB activation,0.004596244779234935,1,0,1,0.0052181329103927095
1492,KV401,Parasite infection,0.0034056948852051573,0,0,1,0.0038664974162240496
1493,KV401,Parasite infection,0.004596244779234935,1,0,1,0.0052181329103927095
1494,KV401,Leishmania parasite growth and survival,0.0034056948852051573,0,0,1,0.0038664974162240496
1495,KV401,Leishmania parasite growth and survival,0.004596244779234935,1,0,1,0.0052181329103927095
1496,KV401,Potential therapeutics for SARS,0.0034056948852051573,0,0,1,0.0038664974162240496
1497,KV401,Potential therapeutics for SARS,0.004596244779234935,1,0,1,0.0052181329103927095
1498,KV401,CD22 mediated BCR regulation,0.0034056948852051573,0,0,1,0.0038664974162240496
1499,KV401,CD22 mediated BCR regulation,0.004596244779234935,1,0,1,0.0052181329103927095
1500,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0034056948852051573,0,0,1,0.0038664974162240496
1501,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004596244779234935,1,0,1,0.0052181329103927095
1502,KV401,Cell surface interactions at the vascular wall,0.0034056948852051573,0,0,1,0.0038664974162240496
1503,KV401,Cell surface interactions at the vascular wall,0.004596244779234935,1,0,1,0.0052181329103927095
1504,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0034056948852051573,0,0,1,0.0038664974162240496
1505,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004596244779234935,1,0,1,0.0052181329103927095
1506,KV401,Scavenging of heme from plasma,0.0034056948852051573,0,0,1,0.0038664974162240496
1507,KV401,Scavenging of heme from plasma,0.004596244779234935,1,0,1,0.0052181329103927095
1508,HV434,Initial triggering of complement,0.0036263145525699814,0,0,1,0.004116967702784354
1509,HV434,Initial triggering of complement,0.004996382745743351,1,0,1,0.005672410955193173
1510,HV434,Regulation of Complement cascade,0.0036263145525699814,0,0,1,0.004116967702784354
1511,HV434,Regulation of Complement cascade,0.004996382745743351,1,0,1,0.005672410955193173
1512,HV434,FCGR activation,0.0036263145525699814,0,0,1,0.004116967702784354
1513,HV434,FCGR activation,0.004996382745743351,1,0,1,0.005672410955193173
1514,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0036263145525699814,0,0,1,0.004116967702784354
1515,HV434,Regulation of actin dynamics for phagocytic cup formation,0.004996382745743351,1,0,1,0.005672410955193173
1516,HV434,Role of phospholipids in phagocytosis,0.0036263145525699814,0,0,1,0.004116967702784354
1517,HV434,Role of phospholipids in phagocytosis,0.004996382745743351,1,0,1,0.005672410955193173
1518,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0036263145525699814,0,0,1,0.004116967702784354
1519,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.004996382745743351,1,0,1,0.005672410955193173
1520,HV434,FCERI mediated MAPK activation,0.0036263145525699814,0,0,1,0.004116967702784354
1521,HV434,FCERI mediated MAPK activation,0.004996382745743351,1,0,1,0.005672410955193173
1522,HV434,FCERI mediated Ca+2 mobilization,0.0036263145525699814,0,0,1,0.004116967702784354
1523,HV434,FCERI mediated Ca+2 mobilization,0.004996382745743351,1,0,1,0.005672410955193173
1524,HV434,FCERI mediated NF-kB activation,0.0036263145525699814,0,0,1,0.004116967702784354
1525,HV434,FCERI mediated NF-kB activation,0.004996382745743351,1,0,1,0.005672410955193173
1526,HV434,Parasite infection,0.0036263145525699814,0,0,1,0.004116967702784354
1527,HV434,Parasite infection,0.004996382745743351,1,0,1,0.005672410955193173
1528,HV434,Leishmania parasite growth and survival,0.0036263145525699814,0,0,1,0.004116967702784354
1529,HV434,Leishmania parasite growth and survival,0.004996382745743351,1,0,1,0.005672410955193173
1530,HV434,Potential therapeutics for SARS,0.0036263145525699814,0,0,1,0.004116967702784354
1531,HV434,Potential therapeutics for SARS,0.004996382745743351,1,0,1,0.005672410955193173
1532,HV434,CD22 mediated BCR regulation,0.0036263145525699814,0,0,1,0.004116967702784354
1533,HV434,CD22 mediated BCR regulation,0.004996382745743351,1,0,1,0.005672410955193173
1534,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0036263145525699814,0,0,1,0.004116967702784354
1535,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004996382745743351,1,0,1,0.005672410955193173
1536,HV434,Cell surface interactions at the vascular wall,0.0036263145525699814,0,0,1,0.004116967702784354
1537,HV434,Cell surface interactions at the vascular wall,0.004996382745743351,1,0,1,0.005672410955193173
1538,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0036263145525699814,0,0,1,0.004116967702784354
1539,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004996382745743351,1,0,1,0.005672410955193173
1540,HV434,Scavenging of heme from plasma,0.0036263145525699814,0,0,1,0.004116967702784354
1541,HV434,Scavenging of heme from plasma,0.004996382745743351,1,0,1,0.005672410955193173
1542,GELS,Apoptotic cleavage of cellular proteins,0.0291116434585938,0,0,1,0.03305055150526443
1543,GELS,Apoptotic cleavage of cellular proteins,0.03011255168956379,1,0,1,0.03418688615043031
1544,GELS,Neutrophil degranulation,0.0291116434585938,0,0,1,0.03305055150526443
1545,GELS,Neutrophil degranulation,0.03011255168956379,1,0,1,0.03418688615043031
1546,GELS,Amyloid fiber formation,0.0291116434585938,0,0,1,0.03305055150526443
1547,GELS,Amyloid fiber formation,0.03011255168956379,1,0,1,0.03418688615043031
1548,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.0291116434585938,0,0,1,0.03305055150526443
1549,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.03011255168956379,1,0,1,0.03418688615043031
1550,S10A9,Antigen processing-Cross presentation,0.0007976976583845704,0,0,1,0.0009056289653164627
1551,S10A9,Antigen processing-Cross presentation,0.0016874009428147275,1,0,1,0.0019157122424177896
1552,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0007976976583845704,0,0,1,0.0009056289653164627
1553,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0016874009428147275,1,0,1,0.0019157122424177896
1554,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0007976976583845704,0,0,1,0.0009056289653164627
1555,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0016874009428147275,1,0,1,0.0019157122424177896
1556,S10A9,Regulation of TLR by endogenous ligand,0.0007976976583845704,0,0,1,0.0009056289653164627
1557,S10A9,Regulation of TLR by endogenous ligand,0.0016874009428147275,1,0,1,0.0019157122424177896
1558,S10A9,RHO GTPase Effectors,0.0007976976583845704,0,0,1,0.0009056289653164627
1559,S10A9,RHO GTPase Effectors,0.0016874009428147275,1,0,1,0.0019157122424177896
1560,S10A9,MyD88 deficiency (TLR2/4),0.0007976976583845704,0,0,1,0.0009056289653164627
1561,S10A9,MyD88 deficiency (TLR2/4),0.0016874009428147275,1,0,1,0.0019157122424177896
1562,S10A9,IRAK4 deficiency (TLR2/4),0.0007976976583845704,0,0,1,0.0009056289653164627
1563,S10A9,IRAK4 deficiency (TLR2/4),0.0016874009428147275,1,0,1,0.0019157122424177896
1564,S10A9,Metal sequestration by antimicrobial proteins,0.0007976976583845704,0,0,1,0.0009056289653164627
1565,S10A9,Metal sequestration by antimicrobial proteins,0.0016874009428147275,1,0,1,0.0019157122424177896
1566,S10A9,Neutrophil degranulation,0.0007976976583845704,0,0,1,0.0009056289653164627
1567,S10A9,Neutrophil degranulation,0.0016874009428147275,1,0,1,0.0019157122424177896
1568,APOA4,Chylomicron assembly,0.014619904371606558,0,0,1,0.016598029002487767
1569,APOA4,Chylomicron assembly,0.007918044125012168,1,0,1,0.008989383424775977
1570,APOA4,Assembly of active LPL and LIPC lipase complexes,0.014619904371606558,0,0,1,0.016598029002487767
1571,APOA4,Assembly of active LPL and LIPC lipase complexes,0.007918044125012168,1,0,1,0.008989383424775977
1572,APOA4,Chylomicron remodeling,0.014619904371606558,0,0,1,0.016598029002487767
1573,APOA4,Chylomicron remodeling,0.007918044125012168,1,0,1,0.008989383424775977
1574,APOA4,Retinoid metabolism and transport,0.014619904371606558,0,0,1,0.016598029002487767
1575,APOA4,Retinoid metabolism and transport,0.007918044125012168,1,0,1,0.008989383424775977
1576,APOA4,Amyloid fiber formation,0.014619904371606558,0,0,1,0.016598029002487767
1577,APOA4,Amyloid fiber formation,0.007918044125012168,1,0,1,0.008989383424775977
1578,LDHB,Pyruvate metabolism,0.0008442143922892983,0,0,1,0.0009584395773989298
1579,LDHB,Pyruvate metabolism,0.0007029814172911985,1,0,1,0.0007980972827065817
1580,CO8A,Terminal pathway of complement,0.0008017770722619794,0,0,1,0.0009102603382809731
1581,CO8A,Terminal pathway of complement,0.0005935349704754807,1,0,1,0.0006738423455816477
1582,CO8A,Regulation of Complement cascade,0.0008017770722619794,0,0,1,0.0009102603382809731
1583,CO8A,Regulation of Complement cascade,0.0005935349704754807,1,0,1,0.0006738423455816477
1584,CO8G,Terminal pathway of complement,0.0008621348512324508,0,0,1,0.0009787847376486786
1585,CO8G,Terminal pathway of complement,0.0010611528079354003,1,0,1,0.001204730525897936
1586,CO8G,Regulation of Complement cascade,0.0008621348512324508,0,0,1,0.0009787847376486786
1587,CO8G,Regulation of Complement cascade,0.0010611528079354003,1,0,1,0.001204730525897936
1588,TSP1,Transcriptional regulation by RUNX1,0.023919019105981796,0,0,1,0.027155346761582013
1589,TSP1,Transcriptional regulation by RUNX1,0.01551950346021001,1,0,1,0.01761934702097292
1590,TSP1,Diseases associated with O-glycosylation of proteins,0.023919019105981796,0,0,1,0.027155346761582013
1591,TSP1,Diseases associated with O-glycosylation of proteins,0.01551950346021001,1,0,1,0.01761934702097292
1592,TSP1,O-glycosylation of TSR domain-containing proteins,0.023919019105981796,0,0,1,0.027155346761582013
1593,TSP1,O-glycosylation of TSR domain-containing proteins,0.01551950346021001,1,0,1,0.01761934702097292
1594,TSP1,Platelet degranulation ,0.023919019105981796,0,0,1,0.027155346761582013
1595,TSP1,Platelet degranulation ,0.01551950346021001,1,0,1,0.01761934702097292
1596,TSP1,Integrin cell surface interactions,0.023919019105981796,0,0,1,0.027155346761582013
1597,TSP1,Integrin cell surface interactions,0.01551950346021001,1,0,1,0.01761934702097292
1598,TSP1,Syndecan interactions,0.023919019105981796,0,0,1,0.027155346761582013
1599,TSP1,Syndecan interactions,0.01551950346021001,1,0,1,0.01761934702097292
1600,TSP1,Signaling by PDGF,0.023919019105981796,0,0,1,0.027155346761582013
1601,TSP1,Signaling by PDGF,0.01551950346021001,1,0,1,0.01761934702097292
1602,RNAS1,Chaperone Mediated Autophagy,0.01576836573673762,0,0,1,0.017901881241337073
1603,RNAS1,Chaperone Mediated Autophagy,0.015332008385401693,1,0,1,0.017406483201183785
1604,RNAS1,Late endosomal microautophagy,0.01576836573673762,0,0,1,0.017901881241337073
1605,RNAS1,Late endosomal microautophagy,0.015332008385401693,1,0,1,0.017406483201183785
1606,CBG,Metabolism of steroid hormones,0.002022436417493387,0,0,1,0.0022960791986051756
1607,CBG,Metabolism of steroid hormones,0.003796472007562751,1,0,1,0.004310148061641186
1608,APOA,LDL remodeling,0.000284846395097894,0,0,1,0.0003233871171052943
1609,APOA,LDL remodeling,0.0002701798907427311,1,0,1,0.0003067361829771009
1610,CD14,Antigen processing-Cross presentation,0.01848600020168393,0,0,1,0.020987221235416832
1611,CD14,Antigen processing-Cross presentation,0.021814997230843777,1,0,1,0.024766643305133076
1612,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.01848600020168393,0,0,1,0.020987221235416832
1613,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.021814997230843777,1,0,1,0.024766643305133076
1614,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.01848600020168393,0,0,1,0.020987221235416832
1615,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.021814997230843777,1,0,1,0.024766643305133076
1616,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.01848600020168393,0,0,1,0.020987221235416832
1617,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.021814997230843777,1,0,1,0.024766643305133076
1618,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.01848600020168393,0,0,1,0.020987221235416832
1619,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.021814997230843777,1,0,1,0.024766643305133076
1620,CD14,Regulation of TLR by endogenous ligand,0.01848600020168393,0,0,1,0.020987221235416832
1621,CD14,Regulation of TLR by endogenous ligand,0.021814997230843777,1,0,1,0.024766643305133076
1622,CD14,Caspase activation via Death Receptors in the presence of ligand,0.01848600020168393,0,0,1,0.020987221235416832
1623,CD14,Caspase activation via Death Receptors in the presence of ligand,0.021814997230843777,1,0,1,0.024766643305133076
1624,CD14,MyD88 deficiency (TLR2/4),0.01848600020168393,0,0,1,0.020987221235416832
1625,CD14,MyD88 deficiency (TLR2/4),0.021814997230843777,1,0,1,0.024766643305133076
1626,CD14,IRAK4 deficiency (TLR2/4),0.01848600020168393,0,0,1,0.020987221235416832
1627,CD14,IRAK4 deficiency (TLR2/4),0.021814997230843777,1,0,1,0.024766643305133076
1628,CD14,Neutrophil degranulation,0.01848600020168393,0,0,1,0.020987221235416832
1629,CD14,Neutrophil degranulation,0.021814997230843777,1,0,1,0.024766643305133076
1630,CFAH,Regulation of Complement cascade,0.0010397424009522356,0,0,1,0.0011804232153281213
1631,CFAH,Regulation of Complement cascade,0.0010910119555338593,1,0,1,0.0012386297214898921
1632,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1633,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1634,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1635,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1636,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1637,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1638,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1639,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1640,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1641,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1642,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1643,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1644,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.012344010569659064,0,0,1,0.014014198741280962
1645,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.006671273628676933,1,0,1,0.007573920482500638
1646,SAA1,TRAF6 mediated NF-kB activation,0.012344010569659064,0,0,1,0.014014198741280962
1647,SAA1,TRAF6 mediated NF-kB activation,0.006671273628676933,1,0,1,0.007573920482500638
1648,SAA1,Class A/1 (Rhodopsin-like receptors),0.012344010569659064,0,0,1,0.014014198741280962
1649,SAA1,Class A/1 (Rhodopsin-like receptors),0.006671273628676933,1,0,1,0.007573920482500638
1650,SAA1,G alpha (q) signalling events,0.012344010569659064,0,0,1,0.014014198741280962
1651,SAA1,G alpha (q) signalling events,0.006671273628676933,1,0,1,0.007573920482500638
1652,SAA1,G alpha (i) signalling events,0.012344010569659064,0,0,1,0.014014198741280962
1653,SAA1,G alpha (i) signalling events,0.006671273628676933,1,0,1,0.007573920482500638
1654,SAA1,Interleukin-1 family signaling,0.012344010569659064,0,0,1,0.014014198741280962
1655,SAA1,Interleukin-1 family signaling,0.006671273628676933,1,0,1,0.007573920482500638
1656,SAA1,Interleukin-4 and Interleukin-13 signaling,0.012344010569659064,0,0,1,0.014014198741280962
1657,SAA1,Interleukin-4 and Interleukin-13 signaling,0.006671273628676933,1,0,1,0.007573920482500638
1658,SAA1,Advanced glycosylation endproduct receptor signaling,0.012344010569659064,0,0,1,0.014014198741280962
1659,SAA1,Advanced glycosylation endproduct receptor signaling,0.006671273628676933,1,0,1,0.007573920482500638
1660,SAA1,Scavenging by Class B Receptors,0.012344010569659064,0,0,1,0.014014198741280962
1661,SAA1,Scavenging by Class B Receptors,0.006671273628676933,1,0,1,0.007573920482500638
1662,SAA1,Amyloid fiber formation,0.012344010569659064,0,0,1,0.014014198741280962
1663,SAA1,Amyloid fiber formation,0.006671273628676933,1,0,1,0.007573920482500638
1664,CO7,Terminal pathway of complement,0.0015255233942049332,0,0,1,0.001731932090483613
1665,CO7,Terminal pathway of complement,0.0034996852347273,1,0,1,0.003973204991572646
1666,CO7,Regulation of Complement cascade,0.0015255233942049332,0,0,1,0.001731932090483613
1667,CO7,Regulation of Complement cascade,0.0034996852347273,1,0,1,0.003973204991572646
1668,MBL2,Initial triggering of complement,9.319562496887528e-05,0,0,1,0.00010580532176000699
1669,MBL2,Initial triggering of complement,0.0004727570205915837,1,0,1,0.0005367227130533232
1670,MBL2,SARS-CoV-2 Infection,9.319562496887528e-05,0,0,1,0.00010580532176000699
1671,MBL2,SARS-CoV-2 Infection,0.0004727570205915837,1,0,1,0.0005367227130533232
1672,CO6,Terminal pathway of complement,0.001263129485174654,0,0,1,0.001434035360008479
1673,CO6,Terminal pathway of complement,0.0023307493149556523,1,0,1,0.002646107918619121
1674,CO6,Regulation of Complement cascade,0.001263129485174654,0,0,1,0.001434035360008479
1675,CO6,Regulation of Complement cascade,0.0023307493149556523,1,0,1,0.002646107918619121
1676,CBPN,Regulation of Complement cascade,0.00047311051539436396,0,0,1,0.0005371240369498167
1677,CBPN,Regulation of Complement cascade,0.0004943762006545014,1,0,1,0.0005612670444369957
1678,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0014007627899477425,0,0,1,0.0015902909363971038
1679,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0019481498624217062,1,0,1,0.0022117414105982105
1680,LBP,Regulation of TLR by endogenous ligand,0.0014007627899477425,0,0,1,0.0015902909363971038
1681,LBP,Regulation of TLR by endogenous ligand,0.0019481498624217062,1,0,1,0.0022117414105982105
1682,LBP,Interleukin-4 and Interleukin-13 signaling,0.0014007627899477425,0,0,1,0.0015902909363971038
1683,LBP,Interleukin-4 and Interleukin-13 signaling,0.0019481498624217062,1,0,1,0.0022117414105982105
1684,A1AG2,Platelet degranulation ,0.0018687084355131743,0,0,1,0.002121551278411872
1685,A1AG2,Platelet degranulation ,0.0023559606184429937,1,0,1,0.0026747304003971887
1686,A1AG2,Neutrophil degranulation,0.0018687084355131743,0,0,1,0.002121551278411872
1687,A1AG2,Neutrophil degranulation,0.0023559606184429937,1,0,1,0.0026747304003971887
1688,CPN2,Regulation of Complement cascade,0.000571932562510009,0,0,1,0.0006493170556193666
1689,CPN2,Regulation of Complement cascade,0.0005972532885141258,1,0,1,0.0006780637651667011
1690,HV102,Initial triggering of complement,0.003798700965745845,0,0,1,0.00431267860572875
1691,HV102,Initial triggering of complement,0.004395046920441942,1,0,1,0.004989712271611366
1692,HV102,Regulation of Complement cascade,0.003798700965745845,0,0,1,0.00431267860572875
1693,HV102,Regulation of Complement cascade,0.004395046920441942,1,0,1,0.004989712271611366
1694,HV102,FCGR activation,0.003798700965745845,0,0,1,0.00431267860572875
1695,HV102,FCGR activation,0.004395046920441942,1,0,1,0.004989712271611366
1696,HV102,Regulation of actin dynamics for phagocytic cup formation,0.003798700965745845,0,0,1,0.00431267860572875
1697,HV102,Regulation of actin dynamics for phagocytic cup formation,0.004395046920441942,1,0,1,0.004989712271611366
1698,HV102,Role of phospholipids in phagocytosis,0.003798700965745845,0,0,1,0.00431267860572875
1699,HV102,Role of phospholipids in phagocytosis,0.004395046920441942,1,0,1,0.004989712271611366
1700,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.003798700965745845,0,0,1,0.00431267860572875
1701,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.004395046920441942,1,0,1,0.004989712271611366
1702,HV102,FCERI mediated MAPK activation,0.003798700965745845,0,0,1,0.00431267860572875
1703,HV102,FCERI mediated MAPK activation,0.004395046920441942,1,0,1,0.004989712271611366
1704,HV102,FCERI mediated Ca+2 mobilization,0.003798700965745845,0,0,1,0.00431267860572875
1705,HV102,FCERI mediated Ca+2 mobilization,0.004395046920441942,1,0,1,0.004989712271611366
1706,HV102,FCERI mediated NF-kB activation,0.003798700965745845,0,0,1,0.00431267860572875
1707,HV102,FCERI mediated NF-kB activation,0.004395046920441942,1,0,1,0.004989712271611366
1708,HV102,Parasite infection,0.003798700965745845,0,0,1,0.00431267860572875
1709,HV102,Parasite infection,0.004395046920441942,1,0,1,0.004989712271611366
1710,HV102,Leishmania parasite growth and survival,0.003798700965745845,0,0,1,0.00431267860572875
1711,HV102,Leishmania parasite growth and survival,0.004395046920441942,1,0,1,0.004989712271611366
1712,HV102,Potential therapeutics for SARS,0.003798700965745845,0,0,1,0.00431267860572875
1713,HV102,Potential therapeutics for SARS,0.004395046920441942,1,0,1,0.004989712271611366
1714,HV102,CD22 mediated BCR regulation,0.003798700965745845,0,0,1,0.00431267860572875
1715,HV102,CD22 mediated BCR regulation,0.004395046920441942,1,0,1,0.004989712271611366
1716,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003798700965745845,0,0,1,0.00431267860572875
1717,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004395046920441942,1,0,1,0.004989712271611366
1718,HV102,Cell surface interactions at the vascular wall,0.003798700965745845,0,0,1,0.00431267860572875
1719,HV102,Cell surface interactions at the vascular wall,0.004395046920441942,1,0,1,0.004989712271611366
1720,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003798700965745845,0,0,1,0.00431267860572875
1721,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004395046920441942,1,0,1,0.004989712271611366
1722,HV102,Scavenging of heme from plasma,0.003798700965745845,0,0,1,0.00431267860572875
1723,HV102,Scavenging of heme from plasma,0.004395046920441942,1,0,1,0.004989712271611366
1724,FBLN1,Molecules associated with elastic fibres,0.0018682102610772396,0,0,1,0.0021209856992175234
1725,FBLN1,Molecules associated with elastic fibres,0.0003187422617083812,1,0,1,0.00036186921403049457
1726,ZA2G,Miscellaneous transport and binding events,0.007329129698056926,0,0,1,0.008320786798551092
1727,ZA2G,Miscellaneous transport and binding events,0.006252553296180479,1,0,1,0.007098545812047595
1728,PON1,Arachidonic acid metabolism,0.0012246949092704089,0,0,1,0.0013904004504124955
1729,PON1,Arachidonic acid metabolism,0.000446982343859407,1,0,1,0.000507460631643183
1730,PON1,Atorvastatin ADME,0.0012246949092704089,0,0,1,0.0013904004504124955
1731,PON1,Atorvastatin ADME,0.000446982343859407,1,0,1,0.000507460631643183
1732,PROP,Initial triggering of complement,0.0010994233264816778,0,0,1,0.0012481791805967327
1733,PROP,Initial triggering of complement,0.0003430072117538637,1,0,1,0.00038941729740790844
1734,PROP,Activation of C3 and C5,0.0010994233264816778,0,0,1,0.0012481791805967327
1735,PROP,Activation of C3 and C5,0.0003430072117538637,1,0,1,0.00038941729740790844
1736,PROP,Regulation of Complement cascade,0.0010994233264816778,0,0,1,0.0012481791805967327
1737,PROP,Regulation of Complement cascade,0.0003430072117538637,1,0,1,0.00038941729740790844
1738,PROP,Diseases associated with O-glycosylation of proteins,0.0010994233264816778,0,0,1,0.0012481791805967327
1739,PROP,Diseases associated with O-glycosylation of proteins,0.0003430072117538637,1,0,1,0.00038941729740790844
1740,PROP,O-glycosylation of TSR domain-containing proteins,0.0010994233264816778,0,0,1,0.0012481791805967327
1741,PROP,O-glycosylation of TSR domain-containing proteins,0.0003430072117538637,1,0,1,0.00038941729740790844
1742,PROP,Neutrophil degranulation,0.0010994233264816778,0,0,1,0.0012481791805967327
1743,PROP,Neutrophil degranulation,0.0003430072117538637,1,0,1,0.00038941729740790844
1744,KAIN,Platelet degranulation ,0.0010445469881835321,0,0,1,0.0011858778801592345
1745,KAIN,Platelet degranulation ,0.001317376027521385,1,0,1,0.0014956216508808303
1746,BLVRB,Cytoprotection by HMOX1,4.129400647923384e-05,0,0,1,4.68812312139579e-05
1747,BLVRB,Cytoprotection by HMOX1,4.962358507409649e-05,1,0,1,5.633783117397796e-05
1748,BLVRB,Heme degradation,4.129400647923384e-05,0,0,1,4.68812312139579e-05
1749,BLVRB,Heme degradation,4.962358507409649e-05,1,0,1,5.633783117397796e-05
1750,PRDX2,Transcriptional Regulation by TP53,0.008516694633954434,0,0,1,0.009669033459223219
1751,PRDX2,Transcriptional Regulation by TP53,0.007455275314717704,1,0,1,0.008464000362104807
1752,PRDX2,Neurodegenerative Diseases,0.008516694633954434,0,0,1,0.009669033459223219
1753,PRDX2,Neurodegenerative Diseases,0.007455275314717704,1,0,1,0.008464000362104807
1754,PRDX2,Detoxification of Reactive Oxygen Species,0.008516694633954434,0,0,1,0.009669033459223219
1755,PRDX2,Detoxification of Reactive Oxygen Species,0.007455275314717704,1,0,1,0.008464000362104807
1756,MASP1,Initial triggering of complement,0.002060408124956404,0,0,1,0.0023391886120271376
1757,MASP1,Initial triggering of complement,0.0014424150908098786,1,0,1,0.0016375789404877977
1758,MASP1,SARS-CoV-2 Infection,0.002060408124956404,0,0,1,0.0023391886120271376
1759,MASP1,SARS-CoV-2 Infection,0.0014424150908098786,1,0,1,0.0016375789404877977
1760,MASP1,Scavenging by Class A Receptors,0.002060408124956404,0,0,1,0.0023391886120271376
1761,MASP1,Scavenging by Class A Receptors,0.0014424150908098786,1,0,1,0.0016375789404877977
1762,LUM,Keratan sulfate/keratin metabolism,0.013080674122704833,0,0,1,0.014850535471518121
1763,LUM,Keratan sulfate/keratin metabolism,0.012746961377326397,1,0,1,0.014471670214570997
1764,LUM,Diseases associated with glycosaminoglycan metabolism,0.013080674122704833,0,0,1,0.014850535471518121
1765,LUM,Diseases associated with glycosaminoglycan metabolism,0.012746961377326397,1,0,1,0.014471670214570997
1766,LUM,Integrin cell surface interactions,0.013080674122704833,0,0,1,0.014850535471518121
1767,LUM,Integrin cell surface interactions,0.012746961377326397,1,0,1,0.014471670214570997
1768,LUM,ECM proteoglycans,0.013080674122704833,0,0,1,0.014850535471518121
1769,LUM,ECM proteoglycans,0.012746961377326397,1,0,1,0.014471670214570997
1770,APOC4,VLDL assembly,0.0016364509203937287,0,0,1,0.0018578685022450755
1771,APOC4,VLDL assembly,0.0005769298964630568,1,0,1,0.0006549905464835678
1772,APOC4,VLDL clearance,0.0016364509203937287,0,0,1,0.0018578685022450755
1773,APOC4,VLDL clearance,0.0005769298964630568,1,0,1,0.0006549905464835678
1774,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0016364509203937287,0,0,1,0.0018578685022450755
1775,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0005769298964630568,1,0,1,0.0006549905464835678
1776,TYB4,Platelet degranulation ,0.0012717148251550237,0,0,1,0.0014437823267716232
1777,TYB4,Platelet degranulation ,0.0016065963398305268,1,0,1,0.0018239744916243561
1778,HBB,Cytoprotection by HMOX1,0.015608361342060726,0,0,1,0.017720227687670176
1779,HBB,Cytoprotection by HMOX1,0.009389606761205167,1,0,1,0.010660053676350593
1780,HBB,Factors involved in megakaryocyte development and platelet production,0.015608361342060726,0,0,1,0.017720227687670176
1781,HBB,Factors involved in megakaryocyte development and platelet production,0.009389606761205167,1,0,1,0.010660053676350593
1782,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.015608361342060726,0,0,1,0.017720227687670176
1783,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.009389606761205167,1,0,1,0.010660053676350593
1784,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.015608361342060726,0,0,1,0.017720227687670176
1785,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.009389606761205167,1,0,1,0.010660053676350593
1786,HBB,Neutrophil degranulation,0.015608361342060726,0,0,1,0.017720227687670176
1787,HBB,Neutrophil degranulation,0.009389606761205167,1,0,1,0.010660053676350593
1788,HBB,Scavenging of heme from plasma,0.015608361342060726,0,0,1,0.017720227687670176
1789,HBB,Scavenging of heme from plasma,0.009389606761205167,1,0,1,0.010660053676350593
1790,HBB,Heme signaling,0.015608361342060726,0,0,1,0.017720227687670176
1791,HBB,Heme signaling,0.009389606761205167,1,0,1,0.010660053676350593
1792,HBB,Chaperone Mediated Autophagy,0.015608361342060726,0,0,1,0.017720227687670176
1793,HBB,Chaperone Mediated Autophagy,0.009389606761205167,1,0,1,0.010660053676350593
1794,HBB,Late endosomal microautophagy,0.015608361342060726,0,0,1,0.017720227687670176
1795,HBB,Late endosomal microautophagy,0.009389606761205167,1,0,1,0.010660053676350593
1796,HBA,Cytoprotection by HMOX1,0.002601360607151186,0,0,1,0.0029533338731872884
1797,HBA,Cytoprotection by HMOX1,0.008172720946543064,1,0,1,0.009278518918592254
1798,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.002601360607151186,0,0,1,0.0029533338731872884
1799,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.008172720946543064,1,0,1,0.009278518918592254
1800,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.002601360607151186,0,0,1,0.0029533338731872884
1801,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.008172720946543064,1,0,1,0.009278518918592254
1802,HBA,Scavenging of heme from plasma,0.002601360607151186,0,0,1,0.0029533338731872884
1803,HBA,Scavenging of heme from plasma,0.008172720946543064,1,0,1,0.009278518918592254
1804,HBA,Heme signaling,0.002601360607151186,0,0,1,0.0029533338731872884
1805,HBA,Heme signaling,0.008172720946543064,1,0,1,0.009278518918592254
1806,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0010293603518007795,0,0,1,0.0011686364383054352
1807,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.00019510506771503271,1,0,1,0.00022150347157917795
1808,LV321,Initial triggering of complement,0.0008731431136329126,0,0,1,0.0009912824567818292
1809,LV321,Initial triggering of complement,0.0009286676634852593,1,0,1,0.0010543196740832757
1810,LV321,Regulation of Complement cascade,0.0008731431136329126,0,0,1,0.0009912824567818292
1811,LV321,Regulation of Complement cascade,0.0009286676634852593,1,0,1,0.0010543196740832757
1812,LV321,FCGR activation,0.0008731431136329126,0,0,1,0.0009912824567818292
1813,LV321,FCGR activation,0.0009286676634852593,1,0,1,0.0010543196740832757
1814,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0008731431136329126,0,0,1,0.0009912824567818292
1815,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0009286676634852593,1,0,1,0.0010543196740832757
1816,LV321,Role of phospholipids in phagocytosis,0.0008731431136329126,0,0,1,0.0009912824567818292
1817,LV321,Role of phospholipids in phagocytosis,0.0009286676634852593,1,0,1,0.0010543196740832757
1818,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008731431136329126,0,0,1,0.0009912824567818292
1819,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0009286676634852593,1,0,1,0.0010543196740832757
1820,LV321,FCERI mediated MAPK activation,0.0008731431136329126,0,0,1,0.0009912824567818292
1821,LV321,FCERI mediated MAPK activation,0.0009286676634852593,1,0,1,0.0010543196740832757
1822,LV321,FCERI mediated Ca+2 mobilization,0.0008731431136329126,0,0,1,0.0009912824567818292
1823,LV321,FCERI mediated Ca+2 mobilization,0.0009286676634852593,1,0,1,0.0010543196740832757
1824,LV321,FCERI mediated NF-kB activation,0.0008731431136329126,0,0,1,0.0009912824567818292
1825,LV321,FCERI mediated NF-kB activation,0.0009286676634852593,1,0,1,0.0010543196740832757
1826,LV321,Parasite infection,0.0008731431136329126,0,0,1,0.0009912824567818292
1827,LV321,Parasite infection,0.0009286676634852593,1,0,1,0.0010543196740832757
1828,LV321,Leishmania parasite growth and survival,0.0008731431136329126,0,0,1,0.0009912824567818292
1829,LV321,Leishmania parasite growth and survival,0.0009286676634852593,1,0,1,0.0010543196740832757
1830,LV321,Potential therapeutics for SARS,0.0008731431136329126,0,0,1,0.0009912824567818292
1831,LV321,Potential therapeutics for SARS,0.0009286676634852593,1,0,1,0.0010543196740832757
1832,LV321,CD22 mediated BCR regulation,0.0008731431136329126,0,0,1,0.0009912824567818292
1833,LV321,CD22 mediated BCR regulation,0.0009286676634852593,1,0,1,0.0010543196740832757
1834,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008731431136329126,0,0,1,0.0009912824567818292
1835,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0009286676634852593,1,0,1,0.0010543196740832757
1836,LV321,Cell surface interactions at the vascular wall,0.0008731431136329126,0,0,1,0.0009912824567818292
1837,LV321,Cell surface interactions at the vascular wall,0.0009286676634852593,1,0,1,0.0010543196740832757
1838,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008731431136329126,0,0,1,0.0009912824567818292
1839,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009286676634852593,1,0,1,0.0010543196740832757
1840,LV321,Scavenging of heme from plasma,0.0008731431136329126,0,0,1,0.0009912824567818292
1841,LV321,Scavenging of heme from plasma,0.0009286676634852593,1,0,1,0.0010543196740832757
1842,FHR1,Regulation of Complement cascade,0.0007959719395458882,0,0,1,0.0009036697506317062
1843,FHR1,Regulation of Complement cascade,0.0008348835613125479,1,0,1,0.0009478462520779932
1844,LG3BP,Platelet degranulation ,0.0002874365570974667,0,0,1,0.0003263277371597964
1845,LG3BP,Platelet degranulation ,0.0003625926477851371,1,0,1,0.0004116527120187444
1846,APOF,LDL remodeling,0.00017740396539706963,0,0,1,0.00020140734767975263
1847,APOF,LDL remodeling,0.00016664982941079641,1,0,1,0.00018919813916102105
1848,ITIH4,Platelet degranulation ,0.0028070872861130415,0,0,1,0.0031868960974810396
1849,ITIH4,Platelet degranulation ,0.0035360827875011627,1,0,1,0.004014527261623429
1850,PCOC1,Crosslinking of collagen fibrils,0.0001346531701898233,0,0,1,0.0001528722190842901
1851,PCOC1,Crosslinking of collagen fibrils,0.0005727486662656303,1,0,1,0.0006502435810918007
1852,PCOC1,Collagen biosynthesis and modifying enzymes,0.0001346531701898233,0,0,1,0.0001528722190842901
1853,PCOC1,Collagen biosynthesis and modifying enzymes,0.0005727486662656303,1,0,1,0.0006502435810918007
1854,PON3,Arachidonic acid metabolism,0.0019363601888757703,0,0,1,0.0021983565526352985
1855,PON3,Arachidonic acid metabolism,0.0029936958625614426,1,0,1,0.0033987534725551808
1856,PON3,Atorvastatin ADME,0.0019363601888757703,0,0,1,0.0021983565526352985
1857,PON3,Atorvastatin ADME,0.0029936958625614426,1,0,1,0.0033987534725551808
1858,FCN2,Initial triggering of complement,0.0006602687766779556,0,0,1,0.0007496054711562753
1859,FCN2,Initial triggering of complement,0.0006453641906368452,1,0,1,0.0007326842420502303
1860,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0021784821023270347,0,0,1,0.002473238415023315
1861,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.009570659006596035,1,0,1,0.010865602929176035
1862,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0021784821023270347,0,0,1,0.002473238415023315
1863,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.009570659006596035,1,0,1,0.010865602929176035
1864,FHR5,Regulation of Complement cascade,0.0008108521285888792,0,0,1,0.0009205632817397299
1865,FHR5,Regulation of Complement cascade,0.0008541302644175134,1,0,1,0.0009696971020027649
1866,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.008737491786168068,0,1,2,0.16286806011306615
1867,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.011773192911381136,1,1,2,0.21945395060044798
1868,Nuclear signaling by ERBB4,Signaling by ERBB4,0.009467886369902057,0,1,2,0.1764827165706736
1869,Nuclear signaling by ERBB4,Signaling by ERBB4,0.009309056867089313,1,1,2,0.1735221125844375
1870,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.00782814945132036,0,1,2,0.14591779272743183
1871,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.005425953289976843,1,1,2,0.10114052273005926
1872,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.005642808752488105,0,1,2,0.10518273866210082
1873,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.004435835762855716,1,1,2,0.08268459454464507
1874,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.004593729444262746,0,1,2,0.08562775468993793
1875,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0061059018797484845,1,1,2,0.11381485885567746
1876,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,4.942634502025351e-05,0,1,2,0.0009213139341282527
1877,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.001038921031572784,1,1,2,0.019365632284861087
1878,Initial triggering of complement,Complement cascade,0.0008767314342412713,0,1,2,0.016342395670239023
1879,Initial triggering of complement,Complement cascade,0.0011582077080856304,1,1,2,0.021589152498263486
1880,Terminal pathway of complement,Complement cascade,0.0017011617712749053,0,1,2,0.03170989162641165
1881,Terminal pathway of complement,Complement cascade,0.002249099246600407,1,1,2,0.0419235222487362
1882,Activation of C3 and C5,Complement cascade,0.0004316167558451242,0,1,2,0.00804539625983668
1883,Activation of C3 and C5,Complement cascade,0.0005669514979597256,1,1,2,0.010568054644363055
1884,Regulation of Complement cascade,Complement cascade,0.002091513709492733,0,1,2,0.03898610595596983
1885,Regulation of Complement cascade,Complement cascade,0.0027666410055285423,1,1,2,0.05157057249690547
1886,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,5.04049088613795e-05,0,1,2,0.0009395545000024642
1887,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0011092215847773863,1,1,2,0.020676044357972788
1888,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,3.3837817959843326e-05,0,1,2,0.0006307416252228274
1889,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0008123082338952411,1,1,2,0.015141538270493766
1890,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,2.0757340580782633e-05,0,1,2,0.00038691971062566725
1891,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.000498927306937577,1,1,2,0.009300074278409908
1892,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,1.3645227397029743e-05,0,1,2,0.0002543489333488169
1893,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0003279932939695189,1,1,2,0.0061138405421423585
1894,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,1.360373499845187e-05,0,1,2,0.00025357550927801963
1895,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.00030083640496332206,1,1,2,0.005607632360276372
1896,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,2.610529196723959e-05,0,1,2,0.00048660626704338946
1897,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0005420535869856184,1,1,2,0.010103954126679013
1898,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,8.781915973711047e-05,0,1,2,0.0016369613313725803
1899,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.001797126135119565,1,1,2,0.03349868069332746
1900,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0015686824041176738,0,1,2,0.029240457827565396
1901,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0012534102136257668,1,1,2,0.023363740420597374
1902,RHO GTPase Effectors,Signaling by Rho GTPases,0.0018049199366322148,0,1,2,0.033643958235708794
1903,RHO GTPase Effectors,Signaling by Rho GTPases,0.00135923012444279,1,1,2,0.025336238251541226
1904,Metabolism of steroid hormones,Metabolism of steroids,0.0020311577138240923,0,1,2,0.03786106181615094
1905,Metabolism of steroid hormones,Metabolism of steroids,0.0022724071235123073,1,1,2,0.04235798431072118
1906,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,9.238327325752911e-05,0,1,2,0.0017220370411298316
1907,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,7.860218508687077e-05,1,1,2,0.001465155644096027
1908,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0002269545168469032,0,1,2,0.004230463707132612
1909,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.000533381704594993,1,1,2,0.009942309034808864
1910,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.002147593706626089,0,1,2,0.040031444889359745
1911,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0050562755070788605,1,1,2,0.09424967752631241
1912,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00021092915043666887,0,1,2,0.0039317486520904135
1913,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0004976118426989848,1,1,2,0.009275553842347607
1914,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0018317815102094558,0,1,2,0.03414466169697388
1915,Transcriptional Regulation by TP53,Generic Transcription Pathway,3.35278299623688e-05,1,1,2,0.0006249634059074246
1916,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.018056205599067197,0,1,2,0.3365701795082856
1917,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0002474423720975132,1,1,2,0.004612360173785263
1918,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.0010107895312002596,0,1,2,0.018841257211799935
1919,Transcriptional regulation by RUNX1,Generic Transcription Pathway,1.4024149178017661e-05,1,1,2,0.0002614120879605085
1920,FOXO-mediated transcription,Generic Transcription Pathway,0.00026438991123635196,0,1,2,0.00492826465653425
1921,FOXO-mediated transcription,Generic Transcription Pathway,3.819282335441946e-06,1,1,2,7.119195304792765e-05
1922,Arachidonic acid metabolism,Fatty acid metabolism,0.0024003826798299566,0,1,2,0.04474346645015413
1923,Arachidonic acid metabolism,Fatty acid metabolism,0.0003829871616005262,1,1,2,0.007138933870797147
1924,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,1.582768112446174e-05,0,1,2,0.0002950301738663851
1925,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,8.906277038926993e-06,1,1,2,0.00016601424066067566
1926,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.00040287633633106574,0,1,2,0.00750967084942765
1927,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.00022753336340079275,1,1,2,0.0042412534872711604
1928,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0003345373056752014,0,1,2,0.006235821828985905
1929,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0001888994653296558,1,1,2,0.003521112262828129
1930,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0002688459992815486,0,1,2,0.0050113267564338
1931,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.00015495926610701897,1,1,2,0.0028884622366509797
1932,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0027035633743746268,0,1,2,0.05039479669373631
1933,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0027483083511928605,1,1,2,0.05122884927456121
1934,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.006661685342355754,0,1,2,0.12417473977036582
1935,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.010274339198950383,1,1,2,0.19151510928178575
1936,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.006823942766812839,0,1,2,0.12719924069202648
1937,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.006656048231627019,1,1,2,0.12406966324365765
1938,G alpha (q) signalling events,GPCR downstream signalling,0.0008108397742566895,0,1,2,0.015114165978932491
1939,G alpha (q) signalling events,GPCR downstream signalling,0.00039823381650666237,1,1,2,0.007423133635277245
1940,G alpha (i) signalling events,GPCR downstream signalling,0.0008793887745959291,0,1,2,0.016391928863427076
1941,G alpha (i) signalling events,GPCR downstream signalling,0.00042669768406344974,1,1,2,0.007953704078802927
1942,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0044713120904203655,0,1,2,0.08334587821641196
1943,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.004528103966204151,1,1,2,0.0844044866666917
1944,Adherens junctions interactions,Cell-cell junction organization,0.0007388218823434674,0,1,2,0.013771742473836064
1945,Adherens junctions interactions,Cell-cell junction organization,0.00038839484836680483,1,1,2,0.007239733902989127
1946,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0035517128082641863,0,1,2,0.06620441990874927
1947,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.004326370684145107,1,1,2,0.08064415027802566
1948,Interleukin-1 family signaling,Signaling by Interleukins,0.0025260393468263947,0,1,2,0.047085724170657095
1949,Interleukin-1 family signaling,Signaling by Interleukins,0.0033492584881358416,1,1,2,0.062430643270353824
1950,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0008410851123630428,0,1,2,0.01567794328086297
1951,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0010687805118156206,1,1,2,0.019922217142638445
1952,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0035042111823496524,0,1,2,0.06531898300600288
1953,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0017877335458344435,1,1,2,0.03332360152487226
1954,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.0021973460222975195,0,1,2,0.04095883496168763
1955,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.0004011305631016506,1,1,2,0.007477129394027111
1956,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.00205520042963155,0,1,2,0.038309221377183005
1957,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.003123716487207646,1,1,2,0.05822650905607669
1958,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0011874708420208395,0,1,2,0.022134621378062748
1959,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0017974911743983207,1,1,2,0.03350548507616993
1960,Defective ABCA1 causes TGD,ABC transporter disorders,0.0024997468563743115,0,1,2,0.04659562849786331
1961,Defective ABCA1 causes TGD,ABC transporter disorders,0.0047404499717269765,1,1,2,0.08836264569432134
1962,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0006041506570025063,0,1,2,0.01126145213410103
1963,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0006938543742372163,1,1,2,0.01293354187890359
1964,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0011204500365569311,0,1,2,0.02088534425823737
1965,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.001287419929131191,1,1,2,0.023997686239938164
1966,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0006595381588641401,0,1,2,0.012293882859471628
1967,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0009395710371672063,1,1,2,0.017513734594187917
1968,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0014875711793381772,0,1,2,0.027728533335213447
1969,Signaling by RAS mutants,Oncogenic MAPK signaling,7.860391617361554e-05,1,1,2,0.0014651879117933142
1970,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0001996712336876437,0,1,2,0.003721899520703447
1971,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,1.051027591184097e-05,1,1,2,0.0001959130023703692
1972,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.002087942687066017,0,1,2,0.03891954160209196
1973,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00010987064935212829,1,1,2,0.002048004159691675
1974,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.001424635582174444,0,1,2,0.026555405065342996
1975,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,7.382025743493747e-05,1,1,2,0.0013760198486833977
1976,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0009582948841179551,0,1,2,0.017862749701194936
1977,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,4.922399887522811e-05,1,1,2,0.0009175421738887964
1978,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.00207477840216812,0,1,2,0.03867415750370685
1979,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.00010968811160982819,1,1,2,0.0020446016308294556
1980,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.000660519093411047,0,1,2,0.012312167615630773
1981,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.0006712477766185812,1,1,2,0.01251215176031917
1982,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0004245728092849169,0,1,2,0.007914096117887797
1983,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.00036918666351686897,1,1,2,0.006881690670289936
1984,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.009879182094611475,0,1,2,0.18414932598852332
1985,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.01042331645806396,1,1,2,0.19429206607746485
1986,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.01617366377831786,0,1,2,0.30147933857467374
1987,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.002150429210003483,1,1,2,0.0400842990660299
1988,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0007818810206552521,0,1,2,0.014574370790818575
1989,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0042349957341458406,1,1,2,0.07894090852243761
1990,VLDL assembly,Plasma lipoprotein assembly,0.0015834947200235301,0,1,2,0.0295165614527714
1991,VLDL assembly,Plasma lipoprotein assembly,0.000780093372356388,1,1,2,0.014541048778309067
1992,Chylomicron assembly,Plasma lipoprotein assembly,0.0006676117090712073,0,1,2,0.012444374956360584
1993,Chylomicron assembly,Plasma lipoprotein assembly,0.00032209988169505297,1,1,2,0.006003986519033771
1994,HDL assembly,Plasma lipoprotein assembly,0.001902887030788867,0,1,2,0.03547007847372341
1995,HDL assembly,Plasma lipoprotein assembly,0.0009760113187180379,1,1,2,0.018192986502104245
1996,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0017788553909197855,0,1,2,0.03315811148451277
1997,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.001624296240701438,1,1,2,0.03027710746358355
1998,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0019753265974051678,0,1,2,0.03682036205383563
1999,Chylomicron remodeling,Plasma lipoprotein remodeling,0.0018213508415879157,1,1,2,0.033950232585548364
2000,LDL remodeling,Plasma lipoprotein remodeling,0.00133033175890736,0,1,2,0.0247975687053627
2001,LDL remodeling,Plasma lipoprotein remodeling,0.0012272987334801266,1,1,2,0.02287701880504936
2002,HDL remodeling,Plasma lipoprotein remodeling,0.00012895012635889448,0,1,2,0.002403648260322831
2003,HDL remodeling,Plasma lipoprotein remodeling,0.00011891872782408537,1,1,2,0.0022166615987534548
2004,HDL clearance,Plasma lipoprotein clearance,0.001815180314620398,0,1,2,0.03383521310608334
2005,HDL clearance,Plasma lipoprotein clearance,0.0014977771844199527,1,1,2,0.027918774687062758
2006,Chylomicron clearance,Plasma lipoprotein clearance,0.0027906921794670233,0,1,2,0.052018889718674244
2007,Chylomicron clearance,Plasma lipoprotein clearance,0.002278019643049917,1,1,2,0.042462602454212225
2008,LDL clearance,Plasma lipoprotein clearance,0.0015841767785211062,0,1,2,0.029529275117871463
2009,LDL clearance,Plasma lipoprotein clearance,0.0013105085387430733,1,1,2,0.02442806112900508
2010,VLDL clearance,Plasma lipoprotein clearance,0.0009864252082055353,0,1,2,0.018387102848141393
2011,VLDL clearance,Plasma lipoprotein clearance,0.0008154479270747136,1,1,2,0.015200062587312055
2012,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0036561874824151725,0,1,2,0.06815184234144929
2013,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0023445222334205523,1,1,2,0.043702219972743754
2014,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00010406189559330051,0,1,2,0.0019397281830695933
2015,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),4.6958739183646265e-05,1,1,2,0.000875317418701695
2016,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0001741370822039849,0,1,2,0.0032459393915780462
2017,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),7.860399856209036e-05,1,1,2,0.001465189447525925
2018,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0014304478398784,0,1,2,0.026663746355988796
2019,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0006375458180317705,1,1,2,0.011883942572674026
2020,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.003644107165386035,0,1,2,0.06792666355464903
2021,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0016628503614249733,1,1,2,0.030995761627190033
2022,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0012649853042280663,0,1,2,0.023579501716649624
2023,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0005740074566431572,1,1,2,0.010699578693956746
2024,Parasite infection,Leishmania infection,0.0004781212352813722,0,1,2,0.00891224621377196
2025,Parasite infection,Leishmania infection,0.0017752678235358752,1,1,2,0.033091238730335495
2026,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0008951247494738919,0,1,2,0.01668524962012512
2027,Cell recruitment (pro-inflammatory response),Leishmania infection,0.003367344417377524,1,1,2,0.06276776750268764
2028,Leishmania parasite growth and survival,Leishmania infection,0.000492845648758295,0,1,2,0.009186711325497214
2029,Leishmania parasite growth and survival,Leishmania infection,0.0018413113155043423,1,1,2,0.034322298590903834
2030,Potential therapeutics for SARS,SARS-CoV Infections,0.0027234957990999627,0,1,2,0.05076633985827516
2031,Potential therapeutics for SARS,SARS-CoV Infections,0.002716454997075406,1,1,2,0.05063509833090744
2032,SARS-CoV-2 Infection,SARS-CoV Infections,0.0004376375915570407,0,1,2,0.008157625473512354
2033,SARS-CoV-2 Infection,SARS-CoV Infections,0.0004178248298938288,1,1,2,0.007788312845066952
2034,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.002584024193299137,0,1,2,0.04816656976022545
2035,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.002577491870617114,1,1,2,0.04804480635840595
2036,Cytoprotection by HMOX1,Cellular response to chemical stress,0.002000518161441063,0,1,2,0.03728993630536574
2037,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0019495233377479298,1,1,2,0.03633938571098849
2038,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0016781053911755614,0,1,2,0.031280117499933584
2039,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0009921296843301008,1,1,2,0.018493435075181662
2040,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0008921961113468618,0,1,2,0.01663065939878979
2041,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.000547351262274274,1,1,2,0.010202703529652777
2042,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.00858596667784281,0,1,2,0.16004361105430714
2043,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.010737499013555456,1,1,2,0.20014847253672713
2044,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00018332236117086638,0,1,2,0.003417154266915791
2045,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0020672412127114804,1,1,2,0.038533663245680666
2046,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0029249804641277074,0,1,2,0.05452204199095681
2047,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0011952550044903676,1,1,2,0.022279719247341886
2048,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.0038185361330340234,0,1,2,0.07117804373143222
2049,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.005193576555397591,1,1,2,0.09680898813150945
2050,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0031092062641987156,0,1,2,0.057956036484415614
2051,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.004912235057984615,1,1,2,0.09156474355487998
2052,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005293307055869556,0,1,2,0.09866797850809415
2053,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001690370909394838,1,1,2,0.031508748462633594
2054,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.002017396847451304,0,1,2,0.037604557356237266
2055,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0033624975048011513,1,1,2,0.06267742037926018
2056,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.004484277566001927,0,1,2,0.08358755648153549
2057,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.004916890208943588,1,1,2,0.09165151621513261
2058,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,7.0034348575338e-05,0,1,2,0.0013054499818591502
2059,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.0005318576837405964,1,1,2,0.009913901074469449
2060,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.009451635134795456,0,1,2,0.17617979129176878
2061,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0018271017399649752,1,1,2,0.03405743012982094
2062,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.005037961247470282,0,1,2,0.0939082971842355
2063,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,9.200765104965027e-05,1,1,2,0.0017150353910190459
2064,Integrin cell surface interactions,Integrin cell surface interactions,0.003229443878622025,0,1,2,0.06019728231250875
2065,Integrin cell surface interactions,Integrin cell surface interactions,0.0021319629099925963,1,1,2,0.03974008466974284
2066,ECM proteoglycans,ECM proteoglycans,0.0053408555737356565,0,1,2,0.09955428948332878
2067,ECM proteoglycans,ECM proteoglycans,0.0028693923188038263,1,1,2,0.05348587124359015
2068,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,0.00013431935205048573,0,1,2,0.002503731372742238
2069,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,0.00011307843938792529,1,1,2,0.0021077978113672436
2070,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.003694276281097557,0,1,2,0.06886182283759779
2071,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0011122064671505753,1,1,2,0.02073168297986615
2072,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0013277932370801546,0,1,2,0.024750250306024565
2073,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0009331995200027635,1,1,2,0.017394968629544306
2074,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.009389873448041952,0,1,2,0.17502854487494493
2075,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.001025581142439248,1,1,2,0.019116974899140642
2076,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0008756758662090576,0,1,2,0.016322719735550748
2077,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0031583859674019802,1,1,2,0.05887275298082846
2078,Neutrophil degranulation,Neutrophil degranulation,0.0018937168547930993,0,1,2,0.03529914511986431
2079,Neutrophil degranulation,Neutrophil degranulation,0.004466717667158037,1,1,2,0.08326023752885695
2080,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.002200880158564067,0,1,2,0.041024711752418244
2081,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.00010483900909907305,1,1,2,0.001954213686721019
2082,Heme degradation,Heme degradation,5.4906490693474574e-05,0,1,2,0.0010234646104067093
2083,Heme degradation,Heme degradation,0.0001609623766620474,1,1,2,0.003000361050941086
2084,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0006503758218622017,0,1,2,0.01212309562554596
2085,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",2.7271071094405703e-05,1,1,2,0.0005083365518446203
2086,Scavenging of heme from plasma,Scavenging of heme from plasma,0.00276302654946001,0,1,2,0.05150319853391329
2087,Scavenging of heme from plasma,Scavenging of heme from plasma,4.1996277041056026e-05,1,1,2,0.000782816435315631
2088,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0032556771604803515,0,1,2,0.060686274328893654
2089,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0008414023710469697,1,1,2,0.015683857026783397
2090,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.004588909237646626,0,1,2,0.08553790536931774
2091,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0005290967707635145,1,1,2,0.009862437273218137
2092,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0002871480992433378,0,1,2,0.005352480441006167
2093,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.00040666092506426655,1,1,2,0.007580216108912524
2094,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.002229652818470185,0,1,2,0.0415610381282119
2095,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0007692884666041178,1,1,2,0.014339643834803132
2096,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.022469909334711758,0,1,2,0.4188422299926368
2097,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.01015680597617748,1,1,2,0.18932427368956659
2098,Retinoid metabolism and transport,Retinoid metabolism and transport,0.022469909334711758,0,1,2,0.4188422299926368
2099,Retinoid metabolism and transport,Retinoid metabolism and transport,0.01015680597617748,1,1,2,0.18932427368956659
2100,Heme signaling,Heme signaling,0.007017767368333317,0,1,2,0.13081215817731692
2101,Heme signaling,Heme signaling,0.00788203538020758,1,1,2,0.1469222339240628
2102,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.009179656505204688,0,1,2,0.17111007187139893
2103,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.004190915102394504,1,1,2,0.07811923942590537
2104,Syndecan interactions,Syndecan interactions,0.006472009322850465,0,1,2,0.12063915242987772
2105,Syndecan interactions,Syndecan interactions,0.002442529154686622,1,1,2,0.045529082593607995
2106,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00575944706241547,0,1,2,0.10735689295461867
2107,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0028087986453747666,1,1,2,0.052356396757315
2108,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.009278196432712441,0,1,2,0.17294686980261717
2109,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.007691287599464427,1,1,2,0.14336666880528465
2110,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0062271459926820085,0,1,2,0.1160748659557554
2111,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.004309832235626815,1,1,2,0.08033587130124675
2112,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.005670550750958183,0,1,2,0.10569985336561721
2113,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.003218901456803936,1,1,2,0.060000770105982384
2114,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005790521844860907,0,1,2,0.10793613121419972
2115,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003610400652837498,1,1,2,0.06729836948052499
2116,Amyloid fiber formation,Amyloid fiber formation,0.007366180482598902,0,1,2,0.13730662700511242
2117,Amyloid fiber formation,Amyloid fiber formation,0.005598517093600237,1,1,2,0.10435713599044208
2118,Platelet sensitization by LDL,Platelet sensitization by LDL,0.008121708139346324,0,1,2,0.15138976743346974
2119,Platelet sensitization by LDL,Platelet sensitization by LDL,0.009211338209227704,1,1,2,0.17170062323345842
2120,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.00047589302875891205,0,1,2,0.008870712134802197
2121,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0004275197491598474,1,1,2,0.007969027486345226
2122,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.010691695480574068,0,1,2,0.1992946883220383
2123,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.009358312646818403,1,1,2,0.17444024715785514
2124,Formation of the cornified envelope,Formation of the cornified envelope,1.494522490677919e-06,0,1,2,2.785810674379026e-05
2125,Formation of the cornified envelope,Formation of the cornified envelope,1.4378228683612313e-05,1,1,2,0.00026801217910946807
2126,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.0009797543354043334,0,1,2,0.01826275685286244
2127,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.001848328909646285,1,1,2,0.034453107520117175
2128,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0017025700996625148,0,1,2,0.031736143063106015
2129,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.003106136807568218,1,1,2,0.057898821386622695
2130,Signaling by PDGF,Signaling by PDGF,0.0030349885610230637,0,1,2,0.05657260819193912
2131,Signaling by PDGF,Signaling by PDGF,0.004868437202309351,1,1,2,0.09074834544366976
2132,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0015174909534976678,0,1,2,0.028286242079969177
2133,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0018662449826361309,1,1,2,0.03478706560833188
2134,Peroxisomal protein import,Peroxisomal protein import,0.0010906575318646863,0,1,2,0.020330007834022733
2135,Peroxisomal protein import,Peroxisomal protein import,0.0032093705959534043,1,1,2,0.059823113536348636
2136,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0010415920831946157,0,1,2,0.019415421057973097
2137,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.003759820375229646,1,1,2,0.07008357385315361
2138,Late endosomal microautophagy,Late endosomal microautophagy,0.014960312917836715,0,1,2,0.27886231005901657
2139,Late endosomal microautophagy,Late endosomal microautophagy,0.017309922887892848,1,1,2,0.3226593661490903
2140,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.012951469960131664,0,1,2,0.2414171983953748
2141,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.00956084898469144,1,1,2,0.17821555261839997
2142,Atorvastatin ADME,Atorvastatin ADME,0.0021466355746927943,0,1,2,0.04001358517708452
2143,Atorvastatin ADME,Atorvastatin ADME,0.003942492219840464,1,1,2,0.07348860240106453
2144,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.002123221514995306,0,2,3,0.059249179697961514
2145,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.004842739777888267,1,2,3,0.13513821205377266
2146,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0184740818882185,0,2,3,0.5155252006535614
2147,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0006323292202829733,1,2,3,0.01764535039618822
2148,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.004210018431817387,0,2,3,0.11748191926127402
2149,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.00029399498604134206,1,2,3,0.008204024702670587
2150,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0017328813552539332,0,2,3,0.0483566119161685
2151,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0023774183044494696,1,2,3,0.0663426229165076
2152,Assembly of collagen fibrils and other multimeric structures,Collagen formation,4.07198271959324e-05,0,2,3,0.0011362998828725944
2153,Assembly of collagen fibrils and other multimeric structures,Collagen formation,5.575569660222185e-05,1,2,3,0.001555880657688874
2154,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0003093181398655786,0,2,3,0.008631622241627187
2155,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0007269023859967748,1,2,3,0.02028444502216487
2156,Heme degradation,Metabolism of porphyrins,5.193923665826362e-05,0,2,3,0.001449381114691283
2157,Heme degradation,Metabolism of porphyrins,0.00014227094067025678,1,2,3,0.003970116386838092
2158,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.002556888594869542,0,2,3,0.0713507991300798
2159,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.0014671088016234765,1,2,3,0.04094014327282403
2160,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0018075578606470922,0,2,3,0.05044048383250261
2161,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0010555197438112157,1,2,3,0.029454618151773613
2162,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0048029058917442025,0,2,3,0.13402663464107722
2163,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0038459964544547112,1,2,3,0.10732376882880908
2164,Late endosomal microautophagy,Late endosomal microautophagy,0.011063953263715948,0,2,3,0.3087431765654481
2165,Late endosomal microautophagy,Late endosomal microautophagy,0.01656384237737046,1,2,3,0.4622193523258933
2166,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,9.286576348118192e-05,0,2,3,0.0025914490171776087
2167,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.00012670351171542522,1,2,3,0.003535702271746524
2168,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0030609121406558366,0,2,3,0.08541573838648231
2169,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0033188567616375827,1,2,3,0.09261376604998017
2170,Post-translational protein phosphorylation,Post-translational protein modification,0.007148247471069084,0,2,3,0.19947414621964557
2171,Post-translational protein phosphorylation,Post-translational protein modification,0.004394128659895862,1,2,3,0.12261957442848741
2172,Signaling by Interleukins,Cytokine Signaling in Immune system,0.001082904662671274,0,2,3,0.030218803125924683
2173,Signaling by Interleukins,Cytokine Signaling in Immune system,0.003738008751858133,1,2,3,0.10431033723388253
2174,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.003238868825529532,0,2,3,0.09038167695015517
2175,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.00019304694906926065,1,2,3,0.0053870372425898925
2176,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0003377641133305603,0,2,3,0.009425416286010669
2177,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00031963124167011834,1,2,3,0.008919412666575805
2178,Toll-like Receptor Cascades,Innate Immune System,0.0003639298927653335,0,2,3,0.010155580782140282
2179,Toll-like Receptor Cascades,Innate Immune System,0.0008724863145798445,1,2,3,0.024347011402937702
2180,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0002974942493067973,0,2,3,0.008301672770270304
2181,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0007077015692434152,1,2,3,0.019748640051212536
2182,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.007788440237587874,0,2,3,0.21733893140429023
2183,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.00037082269174407194,1,2,3,0.010347926555969776
2184,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0001566881396889238,0,2,3,0.004372432965379434
2185,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,8.954244534558924e-05,1,2,3,0.002498710755051596
2186,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0022017522221475672,0,2,3,0.061440604354791345
2187,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.004669549934670299,1,2,3,0.1303052937406282
2188,Platelet sensitization by LDL,Platelet homeostasis,0.00564863098907352,0,2,3,0.15762686566400536
2189,Platelet sensitization by LDL,Platelet homeostasis,0.006798789853215842,1,2,3,0.18972241892657785
2190,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.009860386574252438,0,2,3,0.27515726074890556
2191,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.001935732617459118,1,2,3,0.054017241672164484
2192,Peroxisomal protein import,Peroxisomal protein import,0.0019627675258017687,0,2,3,0.054771659490182485
2193,Peroxisomal protein import,Peroxisomal protein import,0.0030414702855741937,1,2,3,0.08487320716340523
2194,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.0037793887393304214,0,2,3,0.10546505910172797
2195,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.002363113169817612,1,2,3,0.06594343353074615
2196,Atorvastatin ADME,Atorvastatin ADME,0.0030590307648140466,0,2,3,0.08536323798812898
2197,Atorvastatin ADME,Atorvastatin ADME,0.005307378390272862,1,2,3,0.14810410206824307
2198,Heme signaling,Cellular responses to stress,0.006088868278128872,0,2,3,0.16991182889783057
2199,Heme signaling,Cellular responses to stress,0.0068703558317210565,1,2,3,0.19171949058903476
2200,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0003035358454368075,0,2,3,0.00847026545466116
2201,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.00019145181505026505,1,2,3,0.005342524514423603
2202,Diseases of glycosylation,Diseases of metabolism,0.006054456073717309,0,2,3,0.16895154525875478
2203,Diseases of glycosylation,Diseases of metabolism,0.0036144916165231594,1,2,3,0.10086355182051247
2204,Metabolism of steroids,Metabolism of lipids,0.002060349641689471,0,2,3,0.05749471983914027
2205,Metabolism of steroids,Metabolism of lipids,0.0022510109598585775,1,2,3,0.06281518528368743
2206,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0013324879996457937,0,2,3,0.03718350646826666
2207,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00023810424127409155,1,2,3,0.00664437548247368
2208,Retinoid metabolism and transport,Visual phototransduction,0.011789392519032575,0,2,3,0.3289867924551002
2209,Retinoid metabolism and transport,Visual phototransduction,0.007946029338575855,1,2,3,0.2217365059846786
2210,GPCR downstream signalling,Signaling by GPCR,0.0006928598540470914,0,2,3,0.01933447721211051
2211,GPCR downstream signalling,Signaling by GPCR,0.0011391422843492667,1,2,3,0.03178813205795217
2212,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0011894297741019135,0,2,3,0.03319142064365613
2213,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.00021298370530820776,1,2,3,0.005943378841736906
2214,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00038353676902611397,0,2,3,0.010702716974330406
2215,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0016965163783995527,1,2,3,0.04734183553360996
2216,ECM proteoglycans,ECM proteoglycans,0.005443665316912949,0,2,3,0.15190723261771816
2217,ECM proteoglycans,ECM proteoglycans,0.002877915438720475,1,2,3,0.08030915652466158
2218,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.003400069568145755,0,2,3,0.09488003555252386
2219,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.002046539612247295,1,2,3,0.0571093465230379
2220,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.002880383651643694,0,2,3,0.08037803280063553
2221,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.000379198846208534,1,2,3,0.010581665842020619
2222,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0007920256592868316,0,2,3,0.022101730922119856
2223,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00013963131186756073,1,2,3,0.003896456695580112
2224,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.0006725279827869294,0,2,3,0.018767109801135582
2225,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.0015701464322648868,1,2,3,0.04381544151674682
2226,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0005274000037783271,0,2,3,0.014717266839977722
2227,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0022950876251976097,1,2,3,0.06404515881528336
2228,Molecules associated with elastic fibres,Elastic fibre formation,0.007325158446007704,0,2,3,0.20441090391103653
2229,Molecules associated with elastic fibres,Elastic fibre formation,0.0012074325158417678,1,2,3,0.03369379294577693
2230,Cellular response to chemical stress,Cellular responses to stress,0.0027536406710850893,0,2,3,0.07684122913811774
2231,Cellular response to chemical stress,Cellular responses to stress,0.0032547499244355476,1,2,3,0.09082484412618376
2232,Leishmania infection,Infectious disease,0.0001949173476453929,0,2,3,0.0054392313168122024
2233,Leishmania infection,Infectious disease,0.001710229380766539,1,2,3,0.04772450127795267
2234,Integrin cell surface interactions,Integrin cell surface interactions,0.0020885108310364545,0,2,3,0.05828056689105818
2235,Integrin cell surface interactions,Integrin cell surface interactions,0.002622259123271399,1,2,3,0.07317498476350434
2236,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.00023408149647153397,0,2,3,0.006532119494107669
2237,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0005568312049361535,1,2,3,0.015538553980208479
2238,SLC transporter disorders,Disorders of transmembrane transporters,0.002102719919491102,0,2,3,0.05867707607733378
2239,SLC transporter disorders,Disorders of transmembrane transporters,0.0018073274145485362,1,2,3,0.050434053159957325
2240,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.006977681565712568,0,2,3,0.1947144497369938
2241,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.00025957919320166215,1,2,3,0.007243640927353334
2242,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.0017335104770121997,0,2,3,0.048374167761304855
2243,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.0022113957045649976,1,2,3,0.061709708835237284
2244,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.00881050126850344,0,2,3,0.2458598734046043
2245,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,0.007652197425723068,1,2,3,0.21353703189181694
2246,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.00723499322010346,0,2,3,0.20189481426406455
2247,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.004400447604688799,1,2,3,0.12279590661657708
2248,ABC transporter disorders,Disorders of transmembrane transporters,0.002425928263765051,0,2,3,0.06769630894329791
2249,ABC transporter disorders,Disorders of transmembrane transporters,0.002089266131439572,1,2,3,0.05830164379188751
2250,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.002064771046873653,0,2,3,0.05761810057375743
2251,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.0019565020419377954,1,2,3,0.054596819146521
2252,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0011134600092454036,0,2,3,0.03107145990578409
2253,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0024161584364260883,1,2,3,0.06742367876715467
2254,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005308661901400325,0,2,3,0.1481399188593307
2255,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0032602381201381654,1,2,3,0.0909779939935459
2256,Collagen biosynthesis and modifying enzymes,Collagen formation,2.5054085568748767e-05,0,2,3,0.0006991423210188135
2257,Collagen biosynthesis and modifying enzymes,Collagen formation,3.430558697719978e-05,1,2,3,0.0009573084452569008
2258,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0020129057651233338,0,2,3,0.05617078319457344
2259,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.004368873875976399,1,2,3,0.12191483155540062
2260,Neutrophil degranulation,Innate Immune System,0.00042772251656700777,0,2,3,0.011935734479875495
2261,Neutrophil degranulation,Innate Immune System,0.0010199279475741863,1,2,3,0.028461417623177027
2262,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0014569454264423975,0,2,3,0.04065653101749
2263,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00024219583663213082,1,2,3,0.006758552767748763
2264,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0069204291837262856,0,2,3,0.19311680359198047
2265,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.006447957855220159,1,2,3,0.1799323391133149
2266,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0033545759157579485,0,2,3,0.09361052054129917
2267,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.002053972463999459,1,2,3,0.05731676264331645
2268,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.002472590299029854,0,2,3,0.06899842805472893
2269,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.0034904880109207508,1,2,3,0.09740319129776763
2270,Formation of the cornified envelope,Keratinization,4.267497085522872e-06,0,2,3,0.00011908587959143333
2271,Formation of the cornified envelope,Keratinization,1.2133944841112081e-05,1,2,3,0.00033860163589091746
2272,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.004226042476868177,0,2,3,0.11792907539547727
2273,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,0.004576787179472003,1,2,3,0.12771671920273595
2274,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.001965431319092576,0,2,3,0.05484599349925813
2275,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0018216319636522227,1,2,3,0.05083322620636671
2276,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.002491692632492492,0,2,3,0.06953148481775856
2277,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.0023779132357883126,1,2,3,0.06635643413480309
2278,Complement cascade,Innate Immune System,0.0013059152131534753,0,2,3,0.036441984309208086
2279,Complement cascade,Innate Immune System,0.003040672398082328,1,2,3,0.08485094185615846
2280,GPCR ligand binding,Signaling by GPCR,0.004727341651527123,0,2,3,0.13191799019877956
2281,GPCR ligand binding,Signaling by GPCR,0.007662415008271266,1,2,3,0.2138221568211761
2282,Antimicrobial peptides,Innate Immune System,0.00028544855159344154,0,2,3,0.007965533698880234
2283,Antimicrobial peptides,Innate Immune System,0.0006830463612677863,1,2,3,0.019060628537801563
2284,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.001958835117393537,0,2,3,0.05466192436797335
2285,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0022803931158750395,1,2,3,0.06363510380346409
2286,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.00331535955162443,0,2,3,0.09251617527904676
2287,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.003672271253694426,1,2,3,0.10247591119115071
2288,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.009287123166367322,0,2,3,0.2591601608569868
2289,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.007883047778423094,1,2,3,0.21997898527909307
2290,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0015244123047262516,0,2,3,0.042539215969045516
2291,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00025407776771455015,1,2,3,0.007090121878597103
2292,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0038591933822142766,0,2,3,0.10769203334514205
2293,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0023442663210411665,1,2,3,0.06541750615010807
2294,Clathrin-mediated endocytosis,Membrane Trafficking,0.015849419500915417,0,2,3,0.44228315203380414
2295,Clathrin-mediated endocytosis,Membrane Trafficking,0.00045410515347196024,1,2,3,0.012671950453502279
2296,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.005384655505225345,0,2,3,0.1502605448312912
2297,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0014702931204113776,1,2,3,0.04102900271341818
2298,Fatty acid metabolism,Metabolism of lipids,0.001067950054110789,0,2,3,0.029801489961162973
2299,Fatty acid metabolism,Metabolism of lipids,0.0012040071083120076,1,2,3,0.03359820584625097
2300,Syndecan interactions,Non-integrin membrane-ECM interactions,0.0031080465326656747,0,2,3,0.08673103876490337
2301,Syndecan interactions,Non-integrin membrane-ECM interactions,0.002795320611252255,1,2,3,0.07800432128244829
2302,Apoptotic execution phase,Apoptosis,0.005334905753831201,0,2,3,0.148872262007543
2303,Apoptotic execution phase,Apoptosis,0.0076208484827712305,1,2,3,0.21266222954963235
2304,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.0008861849753850178,0,2,3,0.024729276941382442
2305,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,6.061138926571622e-05,1,2,3,0.0016913803241841465
2306,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.002364904397705591,0,2,3,0.06599341832143583
2307,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0035531266099679553,1,2,3,0.09915114156332651
2308,O-linked glycosylation,Post-translational protein modification,0.0004569477704763234,0,2,3,0.01275127459585601
2309,O-linked glycosylation,Post-translational protein modification,0.00028615523435326256,1,2,3,0.007985253908726628
2310,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.0004899394586389163,0,2,3,0.013671918271835762
2311,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,6.873469010315603e-05,1,2,3,0.0019180636483963809
2312,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.001449456702347769,0,2,3,0.04044755576151343
2313,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0020017488455444606,1,2,3,0.05585944576306394
2314,SARS-CoV Infections,Infectious disease,0.00021728467697874505,0,2,3,0.00606339884039638
2315,SARS-CoV Infections,Infectious disease,0.0018374330405106867,1,2,3,0.05127416034140467
2316,Transferrin endocytosis and recycling,Iron uptake and transport,0.0016254910523071894,0,2,3,0.04535985095073329
2317,Transferrin endocytosis and recycling,Iron uptake and transport,0.0006753601452997785,1,2,3,0.018846142207539014
2318,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0023714869675922267,0,2,3,0.06617710705260835
2319,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0014376403584635082,1,2,3,0.040117816882537814
2320,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.0062906337651384755,0,2,3,0.1755421597475559
2321,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.008468780573091828,1,2,3,0.2363240474222646
2322,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.003134257439093481,0,2,3,0.0874624625442969
2323,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0017232200899104423,1,2,3,0.04808701119744771
2324,Cell-cell junction organization,Cell junction organization,0.0006457101900213204,0,2,3,0.018018750663169814
2325,Cell-cell junction organization,Cell junction organization,0.00026848306948242147,1,2,3,0.007492106460526065
2326,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
2327,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
2328,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0003831139420809904,0,2,3,0.010690917852347215
2329,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.00023219156559471586,1,2,3,0.006479380364748589
2330,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0009577586302901227,0,2,3,0.026726562816248783
2331,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.0013072992526333793,1,2,3,0.03648060637632391
2332,Amyloid fiber formation,Amyloid fiber formation,0.004040290542771962,0,2,3,0.11274560789348427
2333,Amyloid fiber formation,Amyloid fiber formation,0.004244019798569364,1,2,3,0.1184307383432381
2334,Metabolism of porphyrins,Metabolism,0.0002562670344699922,0,3,4,0.012883413140978683
2335,Metabolism of porphyrins,Metabolism,1.6499355448591715e-05,1,3,4,0.0008294785681025844
2336,Disorders of transmembrane transporters,Disease,0.0002216976606066925,0,3,4,0.01114549344940793
2337,Disorders of transmembrane transporters,Disease,0.00016454203525853556,1,3,4,0.008272086277805749
2338,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0035834206246204603,0,3,4,0.18015071060688925
2339,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.000717220589038551,1,3,4,0.0360571119922244
2340,Amyloid fiber formation,Metabolism of proteins,0.0022954408008500774,0,3,4,0.11539959573486776
2341,Amyloid fiber formation,Metabolism of proteins,0.0009715691345677991,1,3,4,0.04884407618618529
2342,Peroxisomal protein import,Protein localization,0.0010277556993095733,0,3,4,0.05166876539382267
2343,Peroxisomal protein import,Protein localization,0.0024782729567620993,1,3,4,0.12459118842232372
2344,SLC-mediated transmembrane transport,Transport of small molecules,0.002766512885459521,0,3,4,0.13908198741570715
2345,SLC-mediated transmembrane transport,Transport of small molecules,0.0020345101895312295,1,3,4,0.10228172876574541
2346,Late endosomal microautophagy,Autophagy,0.010829097093546423,0,3,4,0.5444154457418782
2347,Late endosomal microautophagy,Autophagy,0.012130550116297401,1,3,4,0.6098439040309201
2348,Peptide hormone metabolism,Metabolism of proteins,0.003798624004976208,0,3,4,0.19096971455795314
2349,Peptide hormone metabolism,Metabolism of proteins,0.0015939647235075254,1,3,4,0.08013401375469521
2350,Integrin cell surface interactions,Extracellular matrix organization,0.002402488697991623,0,3,4,0.120781256655867
2351,Integrin cell surface interactions,Extracellular matrix organization,0.0005011382066128755,1,3,4,0.025193917625323067
2352,Innate Immune System,Immune System,0.0021985694748225403,0,3,4,0.11052954556509713
2353,Innate Immune System,Immune System,0.0027219342229930985,1,3,4,0.1368408668321917
2354,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.002576821411343007,0,3,4,0.12954555353368757
2355,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.002851022682850852,1,3,4,0.1433305816077175
2356,Metabolism of lipids,Metabolism,0.002837880081269322,0,3,4,0.14266985844341226
2357,Metabolism of lipids,Metabolism,0.00019021979305935144,1,3,4,0.009562994267458378
2358,Degradation of the extracellular matrix,Extracellular matrix organization,0.001563362331803129,0,3,4,0.07859552771319085
2359,Degradation of the extracellular matrix,Extracellular matrix organization,0.0003325532363727334,1,3,4,0.016718579291403756
2360,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,8.014093337068725e-05,0,3,4,0.0040289565774762545
2361,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,5.609141660877496e-06,1,3,4,0.0002819905788226618
2362,Cytokine Signaling in Immune system,Immune System,6.173497041396948e-05,0,3,4,0.0031036263822782
2363,Cytokine Signaling in Immune system,Immune System,7.539223347148371e-05,1,3,4,0.0037902233248341675
2364,Diseases of metabolism,Disease,0.001208751290159767,0,3,4,0.06076802772555903
2365,Diseases of metabolism,Disease,0.0007522148633320331,1,3,4,0.03781639286978281
2366,Apoptosis,Programmed Cell Death,0.0029870645039157748,0,3,4,0.15016986543856747
2367,Apoptosis,Programmed Cell Death,0.004652912380788753,1,3,4,0.23391768915754005
2368,Diseases of hemostasis,Disease,0.000985908251014593,0,3,4,0.049564952211627725
2369,Diseases of hemostasis,Disease,0.0006291142243909018,1,3,4,0.03162770616383526
2370,RNA Polymerase II Transcription,Gene expression (Transcription),0.015735654482476522,0,3,4,0.7910847298823246
2371,RNA Polymerase II Transcription,Gene expression (Transcription),0.0003246449132400189,1,3,4,0.016321001060626474
2372,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0016678152167374453,0,3,4,0.08384672856763975
2373,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0018078732912533708,1,3,4,0.09088792308354982
2374,Iron uptake and transport,Transport of small molecules,0.0033622031031600233,0,3,4,0.16902935538110872
2375,Iron uptake and transport,Transport of small molecules,0.002453849340263286,1,3,4,0.1233633303702656
2376,Membrane Trafficking,Vesicle-mediated transport,0.015638029591929035,0,3,4,0.7861767954678677
2377,Membrane Trafficking,Vesicle-mediated transport,0.002034419039502246,1,3,4,0.10227714634458604
2378,Cellular responses to stress,Cellular responses to stimuli,0.005535312759164847,0,3,4,0.27827894948853404
2379,Cellular responses to stress,Cellular responses to stimuli,0.004189323398186931,1,3,4,0.21061149839906926
2380,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.002715036706636989,0,3,4,0.13649410528696918
2381,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.003122575515664279,1,3,4,0.15698246368445082
2382,ABC-family proteins mediated transport,Transport of small molecules,0.0021890976913273015,0,3,4,0.11005336687826975
2383,ABC-family proteins mediated transport,Transport of small molecules,0.0015977041293447143,1,3,4,0.08032200637107652
2384,Infectious disease,Disease,0.00030516550456632387,0,3,4,0.015341705107855135
2385,Infectious disease,Disease,0.00023567388104241415,1,3,4,0.011848125461344977
2386,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0013723971330008174,0,3,4,0.06899505937044192
2387,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.000999615111930217,1,3,4,0.05025404260675849
2388,Diseases of programmed cell death,Disease,0.0006815167692636299,0,3,4,0.03426215985636857
2389,Diseases of programmed cell death,Disease,0.0004970048103026376,1,3,4,0.024986117771353056
2390,Atorvastatin ADME,Drug ADME,0.002522998244217475,0,3,4,0.12683968034142035
2391,Atorvastatin ADME,Drug ADME,0.007597690996477717,1,3,4,0.3819616995512479
2392,Cell surface interactions at the vascular wall,Hemostasis,0.004860210853604328,0,3,4,0.24433928659125023
2393,Cell surface interactions at the vascular wall,Hemostasis,0.003644741589604322,1,3,4,0.18323352353179198
2394,Dissolution of Fibrin Clot,Hemostasis,0.0012687186466534739,0,3,4,0.06378279015990267
2395,Dissolution of Fibrin Clot,Hemostasis,0.0009028654843316394,1,3,4,0.045390110629841406
2396,Platelet homeostasis,Hemostasis,0.003564450418193906,0,3,4,0.1791970139784157
2397,Platelet homeostasis,Hemostasis,0.0025942893914098326,1,3,4,0.13042372814715175
2398,Visual phototransduction,Sensory Perception,0.010376919300567247,0,3,4,0.5216829341951821
2399,Visual phototransduction,Sensory Perception,0.00817023994405609,1,3,4,0.4107456773669683
2400,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.0007711917892484211,0,3,4,0.03877042730980441
2401,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.0005578988865082972,1,3,4,0.028047469549268206
2402,Signaling by GPCR,Signal Transduction,0.005010192604954133,0,3,4,0.25187937800504984
2403,Signaling by GPCR,Signal Transduction,0.005697296745187635,1,3,4,0.2864224339537529
2404,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.001042105695459646,0,3,4,0.052390188378855444
2405,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.0007556037228192711,1,3,4,0.03798676233201626
2406,Diseases of Immune System,Disease,0.0006484698133971163,0,3,4,0.03260077728189687
2407,Diseases of Immune System,Disease,0.0004945788484181074,1,3,4,0.024864156437983318
2408,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.002443782684007485,0,3,4,0.1228572454118162
2409,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0017495200157628267,1,3,4,0.0879543059765783
2410,Metabolism of carbohydrates,Metabolism,0.0017224977070884788,0,3,4,0.08659580285347981
2411,Metabolism of carbohydrates,Metabolism,0.00011848478025834399,1,3,4,0.005956631831883418
2412,Collagen formation,Extracellular matrix organization,4.814706444528689e-05,0,3,4,0.002420516255853388
2413,Collagen formation,Extracellular matrix organization,1.0550809719854728e-05,1,3,4,0.0005304249954500446
2414,Post-translational protein modification,Metabolism of proteins,0.0048374674821743706,0,3,4,0.24319590015859072
2415,Post-translational protein modification,Metabolism of proteins,0.002018491888566496,1,3,4,0.10147643443839656
2416,Cell junction organization,Cell-Cell communication,0.0007152510924265466,0,3,4,0.035958098716542305
2417,Cell junction organization,Cell-Cell communication,0.00014802858397314458,1,3,4,0.007441899064170863
2418,Keratinization,Developmental Biology,4.251263226814109e-06,0,3,4,0.00021372542369865275
2419,Keratinization,Developmental Biology,6.332050488139512e-06,1,3,4,0.00031833365784622434
2420,Miscellaneous transport and binding events,Transport of small molecules,0.0003288145322485196,0,3,4,0.016530621952514084
2421,Miscellaneous transport and binding events,Transport of small molecules,0.00023727124783838518,1,3,4,0.011928430508823043
2422,"Platelet activation, signaling and aggregation",Hemostasis,0.0036200710225163966,0,3,4,0.18199325043590459
2423,"Platelet activation, signaling and aggregation",Hemostasis,0.0026962288884347994,1,3,4,0.13554857246539356
2424,Diseases of signal transduction by growth factor receptors and second messengers,Disease,5.090861282442367e-05,0,3,4,0.0025593486606954757
2425,Diseases of signal transduction by growth factor receptors and second messengers,Disease,3.851268275526847e-05,1,3,4,0.0019361632062030551
2426,ECM proteoglycans,Extracellular matrix organization,0.005035322914537749,0,3,4,0.25314276391575047
2427,ECM proteoglycans,Extracellular matrix organization,0.0009677592224873312,1,3,4,0.048652538981780555
2428,Integrin signaling,Signal Transduction,0.006035254219580657,0,3,4,0.30341270262288544
2429,Integrin signaling,Signal Transduction,0.006855553608861165,1,3,4,0.3446519355708548
2430,MAPK family signaling cascades,Signal Transduction,2.9976591872316697e-05,0,3,4,0.0015070249610852006
2431,MAPK family signaling cascades,Signal Transduction,3.27496043151683e-05,1,3,4,0.001646433703299038
2432,Reversible hydration of carbon dioxide,Metabolism,0.0055395973832082146,0,3,4,0.2784943520736486
2433,Reversible hydration of carbon dioxide,Metabolism,0.0002982590659595254,1,3,4,0.014994495010824067
2434,Sensory processing of sound,Sensory Perception,0.0021969586197679598,0,3,4,0.11044856241710341
2435,Sensory processing of sound,Sensory Perception,0.0015777333755176515,1,3,4,0.07931800883068682
2436,Elastic fibre formation,Extracellular matrix organization,0.006986306724550545,0,3,4,0.3512253382419413
2437,Elastic fibre formation,Extracellular matrix organization,0.0013484264227074608,1,3,4,0.06778997044969672
2438,Gene Silencing by RNA,Gene expression (Transcription),0.0004926693588341051,0,3,4,0.024768159919156863
2439,Gene Silencing by RNA,Gene expression (Transcription),2.5074027068606282e-05,1,3,4,0.0012605563977475375
2440,Integration of energy metabolism,Metabolism,0.0024073378236664747,0,3,4,0.12102503865291882
2441,Integration of energy metabolism,Metabolism,0.000154456408993642,1,3,4,0.0077650476326485045
2442,Signaling by Nuclear Receptors,Signal Transduction,0.002116537117851507,0,3,4,0.1064055007070769
2443,Signaling by Nuclear Receptors,Signal Transduction,0.002301165554686248,1,3,4,0.11568739852992614
2444,Adaptive Immune System,Immune System,0.0022114658015748804,0,3,4,0.11117788765831674
2445,Adaptive Immune System,Immune System,0.002754352790871589,1,3,4,0.13847065821086535
2446,Platelet Adhesion to exposed collagen,Hemostasis,7.439568900400615e-05,0,3,4,0.003740123653940394
2447,Platelet Adhesion to exposed collagen,Hemostasis,5.313430399454081e-05,1,3,4,0.0026712417058862145
2448,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.003557577034279529,0,3,4,0.17885146565290197
2449,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0014929558673094773,1,3,4,0.07505595590777561
2450,Chaperone Mediated Autophagy,Autophagy,0.004914208620595946,0,3,4,0.24705393751106947
2451,Chaperone Mediated Autophagy,Autophagy,0.00563571150907229,1,3,4,0.2833263352226006
2452,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.0028717718093994363,0,3,4,0.14437371058524176
2453,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.00036808647826886375,1,3,4,0.018504955898652416
2454,Metabolism of vitamins and cofactors,Metabolism,0.004434054941482899,0,3,4,0.2229149832676252
2455,Metabolism of vitamins and cofactors,Metabolism,0.0002953707247304064,1,3,4,0.01484928829930215
2456,Metabolism of proteins,root,0.011743271796214072,0,4,5,1.1978139458282342
2457,Metabolism of proteins,root,0.0037954427518880926,1,4,5,0.3871352326418872
2458,Immune System,root,0.0004931111914269988,0,4,5,0.05029735087334496
2459,Immune System,root,0.0013655130338584766,1,4,5,0.13928235533926908
2460,Protein localization,root,0.0010179805116822165,0,4,5,0.10383403148919952
2461,Protein localization,root,0.0013189701141628235,1,4,5,0.13453497664800945
2462,Disease,root,0.00404011293180225,0,4,5,0.41209159563128545
2463,Disease,root,0.0026819624253005474,1,4,5,0.273560218221977
2464,Cell-Cell communication,root,9.400511853752916e-05,0,4,5,0.009588523872860555
2465,Cell-Cell communication,root,0.0006345202590950956,1,4,5,0.06472107845614876
2466,Sensory Perception,root,0.0056776729443524755,0,4,5,0.5791227479542426
2467,Sensory Perception,root,0.010992892474509304,1,4,5,1.1212752407895863
2468,Gene expression (Transcription),root,0.009979769678678073,0,4,5,1.0179366964092738
2469,Gene expression (Transcription),root,0.003487503110861274,1,4,5,0.3557253834196135
2470,Vesicle-mediated transport,root,0.00903717566576747,0,4,5,0.9217920892238627
2471,Vesicle-mediated transport,root,0.003122891707454739,1,4,5,0.31853501336029566
2472,Cellular responses to stimuli,root,0.00094731110946369,0,4,5,0.09662575112324684
2473,Cellular responses to stimuli,root,0.0013117640473908347,1,4,5,0.1337999577006629
2474,Signal Transduction,root,0.003133171205753513,0,4,5,0.3195835223816366
2475,Signal Transduction,root,0.012620692446458446,1,4,5,1.287310868786214
2476,Metabolism,root,0.006932655386996383,0,4,5,0.7071309808943236
2477,Metabolism,root,0.004171194524769949,1,4,5,0.4254619205988732
2478,Developmental Biology,root,0.00044370850907519033,0,4,5,0.04525827633694565
2479,Developmental Biology,root,0.0020543170468512316,1,4,5,0.20954037772202325
2480,Autophagy,root,0.0024942708027946587,0,4,5,0.2544156691683511
2481,Autophagy,root,0.00042114966866391607,1,4,5,0.04295727418735312
2482,Programmed Cell Death,root,0.005106704562345453,0,4,5,0.520883962165815
2483,Programmed Cell Death,root,0.0040541215688793195,1,4,5,0.4135204768787049
2484,Transport of small molecules,root,0.004720436941448203,0,4,5,0.4814846575119124
2485,Transport of small molecules,root,0.005576784490746039,1,4,5,0.5688321237738676
2486,Drug ADME,root,0.0016877949078906828,0,4,5,0.17215511259997462
2487,Drug ADME,root,0.001010477796518986,1,4,5,0.10306875440032284
2488,Hemostasis,root,0.0025085586993392065,0,4,5,0.25587303488674723
2489,Hemostasis,root,0.006884848193866511,1,4,5,0.7022546462888071
2490,Extracellular matrix organization,root,0.009015029613429155,0,4,5,0.9195331914655372
2491,Extracellular matrix organization,root,0.0009710440681983144,1,4,5,0.09904651336407856
